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ABSTRACT 
 
 
Squamous cell carcinoma of the oesophagus is a formidable disease which poses a 
significant health risk in developing countries where the incidence is frequently high 
and access to health care facilities is often limited.  The identification of genes involved 
in oesophageal tumourigenesis may provide new targets for therapy and improved 
diagnostics techniques, thereby improving the prognosis of this pernicious disease.  In 
this study, real-time RT-PCR and immunohistochemistry described the overexpression 
of N-Myc Downstream-Regulated Gene 1 (NDRG1) in oesophageal squamous cell 
carcinoma (OSCC) tissue compared to normal tissue in a cohort of South African cancer 
patients.  Despite more than ten years of research into the role of NDRG1 in cancer, 
the precise function of this protein remains enigmatic.  Reports have been 
contentious, suggesting both tumour suppressor and tumour promoter functions for 
NDRG1, implicating it in tumourigenic processes such as metastasis and angiogenesis.   
Our immunohistochemical analysis if NDRG1 expression in OSCC tissue and matched 
normal epithelium (n=83) showed that NDRG1 expression is elevated by 2.6-fold in 
cancer tissue compared to normal tissue.  Moreover, the expression and localisation of 
NDRG1 appeared to track with epithelial cell maturation where basal cells of normal 
oesophageal epithelium displayed plasma membrane-associated NDRG1 while 
maturing cells were mostly positive for NDRG1 in the cytoplasm and nucleus.  Likewise, 
NDRG1 displayed interesting patterns of localisation in tumour tissue of the 
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oesophagus.  Dysplastic tissue and poorly differentiated tumour tissue stained 
positively for NDRG1 in the plasma membrane, while moderately and well 
differentiated tumours displayed mixed staining for NDRG1 in the plasma membrane, 
cytoplasm and nucleus.  Analysis of NDRG1 expression in cell lines cultured under 
anchorage-independent conditions revealed that NDRG1 expression is strongly 
induced when cells are prevented from adhering to the surface of culture dishes.  
Induced NDRG1 expression correlated inversely with mRNA expression of invasion 
genes, MMP-2 and MMP-9, as well as the mRNA expression of angiogenic factors Ang-
1, PDGF-B and VEGF-C but, in contrast, showed positive correlation with the 
angiogenesis cytokine, VEGF-A.   Knock-down of NDRG1 expression with siRNA had no 
effect on anchorage-independent cell proliferation or apoptosis but did inhibit VEGF-A 
expression.  Moreover, VEGF-A promoter activity, induced by culturing cells under 
anchorage-independent conditions was shown to be NDRG1-dependent.  In order to 
identify factors that may drive NDRG1 transcription in cultured OSCC cell lines we 
cloned and partly characterised the NDRG1 promoter.  Through the generation of 
promoter deletion constructs, site-directed mutagenesis and Chromatin 
Immunoprecipitation (ChIP) assays, we showed that both EGR-1 and cJun/AP-1 are 
capable of driving transcription of NDRG1 in response to 12-o-tetradecanoylphorbol-
13-acetate (TPA) through activation of PKC/MEK/ERK1/2 and JNK MAPK pathways.  
Taken together, we describe the regulation of NDRG1 expression by EGR-1 and AP-1 
and we show that NDRG1 is overexpressed in squamous cell carcinoma of the 
oesophagus compared to normal oesophageal tissue.  We associate NDRG1 with an 
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oncogenic function in OSCC through its potential role in angiogenesis via modulation of 
VEGF-A expression.  
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CHAPTER 1 
LITERATURE REVIEW 
 
1.1. Cancer 
It is projected that in the year 2030 there will be 27 million new cases of cancer 
diagnosed and nearly 17 million deaths.  In 2008 an estimated 7.6 million people 
succumbed to cancer.  Of these, more than half of the cancer cases and 60% of the 
deaths occurred in less-developed countries.  The global cancer burden, which has 
more than doubled in the last thirty years, poses a growing and devastating threat to 
health and economic systems.  Developing countries will be the hardest hit as they 
generally present with a high background of communicable diseases, patients have 
limited access to health care facilities and governments often have inadequate health 
care budgets.  This scenario, presented in the World Cancer Report 2008[1], highlights 
the urgent need for translational cancer research, particularly in developing countries. 
 
1.2. Oesophageal cancer 
Data from 2002 ranked oesophageal cancer (OC) as the eighth most common 
malignancy and the sixth most common cause of cancer-related death[2](Fig 1.1).  
Indeed, the incidence of OC continues to increase despite widespread efforts to 
improve diagnosis and treatment[3].  The majority of malignant tumours of the 
oesophagus may be classified into two different histological subtypes, namely 
adenocarcinoma (ADC) and oesophageal squamous cell carcinoma (OSCC).  ADC occurs 
in the distal third of the oesophagus,  usually  at the  gastro-oesophageal junction,  and  
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Figure 1.1. Cancer incidence and mortality rates for the world.  Oesophageal cancer is the 
eighth most common cancer in the world and the sixth leading cause of cancer-related death. 
From Ferlay et al., 2004 [4]) 
 
 
arises through the metaplastic transformation of epithelium due to continual acid 
reflux, a condition referred to as Barrett’s oesophagus[5].  The characterisation of 
Barrett’s oesophagus as the precursor lesion to ADC is suggested by the 95% 
correlation between these two conditions and is attributed to a western diet and 
obesity[6;7].  OSCC, which is more prevalent in developing countries is the 
predominant form of oesophageal cancer and primarily occurs in the upper two thirds 
of the oesophagus[1;8].   
 
1.3. Oesophageal squamous cell carcinoma progression, staging and grading 
Squamous cell carcinoma of the oesophagus progresses in a multi-step fashion. The 
pathological staging of OSCC,  described  in detail in Figure 1.2,  is performed according  
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Figure 1.2.  The neoplastic progression of OSCC according to the American Joint Committee 
on Cancer.  Stage 0 is characterised by evidence of intraepithelial neoplasia (dysplasia and 
carcinoma in situ) which gives rise to the invasion of the tumour into the submucosal layer, 
described as Stage I.  Stage II is separated into two categories namely, A, typified by the 
infiltration of the muscle layer, and B, signifying a tumour that has invaded all layers of the 
oesophagus as well as the lymph nodes.  Stage 3 and 4 tumours have metastasised to the 
proximal and distal lymph nodes and organs, respectively. From www.cancer.gov[9]. 
 
to the 2002 American Joint Committee on Cancer tumour-node-metastasis (TNM) 
classification system, which takes into account the primary tumour, regional lymph 
node involvement and extent of metastasis. The disease initiates with dysplastic 
precursor lesions.  These lesions are often multifocal and develop into superficial 
squamous cell carcinomas, confined in situ to the mucosa.  Inconspicuous and 
asymptomatic, these tumours rapidly progress to late or advanced carcinomas that 
aggressively invade the oesophageal basement membrane, giving rise to symptoms of 
dysphagia, and leading to the infiltration of the submucosa, proximal lymph nodes and 
nearby tissues such as the trachea and aorta[6;10].  OSCC most commonly spreads to 
the regional lymph nodes, with the likelihood of distant metastasis increasing with 
tumour invasion[8].  Oesophageal cancer has long been considered a formidable 
disease due to its asymptomatic progression.  Indeed, more than half of patients 
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present at a late stage and have unresectable or metastatic disease[10], explaining the 
reported 5-year survival rate of approximately 10% and a median survival time of 9 
months[11].   
 
Tumour grading, a far more subjective classification, is based on parameters of mitotic 
activity, variability in size and shape of nuclei (anisonucleosis), and degree of 
differentiation.  The differentiation status, or extent to which tumour cells resemble 
their normal counterparts, can vary between tumours or even within the same 
tumour[6].  Although well differentiated tumours exhibit features similar to those of 
normal epithelium, these malignancies are comprised predominantly of keratinocyte-
like cells and a smaller population of basal-like cells.  The cells are frequently arranged 
in keratinising tumour nests, termed keratin pearls.  Moderately differentiated 
tumours display characteristics between the well and poorly differentiated tumour 
types and are the most common type of OSCC[8].  Poorly differentiated tumours are 
largely comprised of pleomorphic, basal-like cells that are arranged irregularly, exhibit 
high mitotic activity and no keratinisation[6].  Poorly differentiated OSCCs are often 
more aggressive tumours and are thus coupled with a poor prognosis[12].  
 
1.4. A South African Perspective 
1.4.1. Epidemiology 
Geographically, OSCC is widespread but a feature highlighted by many studies on 
oesophageal cancer is regional ‘hotspots’ displaying high incidence of this disease.  
Areas of  high  risk  include  China,  South  Central  Asia,   Western   Europe,  as  well  as  
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Figure 1.3. World-wide distribution of oesophageal cancer in males.  Age-standardised 
incidence rates of oesophageal cancer per 100 000 males.  Areas of high incidence include 
China, South Central Asia, Western Europe, as well as Southern and Eastern Africa. (Image 
reproduced from [4]).   
 
 
 
Southern and Eastern Africa[2](Fig 1.3).  In South Africa, cancer of the oesophagus is 
the third leading cancer in males, with a life time risk of 1 in 73[13].  The high incidence 
of OSCC in South Africa is by no means a new phenomenon.  Since the 1950s it has 
been documented that a large number of black South Africans, particularly from the 
former Ciskei and Transkei regions of the Eastern Cape Province, suffer from this 
condition[14-16].  Today, incidence rates within the Eastern Cape have improved, yet 
there is still cause for concern, considering ASR of 31.3/100 000 in males and 18.0/100 
000 in females[17].  Despite an increase in the worldwide incidence of OC, certain 
regions have shown an improved frequency of this disease.  This is likely due to 
reduced smoking habits[18;19] as well as improved socio-economic conditions [20] 
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and access to health care[21].  However, one can also not exclude the effect of the HIV 
epidemic on life expectancy, which may result in an apparent improvement of OC 
incidence.  Indeed the average life expectancy of South Africans has decreased from 
59.6 years (1990-1999) to 47.7 years (2000-2004)[22], well below the 65 year median 
age of OC sufferers[8;13]. However, accounting for between 40% and 45%[17;23] of 
total cancer cases in the in Ciskei and Transkei region of South Africa, it is often heads 
of households and breadwinners that succumb to this disease – a scenario that no 
doubt has significant socio-economic repercussions in a developing country.    
 
1.4.2. Aetiology 
Of the aetiological factors identified as risk for OSCC, the most common is tobacco and 
alcohol consumption[8]. However, since the use of tobacco and alcohol is widespread 
and not confined to regions of high incidence, the regional hotspots of OSCC likely 
arise through interplay between dietary, cultural, genetic and socio-economic 
factors[24].   Dietary risk factors identified include nutritional deficiencies such as a 
lack of trace minerals (e.g. zinc and magnesium), folic acid[25;26] and vitamins A, C 
and E[27]. In developing countries, such as South Africa, maize is a staple source of 
nutrition in many rural areas.  In addition to containing low levels of vitamins and trace 
minerals, this maize is often contaminated with various fungi (e.g. Fusarium 
verticilloides or Aspergillus flavus)[28-30] which produce dangerous mycotoxins that 
have tumourigenic potential[31] and the ability to form DNA adducts[32].  In addition 
to nutritional risk factors, cultural practices such as drinking extremely hot 
beverages[33;34] and the frequent use of emetics (herbal brews used to induce 
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vomiting) have been identified[35].  Polymorphisms in xenobiotic metabolising 
enzymes may contribute to the risk of developing OSCC[36-39], while there is also 
evidence that Human Papilloma Virus (HPV) may be associated, where some 30% to 
75% of tumours from Chinese and South African populations were reported to carry 
HPV DNA[40;41].   
 
1.5. Poor prognosis – a challenge in oesophageal cancer 
Prevention rather than cure is the underlying principle of the primary health care 
ethos, that many health systems presently subscribe to[42;43].  The identification of 
risk factors for oesophageal cancer has however had little effect on improving the 
prognosis associated with OSCC over the last couple of decades[13;44].  Indeed, a 
study performed on nearly 2000 OSCC patients reported that more than 77% of these 
patients presented with Stage III disease, 62% had  difficulty  swallowing   food,  and  
the mean tumour length was between 5 cm and 10 cm[45].  The prognosis of Stage I 
and II OSCC is generally favourable, where treatment comprises of surgery and often 
neoadjuvant chemotherapy[46].  However, detection is most often at a late stage 
where prognosis is poor[24].  Here, metastatic involvement usually excludes surgery, 
and chemo- and radiotherapy are the remaining options, and in many cases serve as 
palliative therapy[47].  Indeed, the asymptomatic progression of OSCC coupled with 
limited or poor access to health care[21;48] are the predominant contributors to the 
poor survival rate of OSCC. 
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Identification of aetiological risk factors may enable the implementation of 
preventative measures against the development of OSCC; however the likelihood of 
lowering mortality rates may be more attainable than improving the incidence of 
OSCC.  Indeed, to effectively reduce the impact of OSCC on South Africans, as well as 
other affected populations, more efficient diagnostic techniques, screening programs, 
as well as more specific therapeutic methods must be developed and implemented 
simultaneously.  This requires an in depth understanding of the multi-gene, multi-step, 
multi-factorial progression to a malignant tumour and a detailed understanding of 
cellular processes that have gone awry in cancer.   
 
1.6. The properties of cancer 
The development and progression of cancer is associated with the acquisition of a 
cohort of characteristics that most cancer cells express. In general these characteristics 
override the systems that maintain the fine balance of tissue homeostasis.  Hanahan 
and Weinberg[49] detailed the hallmark capabilities  of cancer cells (Fig 1.4).  These 
are: 
 
i. Self-sufficiency in growth signals 
Malignant cells acquire the ability to mimic normal mitogenic growth signals,            
thereby facilitating continued proliferation. 
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Figure 1.4.  The Hallmarks of Cancer.  Self-sufficiency in growth signals, insensitivity to anti-
growth signal, limitless replicative potential, sustained angiogenesis and evading apoptosis are 
the six capabilities cells must acquire in order to dictate malignant growth.  (Image reproduced 
from [49]).   
 
 
ii. Insensitivity to antigrowth signals 
Tissue homeostasis is maintained through the balance between growth and antigrowth 
signals.  Cancer cells gain the ability to evade antiproliferative signals. 
 
iii. Evading apoptosis 
Apoptosis, or programmed cell death, is the process by which unwanted or damaged 
cells are eliminated.  Through the activation of oncogenes or the inactivation of 
tumour suppressor genes, incipient cancer cells are able to escape this process.   
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iv. Limitless replicative potential 
Uncontrolled cell growth or proliferation of cells is achieved through acquiring growth 
signal independence, insensitivity to anti-growth signals and escaping apoptosis.  
Moreover, cancer cells become immortalised through maintaining their telomere 
length, through the activation of the telomerase enzyme, thereby escaping replicative 
senescence[50].    
 
 
 
v.  Sustained Angiogenesis 
As the malignant cell mass grows, so too does its need for oxygen and nutrients.  
Cancer cells therefore acquire the capability of regulating new blood vessel growth, a 
process called angiogenesis.   
  
 
 
vi. Tissue invasion and metastasis 
In due course and with increasing size, limited space, nutrients and oxygen, primary 
tumours invade surrounding tissues and shed cells that colonise in distant sites.  This 
process is not well understood but requires the activation of extracellular proteases to 
facilitate cell movement. 
 
In addition to the six hallmarks of cancer identified by Hanahan and Weinberg, a 
seventh, namely genomic instability, has recently been accepted as necessary to 
initiate and/or maintain the malignant phenotype[51].  Indeed, recent investigations 
have shown that partial loss of the mitotic spindle checkpoint results in aneuploidy, 
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which promotes tumour initiation and progression[51].  Taken together, these seven 
features describe the processes required to breach anti-neoplasm defence 
mechanisms, and highlight the complexity of the malignant phenotype.  The 
acquisition of these characteristics is associated with the deregulation of a wide array 
of genes.  Indeed, as genes which are deregulated in cancer are identified, so too can 
they be classified under one or more of the seven hallmarks.   
 
1.7. N-Myc Downstream-Regulated Gene 1 
The high incidence and poor survival rate of OSCC observed in South Africa, and indeed 
in many other developing countries, has driven a feverish, worldwide research 
initiative to elucidate the molecular mechanisms behind this disease.   Certainly, 
through these research efforts diagnostic indicators, therapeutic targets and 
prognostic markers shall be revealed and improve the dismal circumstances of OSCC.  
Differential display and microarray analysis, performed in our laboratory, on tissue 
RNA from OSCC patients, revealed aberrant expression of several genes, amongst 
them N-Myc downstream-regulated gene 1 (NDRG1) (data unpublished).  The altered 
expression of NDRG1 in tumour tissue relative to that of adjacent normal tissue 
suggests a role for this gene in the initiation and/or maintenance of OSCC. 
 
NDRG1 was initially implicated in vascular disease and identified as a tunicamycin and 
homocysteine responsive gene (denoted RTP) in human umbilical vein endothelial 
(HUVEC) cells[52].  Shortly thereafter it was described independently by other groups 
and  named  Drg-1[53],   RTP/rit42[54],   Cap43[55]  and  PROXY-1[56]  according  to  its  
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Figure 1.5.  The predicted secondary structures of the NDRG family members 1-4, showing 
similarities and differences between family members.  Blue regions signify a α-helix, red 
regions represent extended strands and random coils are represented by purple regions. 
(Figure from [57]). 
 
alleged function.  NDRG1 (as it is now accepted)[58] is a member of the NDRG family 
consisting of four members, namely NDRG1, NDRG2, NDRG3 and NDRG4 which share 
53-65% amino acid identity between them (Fig 1.5) [59;60].  Orthologues to NDRG1 
have been described in a variety of organisms including mouse[61;62], rat[63], 
Caenorhabditis elegans[64], zebra fish[65], chicken[66] and some plant species[59;67], 
suggesting a conserved role for this gene.   
 
1.7.1. NDRG1 structure and post-translational modification 
In humans, NDRG1 is mapped to chromosome 8q24.2[54] where the gene encodes a 
3.0 kb mRNA that translates into a 43 kDa protein[53;55].  Studies examining the 
amino acid sequence of NDRG1 revealed three tandem deca-repeats of hydrophilic 
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amino acids (GTRSRSHTSE) in its C-terminal tail – a property not shared by other NDRG 
family members, and perhaps indicative of a unique function for this 
protein[52;59;60].  However, the precise function of these repeats, besides binding 
divalent nickel and copper ions[68;69], remains elusive.  Inspection of the NDRG 
proteins revealed that NDRG1, as well as other family members, contains an α/β 
hydrolase-fold motif (Fig 1.6) [59;70].  This motif is commonly found in hydrolytic 
enzymes, yet the NDRG family stands unique due to its lack of residues required for 
catalytic activity[70]. Indeed, no predicted peptide motifs (including a putative 
cytochrome c family heme-binding motif and a phosphopantethein attachment motif 
[52;71;72]) have successfully exposed a function for NDRG1.   Furthermore, 
examination of the NDRG1 peptide sequence, which could provide clues as to the 
localisation  of  NDRG1 at  the  subcellular  level,  revealed  no  significant  hydrophobic  
 
 
 
 
Figure 1.6.  Schematic diagram of the NDRG1 protein.  Positions of the hydrophilic tandem 
repeats, α/β hydrolase fold, phosphopantethein attachment as well as cytochrome c family 
heme-binding motifs are shown.  Phosphorylation sites for PKA, CaMK-II, SGK-1 and GSK-3β 
are also shown.  (Figure adapted from [72]) 
 
Un
ive
rsi
ty 
of 
Ca
pe
To
wn
 14 
transmembrane domains, no signal sequence and no endoplasmic reticulum retention 
sequence[52].  However, NDRG1 does exist as a multi-phosphorylated protein.  Two- 
dimensional electrophoresis identified more than seven phosphorylation sites for 
NDRG1[73] and experiments using kinase inhibitors have identified NDRG1 as a 
substrate of protein kinase A (PKA)[72;73], calmodulin kinase II[72;73], serum and 
glucocorticoid-induced kinase 1 (SGK-1)[74;75], and glycogen synthase kinase 3 (GSK-
3) [74].   Taken together, the   data   on   NDRG1’s   structure   and   post-translational 
modification does not reveal much regarding its function.  NDRG1 phosphorylation has 
been implicated in HUVEC proliferation[73] and mast cell exocytosis[72], however the 
significance of NDRG1 phosphorylation should be further established.  Indeed, 
phosphorylation may be instrumental in determining the specific functions and 
localisation of the NDRG1 protein. 
 
1.7.2. NDRG1 expression and localisation 
NDRG1 mRNA is ubiquitously expressed in the human body, albeit at varying levels, 
where notably high levels have been observed in the brain, heart, prostate, intestine, 
placenta and kidney[71;76].   Immunohistochemical studies on human tissue revealed 
that protein and mRNA levels do not necessarily correlate, where the 43 kDa NDRG1 
predominates in epithelial tissues, with complete absence of the protein from the 
brain, heart and skeletal muscle[71].  This differs from the other members of the NDRG 
family which are conspicuously detected in the brain, heart, skeletal muscle and spinal 
chord[59;60], suggesting different but related functions for the protein family.  The 
ubiquitous but varying levels of mRNA, and the absence of NDRG1 protein in certain 
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tissues, implicates both transcriptional and translational regulation for this gene, which 
may be tissue or cell type specific. 
 
The subcellular localisation of NDRG1 revealed further variations in NDRG1 expression 
patterns.  Although predominantly detected in the cytoplasm, NDRG1 has been 
reported to associate with the plasma membrane in cells of the intestinal epithelium, 
lactating breast, biliary ducts in the liver and basal cells of the oesophageal epithelium, 
amongst others[71].  Since NDRG1 contains no hydrophobic or transmembrane motifs, 
membrane localisation is probably achieved through protein-protein interactions.  
Closer examination of localisation by electron microscopy revealed that NDRG1 was 
often adjacent to adherens junctions and desmosomes, pointing to a function in cell-
cell adhesion[71].  Indeed, interaction between NDRG1 and the adhesion molecules E-
cadherin and β-catenin has been demonstrated[77], and exogenous overexpression of 
NDRG1 in colon and prostate cancer cells is capable of inducing E-cadherin 
expression[76;78].  Further supporting the relationship with E-cadherin, NDRG1 was 
identified as a Rab4a effector, involved in vesicular recycling of E-cadherin to the 
surface of prostate cancer cell lines[78].  Rab proteins are involved in the processing of 
intracellular vesicles, including budding and fusion, a mechanism by which they 
regulate the spatiotemporal trafficking, recycling and degradation of proteins[79].  
Indeed, many signalling molecules and receptors, for example phosphoinositide 3-
kinase (PI-3K) and epidermal growth factor receptor (EGFR), are recycled and 
redistributed in this manner.  The association of NDRG1 with recycling/sorting and late 
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endosomes therefore opens the floor to speculation as to whether NDRG1 may be 
involved in regulating signal transduction.  
 
As well as membrane-localised NDRG1, this protein was occasionally observed in the 
nucleus of cells, including prostate and kidney[71;80].  With no nuclear localisation 
sequence, it is presumed that NDRG1 enters the nucleus through interaction with one 
or more nuclear proteins.  Molecular chaperones, such as heat shock protein 90 
(HSP90) and heat shock cognate protein 70 (Hsc70) are potential NDRG1 binding 
partners that facilitate nuclear translocation[77;81].  Indeed, in maturing mast cells 
Hsc70 translocated to the nucleus, accompanied by NDRG1[81].   Moreover, DNA 
damaging agents have been reported to induce NDRG1 translocation from the 
cytoplasm to the nucleus[54].  The subcellular translocation of NDRG1 in response to 
stimuli, including DNA damage, suggests a role for NDRG1 in genomic stability, stress 
responsiveness or even transcription.  Recent reports have shown, by co-
immunoprecipitation, that NDRG1 does indeed associate with transcription factors, as 
well as DNA repair proteins ATP-dependent DNA helicase II (Ku70) and RuvB-like 2 
(RUVBL2)[77].  However, the precise function of NDRG1 within the nucleus remains 
uncertain and requires further inspection. 
 
Analysis of the NDRG1 protein using PSORT II software (http://psort.hgc.jp/) also 
predicted NDRG1 association with the mitochondrion and the cytoskeleton[57].  The 
cytoplasmic localisation of NDRG1 has been described as granular, and is suggestive of 
mitochondrial localisation[54;71].  In fact, close inspection using immunoelectron 
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microscopy revealed NDRG1 located at the inner mitochondrial membrane of kidney 
proximal tubule cells[71], which is in agreement with the reports claiming NDRG1 
associates with metabolic and mitochondrial proteins[77].   
 
Taken together, the wide range of tissues in which NDRG1 is expressed as well as the 
diverse subcellular localisation confounds approaches to untangle the cellular function 
of this protein.  The lack of organelle targeting sequences suggests that NDRG1 
achieves translocation via protein-protein interactions.  Such interactions may also 
facilitate specific functionality of NDRG1 which may be cell or tissue specific. 
 
1.7.3. NDRG1 and endoplasmic reticulum stress 
The endoplasmic reticulum (ER) is an extensive membranous organelle that envelopes 
the nucleus and extends into the cytoplasm[82].  The ER is involved in a wide array of 
biologic functions that include protein folding, lipid biosynthesis and calcium storage.  
A rigorous control system ensures that only properly folded proteins are transported 
out of the ER, while misfolded or unfolded proteins are retained in the ER and 
degraded[82;83].  “ER stress” refers to the condition where stimuli, such as oxidative 
stress, calcium depletion, DNA damage or altered glycosylation (amongst others), 
disrupt protein folding, causing an accumulation of misfolded and/or unfolded proteins 
in the ER.  To manage the accumulation of misfolded or unfolded proteins, the ER 
stress response (i) assists protein folding by elevating the levels of ER chaperone 
proteins and/or (ii) promotes degradation of misfolded proteins through the activation 
of the ER-associated protein degradation pathway[82-84].  
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NDRG1 expression is upregulated by several ER stress inducers, including 
tunicamycin[73], calcium ionophore A23187[85;86], homocysteine[52;55;87], and β-
mercaptoethanol[52].  Interestingly, mass spectrometry analysis of the NDRG1 
interactome in prostate cancer cells suggested that NDRG1 could interact with nuclear 
proteins, signaling proteins, adhesion molecules as well as endoplasmic reticulum 
chaperones and proteasome subunits[77].  NDRG1 reportedly complexes with ER 
chaperones heat shock protein 90-α (HSP90)[77;88], heat shock 70 kDa protein 5[77] 
and heat shock cognate protein 70[81], amongst others.  Furthermore, siRNA 
knockdown of NDRG1 lead to a reduction in HSP90 levels in LNCaP cells[77]. On the 
other hand, in hepatocellular carcinoma cell lines inhibition of HSP90 with 
geldanamycin lead to a transcriptional increase in NDRG1 levels as well as an altered 
phosphorylation status[88]. Taken together, the interaction of NDRG1 with ER proteins 
suggests that NDRG1 may play a role in the ER stress response; however, its function 
therein requires further clarification. 
 
1.7.4. NDRG1 in cancer 
Since its first description in 1996[52], many studies have described the aberrant 
expression of NDRG1 in tumour tissue relative to that of normal tissue.  However, the 
role of NDRG1 in the neoplastic progression of cells still remains enigmatic.  Here we 
review the current literature that describes NDRG1 in cancer. 
 
In the past there have been several studies that report the significant downregulation 
of NDRG1 expression in neoplastic tissue, labelling it a tumour and metastasis 
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suppressor.  For instance, immunohistochemical analysis of NDRG1 expression, in 
tumour specimens from breast cancer patients, revealed that the NDRG1 protein levels 
were significantly reduced in tumour tissue compared to its high expression in its 
normal tissue counterpart[89].  Although no significant correlation with the histological 
grade or size of the tumours was observed, reduced NDRG1 expression showed a 
positive correlation with both lymph node and bone metastasis[89].  Moreover, the 
death risk for NDRG1-negative patients was 2.4 times higher than those positive for 
NDRG1.  Taken together, this data shows that breast cancer patients with NDRG1 
negative tumours have an increased likelihood of metastasis and a significantly less 
favourable prognosis[89;90].  Similar observations were also made in studies on 
colon[53;76], neuroblastoma[91], pancreas[92;93] and prostate cancers[90;94].  
Consistently, these studies reported low levels of NDRG1 associated with neoplastic 
tissue, metastasis and a poor patient outcome.   In support of these findings, 
Kurdistani et al.[54] were able to demonstrate primary tumour growth inhibition by 
NDRG1 in mouse xenografts, while ectopic overexpression of NDRG1 in breast and 
bladder cancer cell lines was able to limit soft agarose colony formation and reduce 
their proliferative capacity by as much as 70%.  On the other hand, overexpression of 
NDRG1 in colon and prostate tumour cells was able to suppress liver and lung 
metastasis, respectively, without affecting primary tumour growth[76;94].  The results 
of these studies raise the question as to whether NDRG1 has differential organ-specific 
functions, but support the role of NDRG1 as a tumour suppressor in the development 
of cancer.   
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In contrast, there is mounting evidence suggesting that NDRG1 is in fact an oncogene, 
promoting the process of tumourigenesis.   Cangul and associates[80;95] reported that 
NDRG1 levels were higher in tumour tissues of lung, liver, breast, smooth muscle, 
brain, kidney and skin cancers than their normal tissue counterparts.  Furthermore, 
NDRG1 was identified by microarray analysis as a gene upregulated during the 
progression of cervical tissue from normal to carcinoma in situ, to invasive 
adenocarcinoma[96].  In fact, NDRG1 expression in cervical adenocarcinoma was 
proposed as a poor prognostic indicator as it significantly associated with tumour 
diameter, angiogenesis, lymph node metastasis and invasion[97].  Additionally, 
elevated levels of NDRG1 have been reported in colon[98;99], liver[100;101] and oral 
squamous cell carcinomas[102] while NDRG1 upregulation was reported during mouse 
and human skin tumourigenesis[91;103].   
 
Studies on patients suffering from squamous cell carcinoma of the oesophagus have 
also been conflicting.  In a Japanese cohort of 47 patients, real-time RT-PCR revealed 
that NDRG1 mRNA levels showed no correlation with histologic differentiation, lymph 
node metastasis or invasion.  However, low NDRG1 mRNA correlated with late stage 
tumours and a poor prognosis[104].  In contrast, in a Chinese study, using 
immunohistochemistry on 49 patients, NDRG1 was found to be reduced in tumour 
tissue.  However, no significant correlation between NDRG1 expression and tumour 
stage, differentiation, lymph node metastasis or prognosis was observed[105].  Again, 
conflicting data for the expression of NDRG1 in cancer is given.  However, each of 
these studies measured NDRG1 expression using different methods, namely real-time 
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RT-PCR and immunohistochemistry.  Since it has been shown that NDRG1 mRNA and 
protein levels do not always correlate (see section 1.7.2.) a direct comparison between 
these two studies cannot be made.  Additionally, discrepancies in the reported data 
may arise through the different genetic backgrounds of each cohort studied.   
 
As described above, reports have shown that NDRG1 is downregulated in cancer, 
whereas others claim the opposite.  Certainly, the conflicting evidence in the literature 
does not clarify the role of NDRG1 in carcinogenesis but does highlight the notion that 
NDRG1 may have a cell or tissue-specific function. The conflicting data may also be 
explained through cell culture variability and artefacts reflecting diverse genetic 
milieus.  Moreover, population based studies often emerge from varying genetic 
backgrounds and environments, which may influence the expression of the gene in 
question.   
 
1.7.5. The role of NDRG1 in differentiation 
Differentiation is best described as progressive cell maturation and specialisation of 
cells, and terminal differentiation is mostly associated with an irreversible and 
diminished proliferative capacity and is regulated by a host of spatiotemporal 
signalling networks, regulating the processes of proliferation, differentiation and 
apoptosis. Disruption of these pathways and misdirected signalling is often the cause 
of tumour initiation, growth and/or maintenance[106-109]. 
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NDRG1 was first described as a differentiation associated gene through differential 
display technique during the in vitro differentiation of the colon carcinoma cell line, 
HT29-D4[53].  This finding has been replicated in subsequent studies using different 
systems of differentiation.  Indeed, within specific cellular contexts transforming 
growth factor-β[110], nerve growth factor[39], all-trans retinoic acid[102;111;112] and 
1,25-(OH)2 vitamin D3[113] all induced differentiated phenotypes coupled with a 
marked increase in NDRG1 expression.  Likewise phorbol esters, well described 
inducers of differentiation, were able to induce NDRG1 expression in 
keratinocytes[114], monocytic U937 cells[113;115] and trophoblasts[116].  
Furthermore, ectopic overexpression of NDRG1 in the metastatic colon carcinoma cell 
line, SW620, induced changes consistent with colonic epithelial cell differentiation[66]. 
Here, differentiation markers such as alkaline phosphatase, carcinoembryonic antigen 
and E-cadherin were induced by exogenous NDRG1 overexpression.  Thus, not only is 
NDRG1 a product of the differentiation process, but also has the potential to induce 
the expression of markers consistent with differentiation, depending on the cellular 
context.  
 
The transcription factors N-Myc and c-Myc are proto-oncogenes which have been 
implicated in the differentiation and maturation of tissue, particularly during 
embryogenesis[117;118].  Notably, increases in NDRG1 levels during tissue maturation 
are coupled with a decrease in N-Myc or c-Myc levels[58;62;112].  Moreover, in N-Myc 
deficient mice, a 20-fold increase in NDRG1 levels was recorded[62].  Conversely, 
treatment of estrogen receptor-α positive breast cancer cell lines with 17β-estradiol 
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resulted in a marked increase in cellular proliferation and c-Myc expression, while 
NDRG1 levels were decreased[119]. Moreover, a direct interaction of Myc proteins 
with the NDRG1 core promoter region (from -33 bp to +103 bp) was demonstrated in 
HeLa cells by chromatin immunoprecipitation[112].  In summary, this data points to a 
direct but inverse relationship between NDRG1 and MYC genes and implicates NDRG1 
in the process of cell maturation, differentiation and associated growth arrest.   
 
1.7.6. NDRG1 in the cell cycle and apoptosis 
The cell cycle consists of a series of tightly regulated events that lead to the duplication 
and equal distribution of genome replicas to daughter cells.  The cell cycle is divided 
into four distinct phases, G1 (Gap 1) phase, S (synthesis) phase and G2 phase and M 
(mitosis) phase.  In order to ensure that accurate, error free progeny cells are 
produced, a series of cell cycle checkpoints must be passed.    The G1/S checkpoint 
monitors DNA integrity while the G2/M checkpoint ensures that DNA replication is 
complete.  Finally, the spindle checkpoint ensures that distribution of chromosomes to 
daughter cells is equal.  If errors are present in the cell, the cell has one of two fates; 
either arrest the cell cycle and repair errors in the cell, or undergo apoptosis if the DNA 
integrity cannot be restored[120].   
 
The implication that NDRG1 may play a part in the cell cycle arose through the 
observation that NDRG1 levels increased during differentiation and growth arrest.  
Analysis throughout the cell cycle of normal mammary epithelial cells revealed that 
NDRG1 mRNA levels are biphasic, where expression peaked at the G1 and G2/M phases 
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and was lowest at the S phase[54].  Interestingly, in the breast tumour cell line 
MDAMB435, NDRG1 mRNA levels were unchanged throughout the cell cycle, 
suggesting that NDRG1 may contribute to carcinogenesis via deregulation of the cell 
cycle[54]. This biphasic, cell cycle-associated NDRG1 mRNA expression has not been 
reported elsewhere. The half-life of NDRG1 mRNA is approximately 4h [70], consistent 
with the mRNA half-life of other genes whose expression is tied to the cell cycle, such 
as p21[121] and p19
ARF
[122].  In contrast, NDRG1 protein half-life following return to 
normoxic culture conditions was reportedly 16 hours and 48 hours in A549[80] and 
SW480[71] cells, respectively.  The relatively high stability of the NDRG1 protein raises 
questions around the purpose of its biphasic cell cycle-regulated mRNA and needs 
further exploration in additional cell lines.       
 
Further experimental evidence that NDRG1 may be involved in the cell cycle was 
provided when NDRG1 was shown to maintain spindle structure during cell 
division[123].  Here, NDRG1 was shown to be a microtubule and centrosome 
associated protein, which participated in the spindle checkpoint in a p53-dependent 
manner[123].     
 
p53 is a tumour suppressor which is capable of inducing cell cycle arrest (at the G1 and 
G2 checkpoints) or apoptosis in response to DNA damage.  Indeed, p53 has been 
implicated in the regulation of NDRG1.  Transfection of p53 null mutant cells with a 
tetracycline-regulated p53-inducible system, revealed that NDRG1 mRNA increased in 
tandem with p53 expression levels[54].  In addition, DNA damaging agents induced 
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NDRG1 expression in a p53-dependent manner, coupled with nuclear 
translocation[54].  Similarly, Stein et al. identified NDRG1 as a gene necessary for p53-
dependent apoptosis[124].  Using a p53-inducible colon cancer cell system, the p53 
binding site, 406 bp upstream of the NDRG1 transcriptional start site, was 
identified[124].  Additionally, transient siRNA knockdown of p53 reduced NDRG1 
expression in these cells[124].    Together, these studies provide evidence that the 
reduced expression of NDRG1 observed in some cancers may be explained by the 
frequent loss of p53 expression[54].   
 
Paradoxically, NDRG1 has been implicated as a protective, anti-apoptotic protein in 
both colon cancer and acute myeloid leukaemic cells[125-127].  Irinotecan, or CPT-11, 
is a topoisomerase I inhibitor which is able to induce p53-mediated cell cycle arrest 
and apoptosis.  Treatment of colon cancer cells with CPT-11 resulted in a G2 cell cycle 
arrest which was characterised by a marked upregulation in NDRG1 expression.  
However, the same cells treated with antisense NDRG1 and CPT-11 underwent 
apoptosis, suggesting that NDRG1 expression has a protective, anti-apoptotic effect.  
Moreover, NDRG1-mediated CPT-11 resistance was shown to be independent of p53 
as CPT-11 resistance was also observed in non-functional p53 SW620 cells[125].  
Consistently,  in vivo studies found that high NDRG1 expression imparted chemo-
resistance to CPT-11 in patients suffering from colorectal cancer[126;127].  Similarly, in 
acute myeloid leukaemic cells treated with a camptothecin analog, downregulation of 
NDRG1 expression was associated with apoptosis[128].     
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 1.7.7. NDRG1 in angiogenesis 
The progression of a tumour cell mass to an aggressive, metastatic malignancy is a 
stepwise process that takes advantage of several physiological systems in the body.  
Indeed, as a solid tumour mass grows, so too does its need for oxygen, nutrients and 
waste removal.  Angiogenesis (the formation of new blood vessels) and 
lymphangiogenesis (the formation of new lymph vessels) is an essential capability 
acquired by tumour cell masses to accommodate these needs[129].  In fact, tumour 
cells acquire the ability to produce angiogenic factors (cytokines) that are released into 
the tumour microenvironment and act on receptors on the surface of endothelial cells, 
thereby stimulating endothelial proliferation[49;130].  Not only does angio- and 
lymphangiogenesis alleviate resource pressure on the tumour cell mass, but also 
provides a portal through which shedding cancer cells may spread and metastasise to 
distant sites[49].  Indeed, this process is often coupled with the activation extracellular 
matrix (ECM) proteases, such as matrix metalloproteinases (MMPs), which remodel 
the ECM to facilitate tumour invasion and angiogenesis[129;131;132].   
 
Vascular endothelial growth factors (VEGF-A, -B, -C, and –D) are well characterised 
angiogenic cytokines.  Specifically, VEGF-A binds to its receptors, VEGFR-1 and -2 on 
the surface of vascular endothelial cells, inducing angiogenesis, while VEGF-C and-D 
that bind VEGFR-2 and -3 are predominantly responsible for lymphangiogenesis.  Other 
factors that play a role in angiogenesis include platelet-derived growth factors (PDGFs), 
as well as angiopoietin-1 (Ang-1) and -2 (Ang-2) amongst many that have been 
extensively reviewed[133-136].    
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The effect of NDRG1 expression on tumourigenesis in mouse xenograft models, using 
colon and prostate cancer cells showed that either reduced or overexpressed NDRG1 
had no effect on tumour growth[94;125].  However, while Maruyama et al. [93] 
showed that ectopic NDRG1 overexpression had no effect on cellular proliferation in 
vitro, pancreatic ductal adenocarcinoma cells overexpressing NDRG1 showed a notable 
decrease in tumourigenicity in a mouse xenograft model.  This disparity between in 
vitro and in vivo effects of NDRG1 was suggested to be the result of the tumour 
microenvironment[93].  In fact, pancreatic cells expressing high levels of NDRG1 were 
shown to have reduced levels of VEGF-A, whilst in vivo studies showed that the 
angiogenic potential of pancreatic ductal adenocarcinomas was compromised in 
tumours expressing high levels of NDRG1[93].  The mechanism through which NDRG1 
exerted this anti-angiogenic effect was through the attenuation of nuclear factor-κB 
(NF-κB) signalling[137].  Indeed, NDRG1 expression led to a decrease in inhibitor of κB 
kinase (IKK) β expression and IκBα phosphorylation, thereby reducing nuclear 
translocation of p65 and p50, as well as their binding to the NF-κB motif.  This 
inhibition of NF-κB signalling, suppressed expression of VEGF-A, amongst other 
genes[137].  Consistently, treatment of glioblastoma and gastric cancer cell lines with 
the anti-tumour, anti-angiogenic drugs, ZD6474 and mycophenolic acid, was 
characterised by a significant induction in NDRG1 mRNA levels[138;139].        
 
In contradiction to the above findings that NDRG1 is an anti-angiogenic factor, a report 
examining cervical adenocarcinoma specimens implicated NDRG1 as pro-
angiogenic[97].  Here, high NDRG1 expression was significantly associated with 
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increased microvessel density and VEGF-A expression, making NDRG1 a poor 
prognostic indicator for cervical adenocarcinoma[97].   
 
Once again, a singular role for NDRG1 in angiogenesis cannot be resolved because of 
contradictory observations.  Reports indicating NDRG1 inhibits angiogenesis in 
pancreatic cancer are internally consistent and identify altered NF-κB signalling as the 
mechanism. Data that NDRG1 is pro-angiogenic is merely associative in cervical 
adenocarcinoma, however, it does highlight the fact that NDRG1s influence on 
angiogenesis is not simplistic, and requires further exploration.   
 
1.7.8. Regulation of NDRG1 expression 
Not surprisingly, the aberrant, albeit varying, expression of NDRG1 in a wide range of 
tumours, as well as its potential tumour suppressor and oncogenic functions, spurred a 
strong interest in the mechanisms underlying NDRG1 regulation and expression.   
 
Analysis of the 5’-untranslated region of NDRG1 identified two potential CpG islands.  
One well characterised mechanism of transcriptional silencing, often observed in 
different cancers, is atypical methylation of cytosines positioned 5’ to guanosines 
(CpG) in the promoter of tumour and metastasis suppressor genes[89;140;141].  
Promoter methylation was implicated in the suppression of NDRG1 expression, in both 
breast and colon cancer cell lines, since treatment with 5’-aza-2’-dexoycytidine (an 
inhibitor of DNA methylation) lead to an increase of both NDRG1 mRNA and protein 
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levels[76;89].  Additionally, NDRG1 induction by treatment with trichostatin A 
implicated histone deacetylation in NDRG1 suppression[76].   
 
In silico analysis of the 5’-untranslated region of NDRG1 reveals the presence of 
multiple putative transcription factor binding sites.  Indeed, research efforts have 
validated the direct interaction between these factors and the NDRG1 promoter, while 
others have merely established some form of correlative relationship.  Since this data 
has been extensively reviewed by Ellen et al.[142] and Kovacevic et al.[57], this section 
will focus on transcriptional regulation most pertinent to this research project. 
 
In addition to the evidence that NDRG1 is a target of both the Myc and p53 proteins 
(see sections 1.7.4 and 1.7.5), hypoxia-inducible factor 1 (HIF-1) has also been 
implicated in its regulation.  HIF-1 is a heterodimeric transcription factor that responds 
to low oxygen tension by, together with co-factors (e.g. AP-1), activating transcription 
of target genes that alleviate this stress[143;144].  The complex is composed of two 
subunits α and β.  HIF-1β is constitutively expressed whilst HIF-1α levels respond to the 
hypoxic (low oxygen) state and are largely regulated at the post-transcriptional 
level[143].  Although HIF-1α is constitutively expressed, under conditions of normoxia 
(adequate oxygen) it is targeted for degradation.  This process is regulated by the 
prolyl-4-hydroxylases (PHD), which hydroxylate HIF-1α prolyl residues, facilitating the 
interaction between HIF-1α and the Von Hippel-Lindau (VHL) tumour suppressor, and 
thereby its proteasomal degradation[145].  In addition, HIF-1α is prevented from 
interacting with co-factors through the activity of Factor Inhibiting HIF (FIH), an 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 30 
asparagine hydroxylase[146;147].  Under conditions of hypoxia, oxygen-dependent 
prolyl and asparagine hydroxylases are inhibited, HIF-1α accumulates, translocates to 
the nucleus where it heterodimerises with HIF-1β and activates transcription of target 
genes by binding to hypoxia-responsive elements, together with co-factors[148].   
 
A number of studies have reported that NDRG1 is strongly induced by hypoxia and 
hypoxia mimicking agents[55;56;80;85;149;150].   Both HIF-1α regulating enzymes, FIH 
and PHD, require iron (Fe
2+
) for activity.  Thus, iron chelators (such as deferoxamine) 
and transition metals, such as cobalt (Co
2+
) and nickel (Ni
2+
), through competitive 
binding are capable of stabilising HIF-1α[151].  Indeed, the NDRG1 response, in HIF-1α 
double knockout mouse embryonic fibroblasts (HIF-1α
-/-
 MEF), to short term exposure 
of hypoxia, Co
2+
 and Ni
2+
 was diminished compared to HIF-1α proficient (HIF-1α
+/+
 
MEF) cells.  Moreover, hypoxia mimetics, deferoxamine and okadaic acid, were not 
able to induce NDRG1 core promoter activity in HIF-1α
-/- 
MEF cells to the same extent 
as in HIF-1α proficient cells[80;85;150].  What is more, in 786-O cells, which are VHL 
deficient and therefore constitutively express HIF-1α, NDRG1 had high basal, but 
uninducible levels compared to normal cells[152].  This data, together with the 
observation that the NDRG1 promoter contains putative hypoxia responsive elements, 
(HREs) at -1376 bp and -7503 bp[150], supports the hypothesis that HIF-1α activates 
NDRG1 expression in response to hypoxia.  However, direct binding of HIF-1α to the 
HREs in the NDRG1 promoter has not been reported.  Additionally, according to Zhang 
et al.[153] the HREs in the NDRG1 promoter contain only 4 (ACGT) of the nine bases of 
the consensus hypoxia response motif.  Moreover, NDRG1 accumulation in HIF-1α
-/- 
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MEF cells is observed after long term exposure to hypoxia[80], suggesting that NDRG1 
may be upregulated in a HIF-1-independent manner.   
 
AP-1 is a dimeric transcription factor composed of members of the Jun family of 
proteins, comprising of c-Jun, JunB, JunD, that form homodimers or heterodimerise 
with the Fos family proteins (c-Fos, Fos B, Fra-1 and Fra-2) [154;155].  AP-1 can activate 
or repress transcription of target genes by binding to AP-1 consensus DNA binding 
sites, TGAG/CTCA, also known as TPA 12-o-tetradecanoylphorbol-13-acetate response 
elements (TREs) and cAMP response elements (CREs), TGACGTCA, found in the 
promoter and enhancer regions of target genes [156;157].  AP-1 has been implicated in 
many biological processes and regulates numerous genes involved in proliferation, 
differentiation and apoptosis[155;158;159]. In addition, both c-Jun and c-Fos have 
been linked with neoplastic transformation and progression.  Activation of AP-1 may 
be induced by a number of growth factors, stress, hormones, reactive oxygen species 
and ultraviolet (UV) radiation, which signal through mitogen activated protein kinase 
(MAPK) pathways such as Jun amino-terminal kinase (JNK), p38 MAPK and 
extracellular-signal-related kinase (ERK)[155].  During hypoxia, AP-1 coordinates with 
HIF-1 to facilitate hypoxia induced gene expression[148].  However, independently of 
HIF-1, hypoxia can induce and activate AP-1 through increases in intracellular calcium 
(Ca
2+
).  In HIF-1α proficient cells, BAPTA-AM (a Ca
2+
 chelator) completely abrogated 
NDRG1 upregulation by Ni
2+
 and hypoxia, implicating intracellular Ca
2+
 and its effectors 
(e.g. AP-1) in NDRG1 regulation[85].   In fact, Ca
2+
 ionophore was able to induce 
NDRG1 expression in both HIF -proficient and -deficient fibroblasts and an AP-1 
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dominant negative was able to abrogate hypoxia-mediated NDRG1 upregulation[86]. 
Thus, under hypoxic conditions, an increase in intracellular Ca
2+
 activates a HIF-1-
independent, activating protein-1 (AP-1)-dependent pathway that also regulates 
NDRG1 expression.   
 
Taken together, this data suggests that hypoxia-induced NDRG1 expression may be 
regulated by co-operative binding of transcription factors to the NDRG1 promoter and 
not necessarily by direct binding of HIF-1. 
 
In addition to HIF-1 and AP-1, early growth response-1 (EGR-1) has been implicated in 
the hypoxic regulation of NDRG1.  EGR-1 is a member of the immediate early gene 
family, and rapidly and transiently responds to stimuli to regulate genes implicated in 
cell proliferation, differentiation and survival.  EGR-1 contains three zinc finger motifs 
and regulates transcription through binding to GC-rich elements such as 5’-
GCGGGGGCG-3’ or the consensus sequence ′5-GCG(T/G)GGGCG-3’[160]. Under 
conditions of hypoxia, EGR-1 is synthesised in a HIF-1α-independent, Elk-dependent 
manner through the activation of protein kinase C (PKC) and ERK MAPK 
signalling[161;162].  In both murine RAW264.7 macrophage cells and A549 lung cancer 
cells, hypoxia and deferoxamine were able to induce activity of an NDRG1 reporter 
plasmid. Furthermore, mutation of the EGR-1 binding site, within the reporter, was 
able to abrogate promoter activity in RAW264.7 cells, and binding of EGR-1 to this site 
was demonstrated by electrophoretic mobility shift assay (EMSA)[153].   However, 
Zhang et al. did not demonstrate in vivo binding of EGR-1 to the NDRG1 promoter.   
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It has become apparent that NDRG1 must play an important role in the hypoxic 
response.  The data above reveals that multiple pathways converge on the NDRG1 
promoter in response to hypoxia.  Certainly, if the role of NDRG1 in angiogenesis was 
more clearly defined perhaps NDRG1 and its activators could be targets for cancer 
therapy. 
 
1.8. Significance 
In 1985 the first formal proposal to decode the DNA sequence of the human genome 
was put forward[163].  Fifteen years later the first survey of the entire human genome 
was announced[164] - a pinnacle event in the history of modern science, which has 
provided us with the framework to move forward in translational research.  Aptly 
stated by Venter et al. [165], “It
 
provides the boundaries for scientific inquiry. The 
sequence is
 
only the first level of understanding of the genome. All genes
 
and their 
control elements must be identified; their functions,
 
in concert as well as in isolation, 
defined; their sequence variation
 
worldwide described; and the relation between 
genome variation
 
and specific phenotypic characteristics determined. Now we know
 
what we have to explain.”   
Our laboratory identified NDRG1 as a gene with altered expression in oesophageal 
tumour tissue when compared to normal tissue.  Given the elusive function of this 
gene as well as the conflicting evidence in the literature for its role in cancer, we 
sought to explain its role in OSCC, a disease that occurs with a high incidence in South 
Africa.  
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1.9. Project aims 
The aims of this study are: 
 
(i) To determine the expression status of NDRG1 in archived tissue of OSCC 
patients from South Africa, as well as in cultured OSCC cell lines. 
 
(ii) To characterise the functional relevance of NDRG1 expression in cancer cells. 
 
(iii) To determine the transcriptional regulatory mechanisms responsible for 
NDRG1 expression in OSCC cell lines. 
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CHAPTER 2 
NDRG1 EXPRESSION IN OESOPHAGEAL SQUAMOUS CELL CARCINOMA 
PATIENT MATERIAL AND CULTURED CELLS 
 
 
2.1. INTRODUCTION 
The stepwise progression of a cell from a normal to a transformed, malignant state is 
driven by temporal and spatial changes in gene expression.  In fact, progression from 
dysplastic precursor lesions, to carcinoma in situ, to invasive carcinoma, and the 
maintenance of the tumourigenic phenotype, is made possible through the silencing or 
inappropriate expression of genes that regulate cellular processes such as the cell 
cycle, proliferation, differentiation, apoptosis, angiogenesis and DNA repair.    
Procedures for monitoring genome-wide changes in gene expression and 
transcriptome profiling have been available for many years due to rapid technological 
advances and conceptual advances about cell function and molecular biology.   
Techniques such as differential display reverse transcription PCR (DDRT-PCR), as well 
as microarray analysis, deepen our understanding of the diseased state through the 
simultaneous examination of the expression of multiple genes, and the identification 
of genes that are differentially expressed[166].   
 
Squamous cell carcinoma of the oesophagus is major problem in the developing world 
and a better understanding of the molecular nature of OSCC and the underpinning 
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tumourigenic processes is required in order to devise improved screening methods and 
rational drug design.   In our laboratory a preliminary study was conducted, using 
DDRT-PCR and microaray analysis, in order to identify genes that are expressed 
differently in oesophageal squamous cell carcinoma tissue compared to normal 
oesophageal tissue.  Amongst the genes deregulated, NDRG1 was identified as having 
altered expression in tumour tissue compared to that of normal tissue.   
 
To date, the precise function of NDRG1, and specifically the role of NDRG1 in 
tumourigenesis, remains enigmatic.  Paradoxically, research has suggested both a 
tumour-suppressor as well as an oncogenic role for NDRG1, which may be tissue or cell 
type specific.  As presented in chapter 1, previous studies describe the downregulation 
of NDRG1 protein and mRNA in OSCC but report inconsistent data with respect to 
tumour stage, differentiation and prognosis[104;105].     While much research has 
been conducted on NDRG1’s expression in cancer, a defined role for this protein in 
tumour biology, as well as normal cell and tissue systems is yet to be put defined.   
 
This chapter describes the characterisation of NDRG1 protein and mRNA expression in 
normal and cancerous squamous epithelium of the oesophagus, derived from a South 
African cohort of patients, as well as the expression of NDRG1 in our panel of cultured 
oesophageal squamous cell carcinoma cells.    
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2.2. RESULTS 
2.2.1. Quantitative real-time RT-PCR analysis of NDRG1 expression in biopsies of 
oesophageal  squamous cell carcinoma patients 
To determine the expression status of NDRG1 in oesophageal tumour tissue and 
normal tissue, RNA from a sample of normal (n=6) and oesophageal cancer (n=8) tissue 
biopsies was subjected to real-time RT-PCR analysis, using primers designed to 
specifically amplify NDRG1 mRNA.  Only samples where RNA was of high quality, as 
determined by RNA gel electrophoresis, were included.  Each RNA sample was 
normalised to the expression of the cyclophilin D (peptidylprolyl isomerase D) and β-
glucuronidase (gusB) genes in order to accommodate for possible differences in RNA 
quantity and quality.  In this case, two house-keeping genes were utilised as this is 
recommended when examining gene expression in human tissue biopsies [167].   
 
The specificity of the real-time RT-PCR was assessed by melting curve analysis (data 
not shown) and electrophoresis of the PCR product (Fig 2.1.A).  Real-time RT-PCR data 
was then analysed using the comparative threshold cycle (CT) method  to compute the 
expression fold change between samples[168]. Real-time RT-PCR using RNA isolated 
from OSCC tissue and normal tissue confirmed that the relative expression of NDRG1 
was significantly higher in tumour tissue compared to normal tissue (at least 2-fold, p< 
0.05)(Fig 2.1.B) and that a distinctly broad range of NDRG1 expression in tumour 
specimens was observed. 
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Figure 2.1.  Expression of NDRG1 mRNA in normal and oesophageal cancer tissues.  
A. Specificity of NDRG1, GUSB and Cyclophilin D real-time RT-PCR was confirmed by 
agarose gel electrophoresis of real-time RT-PCR products alongside GeneRuler DNA 
Ladder (M; Fermentas) (NTC - no template control). B. Quantitative real-time RT-PCR 
analysis (using comparative threshold cycle method) revealing the upregulation of 
NDRG1 mRNA in oesophageal cancer tissue biopsies compared to normal tissue 
biopsies [normal (n = 6), tumour (n = 8), *p < 0.05]. The Box-and-Whisker plot was 
generated using Graphpad Prism 5 software.  
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2.2.2. Immunohistochemical analysis of NDRG1 expression in oesophageal 
squamous cell carcinoma tissue and adjacent normal tissue 
Although our analysis strongly suggested an overexpression of NDRG1 mRNA levels in 
tumour tissue compared to normal tissue, this result could reflect the small number of 
samples analysed.  Since additional samples could not be readily obtained, we next 
examined the level of NDRG1 protein expression in archived, paraffin embedded 
tumour and normal tissue specimens.  Measuring NDRG1 protein levels directly also 
addressed the problem that NDRG1 mRNA and protein levels within a tissue do not 
always correlate[71], so it was important to determine whether NDRG1 protein levels 
were also upregulated in patient material.    
 
NDRG1 protein expression was analysed using antibodies raised against NDRG1, and 
visualized using peroxidase/diaminobenzidine (DAB) staining on tissue sections cut 
from archived tissue blocks of OSCC patients.  This allowed for the examination of both 
levels of protein expression as well as localisation of NDRG1 in the normal and 
oesophageal cancer tissue sections.  Tissue sections of squamous cell carcinoma and 
adjacent normal tissue from eighty-three patients were examined.  Patients ranged in 
age from 23 to 80 years and were comprised of twenty females and sixty-three males.  
The bias in the male to female ratio in the samples analysed reflect the higher 
incidence of the disease in males, and also the availability of tissues.  The average 
survival time of the eighty-three patients was 3.2 years (range: 0-17 years). Five 
percent of patients presented with either stage 0 or I disease, 50 % with stage II and 34 
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% with stage III disease.  Staging data for 11 % of patients was not attainable.  Given 
the heterogenous nature of the NDRG1 stain, as well as the subjective nature of 
immunohistochemical scoring, Axiovision software (version 4.7) was used to quantitate 
NDRG1 positivity in oesophageal tissue sections. Three fields of view, per tumour or 
normal specimen, under 200 x maginification were analysed.  Briefly, greyscale images 
of stained sections were captured using a Zeiss AxioCamHR camera. Using the 
Axiovosion software, regions containing epithelial cells/tumour cells were selected (i.e. 
the stroma excluded) and the average grey-scale intensity per pixel determined.   
 
 
 
 
 
 
 
 
 
Figure 2.2.  Overexpression of NDRG1 protein in squamous cell carcinoma of the 
oesophagus compared to normal oesophageal epithelium.  Quantification of NDRG1 
protein expression in normal and oesophageal cancer tissue sections.  
Immunohistochemistry was quantified using AxioVision version 4.7 software 
(*p<0.0001). A total of three views per slide (magnification 200x) were used to 
calculate the average signal intensity per sample.  
* 
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Examination of the eighty-three patient specimens revealed that NDRG1 protein 
expression was approximately 2.6-fold higher (p<0.0001) (Fig 2.2) in cancer tissues 
compared to normal tissues, using the AxioVision quantification software.  This 
confirmed our initial observations using quantitative real-time RT-PCR.   
 
In normal esophageal epithelial tissue, NDRG1 protein displayed an interesting bi-
modal pattern of expression.  NDRG1 protein was exclusively associated with the 
plasma membrane of basal cells of the epithelium, whereas supra-basal cells exhibited 
nuclear staining with a blush of cytoplasmic staining as they matured towards the 
surface of the esophageal epithelium (Fig. 2.3.A). The flattened luminal surface 
epithelial cells did not stain for NDRG1.  The abrupt change in the cellular location of 
the NDRG1 protein from plasma membrane-associated (in basal cells) to exclusively 
nuclear/cytoplasmic as the epithelial cells mature, suggests that the subcellular 
localization of NDRG1 may be associated with the differentiation status of oesophageal 
epithelial cells.  
 
The NDRG1 protein was exclusively localised in the plasma membrane of dysplastic 
cells (Fig. 2.3.B) regardless of the stage of dysplasia. This expression pattern was 
identical to that displayed by the basal layer cells of the normal esophageal epithelium.  
In contrast, tumours of the oesophageal epithelium displayed a mixed staining pattern 
where membrane, cytoplasmic and nuclear localised NDRG1 was observed.  
Specifically,  in  well  differentiated  tumours,  characterised  by the presence of keratin  
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Figure 2.3.  Expression and localisation pattern of NDRG1 in normal and dysplastic 
oesophageal epithelium.  Representative images showing immunohistochemical 
staining for NDRG1 expression in sections of normal (A; magnification 250x) and 
dysplastic (B; magnification 200x) oesophageal epithelium.  The basal layer of cells (BL) 
in normal epithelium displayed plasma membrane staining for NDRG1 protein, 
whereas suprabasal and mature cells displayed cytoplasmic and nuclear staining for 
NDRG1.  Areas of dysplasia (DYS) displayed intense, plasma membrane-associated 
NDRG1 expression.    
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pearls, plasma membrane, cytoplasmic and mixed (cytoplasmic and nuclear) staining 
for NDRG1 was noted.  This staining pattern was coupled with a marked increase in the 
intensity of NDRG1.  Keratinised pearls at the centre of tumour nests stained 
predominantly negative for NDRG1.  Basal-like cells, distal from the keratin pearl, 
display plasma membrane-associated NDRG1.  Cells closer to the keratin pearl (and 
with a more mature appearance, morphologically) display cytoplasmic and nuclear 
staining with varying intensity (Fig 2.4. A and B).  Correspondingly, moderately 
differentiated tumours also exhibit a tiered NDRG1 expression pattern.  Here, keratin 
pearls are absent and the centre of the tumour nest is characterised by strong 
cytoplasmic and nuclear NDRG1 expression, with varying intensity (Fig 2.5. A). NDRG1 
staining at the periphery of the tumour nest was either plasma membrane-associated 
or altogether lost.  In contrast, poorly differentiated tumours displayed strikingly 
predominant plasma membrane-associated NDRG1.  However, cells with nuclear and 
cytoplasmic positivity were also sporadically observed (Fig 2.5. B). The specificity of 
these staining patterns was confirmed through using NDRG1 antibodies from three 
different sources (see materials and methods, section 6.2), since it is possible that the 
variation in NDRG1 staining reported in the literature could be due to the use of 
different antibodies.   
 
Since a relationship between NDRG1 expression and differentiation emerged, we 
wanted to determine whether this was unique to oesophageal epithelium or whether  
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Figure 2.4.  Expression and localisation pattern of NDRG1 in well differentiated 
squamous cell carcinoma of the oesophagus.  Representative images showing 
immunohistochemical detection of NDRG1 expression in sections of well differentiated 
oesophageal cancer (A and B; magnification 200x).  Tumour nests arranged around 
keratin pearls (KP) stained positive for NDRG1 in the nucleus, plasma membrane and 
cytoplasm of cells.   
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Figure 2.5.  Expression and localisation pattern of NDRG1 in moderately and poorly 
differentiated squamous cell carcinoma of the oesophagus.  Representative images 
showing immunohistochemical staining of NDRG1 expression in sections of moderately 
differentiated (A; magnification 200x) and poorly differentiated (B; magnification 200x) 
OSCC.  Moderately differentiated tumours were characterised by the presence of 
mixed nuclear, cytoplasmic and plasma membrane localised NDRG1, as well as 
unstained cells. In poorly differentiated tumours NDRG1 predominantly localised to 
the plasma membrane.   
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Figure 2.6.  Expression and localisation pattern of NDRG1 in normal cervical 
squamous epithelium (magnification 200x). Cells adjacent to the basement 
membrane (BM) showed plasma membrane staining for NDRG1, whereas mature cells 
displayed cytoplasmic and nuclear staining for NDRG1.   
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it was present in other types of epithelium.  Immunohistochemical staining for NDRG1 
was therefore carried out on sections of normal cervical epithelium.  As observed with 
normal oesophageal epithelium, NDRG1 was localised exclusively in the plasma 
membrane of cells adjacent to the basement membrane of the cervical epithelium.  
Similarly, NDRG1 expression localised in the cytoplasm and nucleus of maturing cells 
(Fig. 2.6.).  The immunohistochemical staining of NDRG1 in normal oesophageal and  
cervical squamous  epithelium  are  remarkably similar and both suggest a relationship 
between NDRG1, cellular localisation and differentiation.      
 
2.2.3. Expression of NDRG1 in cultured oesophageal squamous cell carcinoma cells 
Since NDRG1 was observed to be overexpressed in oesophageal cancer tissue 
specimens, we next investigated the expression levels of NDRG1 mRNA and protein in 
cultured OSCC cell lines.  Protein and RNA were prepared from cultured cancer cells 
grown at subconfluence overnight.  Western blot analysis and real-time RT-PCR was 
used to evaluate NDRG1 expression levels in WHCO1, WHCO5, WHCO6, KYSE70, 
KYSE180, KYSE450 and KYSE520 cell lines.  Western blot analysis revealed that NDRG1 
was expressed in all of the cell lines, with highest protein levels observed in WHCO1 
and KYSE520 cells.  KYSE70, KYSE180 and KYSE450 cells expressed low levels of NDRG1 
while the remainder of the cell lines, WHCO5 and WHCO6, expressed moderate 
NDRG1 levels (Fig 2.7.A).  Similarly, NDRG1 mRNA expression was highest in WHCO1 
cells. Whereas KYSE70 and KYSE180 cells showed relatively low levels of NDRG1 mRNA  
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Figure 2.7. NDRG1 is differentially expressed in cultured oesophageal squamous cell 
carcinoma cell lines.  A. Western blot analysis of NDRG1 in cultured OSCC cells reveals 
that NDRG1 is differentially expressed.  Forty micrograms of whole cell lysate from 
cells cultured overnight was subjected to Western blot analysis. β-tubulin was used as 
a control for protein loading. Results shown are representative of Western blots 
performed in triplicate. B. Real-time RT-PCR analysis of NDRG1 in oesophageal cancer 
cell lines, WHCO1, WHCO5, WHCO6, KYSE70, KYSE180, KYSE450 and KYSE520, cultured 
overnight.  Results shown are the mean ± SD of experiments performed in triplicate 
and repeated at least two times. 
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expression, WHCO6 cells expressed the lowest levels of NDRG1 mRNA, some 30-fold 
lower than that observed in WHCO1 cells, yet expressed high levels of NDRG1 protein 
(Fig 2.7.B).   In agreement with patient-derived data, this shows that NDRG1 is 
differentially expressed at both the mRNA and protein level in cultured cells. However, 
the discrepancy between protein levels and mRNA levels in some of the cell lines are 
intriguing and is perhaps indicative of transcriptional as well as post-translational 
mechanisms of NDRG1 expression regulation.  Indeed, analysis of NDRG1 protein and 
mRNA stability within these cells may be appropriate. 
 
2.2.4. Subcellular localisation of NDRG1 in cultured oesophageal squamous cell 
carcinoma cells 
In patient specimens, NDRG1 was detected in the plasma membrane, cytoplasm and 
nucleus and the expression patterns appeared to be related, in part, to differentiation.  
Given this interesting staining pattern of NDRG1 in patient tissue, we examined the 
localisation of NDRG1 in cultured OSCC cell lines.   
 
NDRG1 subcellular localisation was determined by immunofluorescence staining of 
cultured OSCC cells, grown for 24 hours on glass coverslips.  Fixed cells were probed 
with primary antibodies to NDRG1 as well as E-cadherin (a plasma membrane 
associated protein) and secondary antibodies labelled with Cy3 and Alexa-488 fluors, 
respectively (see materials and methods, section 6.10).  4’,6’-diamidino-2’-
phenylindole  dihydrochloride  (DAPI)  was  used  to  stain  nucleic  acid  and  reveal the  
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Figure 2.8. Localisation of NDRG1 in cultured oesophageal cancer cell lines.  
Representative fluorescent images for NDRG1 and E-cadherin expression as well as 
blue nuclear staining (DAPI) in cultured KYSE30 OSCC cells (maginification 400x).  
NDRG1 localised predominantly in the cytoplasm of cultured cells, unlike E-cadherin, 
which was localised to the plasma membrane. 
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location of cell nuclei.  Whereas E-cadherin was, as expected, located in the plasma 
membrane, NDRG1 appeared to localise largely in the cytoplasm, with no predominant 
nuclear or plasma membrane localisation (Fig. 2.8.).  This staining pattern was or 
nucleus.  The cytoplasmic localisation of NDRG1 was explored further in order to 
ascertain which subcellular organelles may be associated with NDRG1 expression. 
observed across the panel of seven OSCC cell lines.   In contrast to that seen in patient 
material, NDRG1 did not show a strong association with either the plasma membrane 
NDRG1 localisation in cultured cells was determined using an antibody to NDRG1 and a 
Cy3-labelled secondary antibody.  Cells were examined under high power 
magnification using a Axiovert 200M microscope (Zeiss). KYSE450 and WHCO1 cells 
were examined based on the expression data generated by western blot, as seen in 
figure 2.7. Close inspection of stained cells revealed a punctate staining pattern for 
NDRG1, which on occasion appeared more concentrated in the perinuclear region (Fig. 
2.9.).   
 
 
2.3. DISCUSSION 
In a preliminary study in our laboratory, DDRT-PCR and cDNA microarray technology 
was used to examine the global gene expression patterns of normal and oesophageal 
cancer tissues.  Here, NDRG1 was identified as a deregulated gene in OSCC.  This study, 
confirmed, using real time RT-PCR and immunohistochemistry, that NDRG1 mRNA and 
protein  is  overexpressed  in  oesophageal  cancer  tissue  compared  to  normal tissue.  
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Figure 2.9.  Immunofluorescent localisation of NDRG1 in KYSE450 and WHCO1 cells.  
Immunofluorescent analysis of NDRG1 subcellular localisation in cultured KYSE450 and 
WHCO1 cells (magnification 1000x) reveals a punctate pattern of NDRG1 expression, 
which predominates in the cytoplasm and occasionally appears perinuclear.  DAPI 
staining for nuclei is shown. 
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Real-time RT-PCR of RNA isolated from patient biopsies revealed that NDRG1 was 
overexpressed in tumour tissue compared to normal tissue. Although our results of 
NDRG1 mRNA overexpression were obtained from only six normal and eight cancer 
biopsies, this observation was consistent with the immunohistochemical analysis of 
NDRG1 in a cohort of eighty-three patients reported here.  This finding is in agreement 
with an earlier study reporting an approximate 4-fold increase of NDRG1 mRNA in 
OSCC[169]. In contrast, a study on a cohort of 47 Japanese OSCC patients reported 
NDRG1 mRNA expression levels to be significantly lower in advanced stage tumours 
(i.e. stage II-IV) compared to early stage tumour (stage 0-I)[104].  This discrepancy may 
be explained by differences in patient profiles, differences in population genetics or 
possibly different  aetiological  profiles  of  the  cancer,  although  these are unlikely.  A   
more likely scenario is that differences in reported NDRG1 expression probably reflect 
differences in methodological approaches.  It should be noted that the majority of 
OSCC patients (84 %) used in our study presented with advanced cancer  (stage II-III), 
similar to the patient sample used by Ando et al.[104].  However, Ando et al.[104] 
normalised their real-time RT-PCR data using the house-keeping gene, glyceraldehyde 
3-phosphate dehydrogenase (gapdh).  GAPDH as well as β-actin mRNA expression is 
reportedly deregulated in some cancers, making these genes inappropriate 
normalisers for real-time RT-PCR[170-172].  Moreover, GAPDH mRNA was found to 
have significantly different expression levels in the same tissues from different 
donors[173].  The reliability of the Ando et al.[104] study may be greatly improved if 
more than one house-keeping gene were used in combination with, or as an 
alternative to, gapdh. Similarly, a previous immunohistochemical study described the 
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downregulation of NDRG1 protein in OSCC tissue specimens[105].  However, no 
NDRG1 positivity was associated with the plasma membrane of normal tissues, unlike 
our observation, and an earlier report that examined the expression of NDRG1 in a 
wide range of tissues [71].  A previous PhD study in our laboratory also observed 
membrane staining of NDRG1 in basal cells of the oesophageal epithelium, although 
only one antibody to NDRG1 was used in that study[174].  So whilst the study by Ando 
et al. should not be discounted, the poor quality of He and associates[105] 
immunohistochemical data undermines the veracity of their report.  The observation 
that the same staining pattern was obtained using three different antibodies for 
NDRG1 underscores our confidence in the immunohistochemical data presented here. 
 
In agreement with previous reports, we describe the membrane localisation of NDRG1 
in basal cells of the oesophageal epithelium[71] as well as the cytoplasmic and nuclear 
localisation in mature epithelial cells.  Indeed, examination of normal and tumour 
tissue counterparts revealed a staining pattern which paralleled cellular and tumour 
differentiation.  Our observation of a near identical staining pattern in cervical 
epithelium which correlates with that reported for intestinal epithelium[71] suggests 
that NDRG1 may function and be regulated, at least in part, in the same manner in 
some epithelial tissues in the body.   
 
The proliferative stem cell compartment of the oesophageal epithelium lies adjacent 
to the basement membrane. Stem cells in the basal compartment divide, giving rise to 
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transit amplifying daughter cells whose progressive specialization culminates in 
terminal differentiation and is often associated with a diminished proliferative 
capacity[106;107;109;175].  Membrane localised NDRG1, in areas of oesophageal 
epithelial dysplasia, mimics the staining pattern observed in cells adjacent to the 
basement membrane of normal epithelium.  This invites speculation that dysplastic 
cells could arise from the premalignant expansion of the stem cell compartment of the 
epithelium.  Additional work is required to explore this idea further. 
 
In the cultured OSCC cell system, NDRG1 did not localise to the plasma membrane or 
nucleus but rather predominated in a punctate cytoplasmic pattern.  Indeed, NDRG1 
has been described as an endosome-associated protein which, similarly, appears in a 
cytoplasmic, punctate profile in prostate cancer cells[78].  However, a punctate 
cytoplasmic stain could also be indicative of mitochondrial localisation.  Given that 
NDRG1 reportedly associates with mitochondria[71] and mitochondrial proteins[77] in 
other tissue and cell culture systems, this too is a possibility in cultured OSCC cells.  
The absence of distinctly nuclear or plasma membrane-associated NDRG1 in cultured 
cells (unlike in patient specimens) could be explained by culture conditions and the 
surrounding cellular milieu.  Indeed, tissue culture systems far from accurately mimic 
conditions within an intact tissue or tumour mass.  Hypoxia has been shown to 
increases cytoplasmic expression of NDRG1, but is insufficient for its membrane 
localisation in human hepatocellular carcinoma cell lines[101].  However, grown in 
vivo, within mouse xenografts, these same cells express NDRG1 in the plasma 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 56 
membrane[101].   This suggests that the tumour microenvironment may play a role in 
the recruitment of NDRG1 to the plasma membrane, a finding that should be 
considered when exploring NDRG1 function in vitro. Some of these issues will be 
explored at a later stage within this study.    
 
Although the precise function of NDRG1 remains enigmatic, numerous studies 
revealing altered expression of NDRG1 in tumour tissue relative to normal tissue 
suggesting that this protein may have a role in tumour biology.  A growing number of 
studies have implicated an oncogenic role for NDRG1 in neoplasia.  For example, 
elevated NDRG1 levels have been observed in oral squamous cell carcinoma[102], 
cervical adenocarcinoma[96;97], liver[100;101] and colon cancer[98;99], to mention 
but a few, where high NDRG1 levels correlated with metastasis, enhanced vascularity 
and a poor prognosis.  To our knowledge, our laboratory is the first to report the 
overexpression of NDRG1 protein in squamous cell carcinoma of the oesophagus.    
The significance of this finding depends on whether this overexpression is necessary to 
sustain the malignant phenotype; a question which is explored in the next chapter.  
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CHAPTER 3 
IMPACT OF NDRG1 EXPRESSION IN OSCC CELL LINES CULTURED IN AN 
ANCHORAGE-INDEPENDENT MANNER 
 
3.1. INTRODUCTION 
In the previous chapter we reported the overexpression of NDRG1 in primary 
oesophageal tumour tissue at both the mRNA and protein levels, relative to normal 
tissue.  This upregulation of NDRG1 expression suggests that it may have some 
functional importance in the initiation, maintenance and/or progression of 
oesophageal cancer.  Conflicting data has been reported with regards to NDRG1 
expression in OSCC[104;105;169], however, no functional in vitro studies have been 
published supporting an oncogenic or tumour suppressor role for NDRG1 in this 
cancer.   
 
Recently, it was reported that hypoxia induced expression of NDRG1 in the 
hepatocellular carcinoma cell line, Hep3B, but was not associated with the plasma 
membrane localisation of this protein[101].  On the other hand, NDRG1 in Hep3B cells, 
grown in vivo in mouse xenografts, showed a strong association with the plasma 
membrane.  Sibold et al.[101] therefore suggested that the tumour milieu influences 
the subcellular localisation of NDRG1 and may therefore have implications with 
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regards to NDRG1 function.  In fact, they proposed that plasma membrane-associated 
NDRG1 within the neoplastic microenvironment may be involved in signal 
transduction, cell mobility and/or cell adhesion[101].   
 
In sections of normal oesophageal tissue, we observed a change in localisation of 
NDRG1 from the plasma membrane, in cells adjacent to the basement membrane, to 
the cytoplasm and nucleus of mature cells (Chapter 2, Figure 2.3.).  One might 
speculate that proximity to the basement membrane may influence NDRG1 
localisation; however, NDRG1 is also associated with the plasma membrane in 
dysplastic and tumour tissue sections where the basement membrane is uninvolved.  
Certainly, the differential localisation of NDRG1 observed in tissue and that reported 
by Sibold et al.[101] could provide insights regarding the role of NDRG1, and suggests 
that tissue architecture may affect NDRG1 function.  
 
In this study we therefore examined the impact of NDRG1 expression on selected 
cellular processes involved in tumourigenesis, using cells cultured in an anchorage-
independent (non-adherent) manner.  Using RNA interference (RNAi) we examined 
how targeted downregulation of NDRG1 would influence cellular processes such as cell 
proliferation and apoptosis, and also examined how NDRG1 may affect the tumour 
microenvironment through modulation of genes involved in metastasis, invasion and 
angiogenesis. 
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3.2. RESULTS 
3.2.1. NDRG1 expression is induced by anchorage-independent growth 
It has been reported previously that the localisation of NDRG1 in cultured 
hepatocellular carcinoma cells (grown in vitro) differs from that in mouse xenograft 
models, despite using the same cell lines.  In the cultured cell system, NDRG1 is located 
in the cytoplasm, whereas this protein is located at the plasma membrane in 
xenografts[101].  This finding prompted us to examine the effect anchorage-
independent growth on NDRG1 expression in cultured OSCC cell lines.  Cells were 
seeded in tissue culture dishes coated with Poly(2-hydroxyethyl methacrylate) (poly-
HEMA), to prevent adhesion, or grown in normal culture dishes, to allow adherence, 
for 24 hours.  Western blot analysis of whole cell lysates showed that NDRG1 levels 
were strongly upregulated in cells cultured in an anchorage-independent manner (Fig. 
3.1.).  This upregulation was observed across the panel of seven cell lines, albeit to 
differing degrees.  Given the strong signal obtained from NDRG1 expression in WHCO1, 
WHCO5 and WHCO6 cells cultured anchorage-independently, the exposure of the 
Western blot to x-ray film was short and gives the impression that NDRG1 is absent in 
KYSE70, KYSE180 and KYSE450 cells cultured under anchorage-independent conditions.  
Longer exposure times did however confirm that NDRG1 is present in these cells (data 
not shown). 
 
To determine the time course of NDRG1 induction under anchorage-independent 
culture conditions, randomly selected WHCO1, WHCO6, KYSE70, KYSE180 and KYSE450  
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Figure 3.1. Anchorage-independent growth conditions induce NDRG1 expression in 
cultured OSCC cell lines.  Western blot analysis of NDRG1 protein expression, 
performed on 20 µg of whole cell lysate, prepared from cell cultures grown under 
anchorage-dependent (a) or -independent (n) conditions for 24 hours.   β-tubulin was 
used as a control for protein loading.   
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cells were cultured in an anchorage-independent manner for 24, 48 and 72 hours and 
NDRG1 mRNA and protein levels examined.  Real-time RT-PCR analysis showed a 
strong induction of NDRG1 mRNA levels in all cell lines, with the bulk of NDRG1 mRNA 
induction completed within the first 24 hours.  With a 12-fold increase in mRNA levels, 
WHCO1 cells showed the weakest NDRG1 response, while KYSE450 cells showed the 
strongest relative increase in NDRG1 mRNA levels of 129-fold.  After 72 hours of 
anchorage-independent growth, NDRG1 mRNA showed a decline in all cell lines but 
had not yet reached basal (anchorage-dependent) levels (Fig. 3.2.).  Similarly, Western 
blot analysis of whole cell lysates from the same cell lines demonstrated a strong 
upregulation in NDRG1 levels within 24 hours of anchorage-independent growth.  
However, in contrast to mRNA levels, NDRG1 protein levels showed no decline after 72 
hours of anchorage-independent cell cultire, likely owing to its reportedly long half-life 
of 16-24 hours[71;80] (Fig. 3.3).   
 
3.2.2. NDRG1 localisation is altered in oesophageal cancer cells cultured in an 
anchorage-independent manner 
Since the three-dimensional tumour microenvironment was reportedly associated with 
a change in NDRG1 localisation[101], we next examined the effect of in vitro 
anchorage-independent cell culture conditions on NDRG1 subcellular localisation.  
WHCO1, WHCO6, KYSE70 and KYSE180 cells were cultured in an anchorage-dependent 
and –independent manner for 48 hours.  Adherent cells were lifted from culture plates 
using 0.2 % w/v EDTA, to preserve   membrane   associated  proteins.  Cells were  fixed,  
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Figure 3.2. Time course of NDRG1 mRNA expression in OSCC cell lines cultured under 
anchorage-independent conditions.  Real-time RT-PCR to determine NDRG1 mRNA 
expression was performed on RNA extracted from WHCO1, WHCO6, KYSE70, KYSE180 
and KYSE450 cells (A-E) cultured under anchorage-dependent conditions for 24 hours 
(0 hr) and anchorage-independent conditions for  24, 48 and 72 hours.  RNA of a high 
quality, determined by RNA gel electrophoresis, was used and normalised to GUSB 
mRNA expression.  The specificity of the real-time RT-PCR was assessed by melting 
curve analysis. Results shown are the mean ± SD of experiments performed in triplicate 
and repeated at least two times.  
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Figure 3.3. Time course of NDRG1 induction in OSCC cell lines cultured under 
anchorage-independent conditions.  Western blot analysis of NDRG1 protein 
expression, performed on 20 µg of whole cell lysate prepared from WHCO (A) and KYSE 
(B) cell line cultures, grown under anchorage-dependent conditions for 24 hours (0) 
and anchorage-independent conditions 24, 48 and 72 hours.   β-tubulin was used as a 
control for protein loading. Results shown are representative of experiments 
performed three times.  
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mounted in paraffin, sectioned and stained for NDRG1 using peroxidase/DAB staining.  
Compared to anchorage-dependently cultured cells, in all cases cell lines cultured in an 
anchorage-independent manner showed increased levels of NDRG1.  In anchorage-
independently cultured WHCO1 and WHCO6 cells, a strong upregulation in NDRG1 
levels was evident.  Here, NDRG1 localisation was cytoplasmic (albeit at varying levels) 
and in some cells nuclear-associated NDRG1 was observed (Fig. 3.4.1.).  Likewise, 
immunohistochemical analysis of NDRG1 expression in KYSE70 and KYSE180 cells 
demonstrated an increased expression of NDRG1 protein in cells grown in an 
anchorage-independent manner.  However, unlike WHCO1 and WHCO6 cells, NDRG1 
positivity appeared to predominate at the periphery of stained KYSE70 and KYSE180 
cells, reminiscent of plasma membrane localisation (Fig. 3.4.2).  Taken together, these 
results suggest that anchorage-independent growth affects both expression levels and 
localisation of NDRG1. 
 
3.2.3. Inhibition of NDRG1 expression has no effect on anchorage-independent 
proliferation of oesophageal cancer cells  
In order to determine the biological significance of elevated NDRG1 protein levels in 
anchorage-independently cultured oesophageal cancer cells, small interfering RNA 
(siRNA) was used to inhibit its expression.  The efficacy of NDRG1 siRNA in down-
regulating NDRG1 expression was determined in WHCO1 and KYSE450 cells.  Cells were 
transiently transfected with 20 nM siRNA targeted against NDRG1 or a scrambled 
sequence control siRNA,  which served  as  a  negative control,  and then cultured in an  
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Figure 3.4.1. Immunohistochemistry of NDRG1 in WHCO1 and WHCO6 cells cultured 
in an anchorage-dependent and -independent manner (magnification 400x).  Cell 
lines, cultured in an anchorage-dependent and -independent manner for 48 hours, 
were fixed, embedded in paraffin blocks, sectioned and stained for NDRG1.  WHCO1 
and WHCO6 cells displayed intense cytoplasmic, and perhaps nuclear (arrows), 
localised NDRG1 when cultured in an anchorage-independent manner. Representative 
images of hematoxylin and eosin (H&E) staining are shown.  
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Figure 3.4.2. Immunohistochemistry of NDRG1 in KYSE70 and KYSE180 cells cultured 
in an anchorage-dependent and -independent manner (magnification 400x).  Cell 
lines, cultured in an anchorage-dependent and -independent manner for 48 hours, 
were fixed, embedded in paraffin blocks, sectioned and stained for NDRG1.  NDRG1 
appeared to localise to the periphery of KYSE70 and KYSE180 cells, reminiscent of 
plasma membrane localisation (arrows), when cultured in an anchorage-independent 
manner. Representative images of hematoxylin and eosin (H&E) staining are shown.  
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anchorage-independent manner for 24, 48, 72 and 96 hours.  The effect of NDRG1 and 
control siRNAs on NDRG1 protein expression was evaluated by Western blot.  NDRG1 
protein levels were significantly reduced in cells treated with NDRG1 targeted siRNA 
(Fig. 3.5.).  Western blot densitometry, using Quantity One software (version 4.6.6.), 
showed that NDRG1 siRNA knocked down NDRG1 expression by as much as 80 %.   A 
time-course of siRNA treatment showed that NDRG1 siRNA down-regulated NDRG1 
protein levels up to five days post-transfection. 
 
Having established that targeted siRNA was indeed effective at inhibiting NDRG1 
protein expression, we next evaluated the biological effects of knocking down this 
protein’s expression. Anchorage-independent cell proliferation assays were performed 
on WHCO1, WHCO6, KYSE70, KYSE180 and KYSE450 cell lines to determine the role of 
NDRG1 in anchorage-independent cell growth.  Cells were transiently transfected with 
20 nM of either NDRG1 siRNA or control siRNA and grown on poly-HEMA coated plates 
in media containing 1.5 % methyl cellulose.  Cell proliferation was assayed one, three 
and seven days after anchorage-independent growth.  While KYSE cell lines steadily 
increased in number over the seven day assay, WHCO cells showed a decline after 3 
days of anchorage-independent cell culture.  However, results showed that there was 
no significant change in anchorage-independent proliferation, in all cell lines, despite a 
5-fold reduction in NDRG1 (Fig. 3.6. A-E).  
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Figure 3.5. Inhibition of NDRG1 protein expression using siRNA. WHCO1 (A) and 
KYSE450 (B) cells were transfected with 20 nM control or NDRG1 siRNA and then 
cultured under anchorage-independent conditions.  Whole cell lysates were harvested 
for 4 days following anchorage-independent growth.  Western blot analysis on 30 µg of 
protein revealed that NDRG1 siRNA resulted in specific knockdown of NDRG1 protein 
expression in cells cultured in an anchorage-independent manner. The control siRNA 
had no effect on NDRG1 expression.  Western blots shown are representative of 
experiments performed three times.  
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Figure 3.6. Effect of NDRG1 inhibition on anchorage-independent proliferation of 
OSCC cell lines. WHCO1, WHCO6, KYSE70, KYSE180 and KYSE450 cells (A-E) were 
transfected with 20 nM NDRG1 or control siRNA and grown under anchorage-
independent conditions. Cell proliferation was monitored one, three and seven days 
after transfection, using MTT.  No significant changes in proliferation were observed 
when NDRG1 expression was knocked down with siRNA.  Results shown are the mean ± 
SD of experiments performed in triplicate and repeated at least two times.  
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3.2.4. Effect of NDRG1 siRNA knock-down on Caspase-3/7 activity in cancer cells 
cultured in an anchorage-independent manner 
To determine the effect of anchorage-independent growth conditions on apoptosis, 
Caspase-3/7 activity was measured in WHCO1, WHCO6, KYSE70 and KYSE180 cell lines 
cultured under anchorage-independent growth conditions for 72 hours.  A 4- and 5-
fold increase in Caspase-3/7 activity was observed in anchorage-independently 
cultured WHCO1 and WHCO6 cells, respectively (p < 0.001) (Fig. 3.7.A.)  In KYSE70 and 
KYSE180 cells Caspase-3/7 increased by 3- and 2-fold, respectively (p < 0.001).  To 
determine whether NDRG1 has an affect on apoptosis in these cells, Caspase-3/7 
activity was measured after NDRG1 inhibition with siRNA.  Cells were transfected with 
control or NDRG1 siRNA and cultured in an anchorage-independent manner for 72 
hours.  No significant change in Caspase-3/7 activity and therefore apoptosis was 
observed between untransfected, control or NDRG1 siRNA-transfected cells (Fig. 
3.7.B.).     
 
Taken together these results show that NDRG1 expression does not affect proliferation 
or apoptosis, and suggests that it’s induction under anchorage-independent growth 
conditions is either a by-product of this culture condition, or that NDRG1 plays a role in 
processes not measured in the assays used here. 
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Figure 3.7. NDRG1 does not does not induce or protect cells from apoptosis under in 
cell lines cultured under anchorage-independent conditions. A.  Caspase-3/7 activity, 
measured after culturing cells under anchorage-dependent or -independent conditions 
for 72 hours, revealed an increase in apoptosis in cells cultured in an anchorage-
independent manner (*p < 0.001). B. Caspase-3/7 activity was measured post-
transfection with NDRG1 or control siRNA, after 72 hours of anchorage-independent 
growth. NDRG1 knockdown with siRNA caused no significant increase or decrease in 
Caspase-3/7 activity. Results shown are the mean ± SD of experiments performed in 
quadruplicate and repeated at least two times.  
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3.2.5. Effect of anchorage-independent growth on the expression of invasion and 
angiogenesis factors 
Given the above results, we sought to examine the effect of anchorage-independent 
cell culture conditions on processes involved in invasion and angiogenesis.  Specifically, 
we examined the expression of MMP-2, MMP-9, Ang-1, PDGF-B, VEGF-C and VEGF-A 
mRNA every 24 hours for three days in OSCC cell lines cultured in an anchorage-
independent manner.  A panel of five cell lines was examined to identify common 
trends in gene expression.  Real-time RT-PCR results showed a strong down-regulation 
of MMP-2 expression and a partial down-regulation of MMP-9 expression with 
increasing time of anchorage-independent culture in all cell lines (Fig. 3.8.).  Similarly, 
when angiogenesis cytokines Ang-1, PDGF-B and VEGF-C were examined, a downward 
trend in mRNA expression was observed across all cell lines (albeit to differing extents), 
with the exception of WHCO6 which showed an increase in PDGF-B levels when cells 
were cultured under anchorage-independent conditions (Fig. 3.9.1. and 3.9.2.).      
 
In contrast to the above-mentioned results, real-time RT-PCR analysis of VEGF-A mRNA 
expression in WHCO1, WHCO6, KYSE70, KYSE180 and KYSE450 cells cultured under 
anchorage-independent conditions showed an induction of VEGF-A expression in all 
cell lines (Fig. 3.10.), reminiscent of the increase observed in NDRG1 mRNA (section 
3.2.1, Figure 3.2).  WHCO1 and WHCO6 cells showed a steady increase in mRNA levels 
over time giving rise to a 9.9-fold and 8.8-fold increase in VEGF-A mRNA levels, 
respectively.    KYSE450 cells showed an 8–fold increase in VEGF-A mRNA levels after  
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Figure 3.8. Matrix metalloproteinase mRNA expression in OSCC cell lines grown 
under anchorage-independent conditions. Real-time RT-PCR analysis of MMP-2 and 
MMP-9 mRNA expression in WHCO1, WHCO6, KYSE70, KYSE180 and KYSE450 cell lines 
(A-E) cultured anchorage-dependently for 24 hours (0 hr) or anchorage-independently 
for 24 hr, 48 hr and 72 hr.  RNA of a high quality, determined by RNA gel 
electrophoresis, was used and normalised to GUSB mRNA expression.  The specificity of 
the real-time RT-PCR was assessed by melting curve analysis.  Results are expressed 
relative to anchorage-dependent (0 hr) expression levels. Results shown are the mean 
± SD of experiments performed in triplicate and repeated two times.  
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Figure 3.9.1. Messenger RNA expression of angiogenesis factors Ang-1, PDGF-B and 
VEGF-C in WHCO1(A) and WHCO6(B) cells grown under anchorage-independent 
conditions. Real-time RT-PCR analysis of Ang-1, PDGF-B and VEGF-C mRNA expression 
cells cultured under anchorage-dependent conditions for 24 hours (0 hr) or under 
anchorage-independent conditions for 24 hr, 48 hr and 72 hr, revealed a decrease in 
gene expression, with the exception of PDGF-B mRNA which increased in WHCO6 cells. 
RNA was normalised to GUSB mRNA expression.  The specificity of the real-time RT-PCR 
was assessed by melting curve analysis. Gene expression relative to 0 hr are shown as 
means ± SD of experiments performed in triplicate and repeated two times.  
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Figure 3.9.2. Messenger RNA expression of angiogenesis factors Ang-1, PDGF-B and 
VEGF-C in KYSE70(A), KYSE180(B) and KYSE450(C) cells grown under anchorage-
independent conditions. Real-time RT-PCR analysis of Ang-1, PDGF-B and VEGF-C 
mRNA expression cells cultured under anchorage-dependent conditions for 24 hours (0 
hr) or anchorage-independent conditions for 24 hr, 48 hr and 72 hr, revealed a 
decrease in gene expression.  Gene expression relative to 0 hr are shown as means ± 
SD of experiments performed in triplicate and repeated two times.  
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Figure 3.10. Anchorage-independent growth induces VEGF-A mRNA expression in 
OSCC cell lines. Real-time RT-PCR analysis showing an increase in VEGF-A mRNA 
expression in WHCO1, WHCO6, KYSE70, KYSE180 and KYSE450 cells (A-E) cultured 
under anchorage-dependent conditions for 24 hours (0 hr) or anchorage-independent 
conditions for 24 hr, 48 hr and 72 hr. RNA of a high quality, determined by RNA gel 
electrophoresis, was used and normalised to GUSB mRNA expression.  The specificity of 
the real-time RT-PCR was assessed by melting curve analysis.  Results are expressed 
relative to anchorage-dependent (0 hr) expression levels.  Results shown are the mean 
± SD of experiments performed in triplicate and repeated two times.  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 77 
24 hours of anchorage-independent cell culture, which then decreased to 2.5-fold for 
the following two days.  KYSE70 and KYSE180 cells displayed the largest change in 
VEGF-A mRNA levels at 20- and 85-fold, respectively.    
 
To determine whether anchorage-independent cell culture induction of VEGF-A mRNA 
translates to an increase in VEGF-A cytokine release into the media of cultured cells, a 
VEGF-A ELISA was performed.  Again, cells were cultured under anchorage-dependent 
conditions for 24 hours or anchorage-independent conditions and VEGF-A levels 
monitored every 24 hours for three days.  ELISA results confirmed that VEGF-A protein, 
secreted into the media of cells cultured under anchorage-independent conditions, 
increased with time of cell culture.  Of the cells cultured under anchorage-dependent 
conditions for 24 hours, media from WHCO1 cells contained the highest concentration 
of VEGF-A at 737 pg/10
6 
cells while media of KYSE70 cells contained the lowest VEGF-A 
at 131 pg/10
6 
cells (Fig. 3.11.).  After 72 hours of anchorage-independent growth VEGF-
A cytokine concentration in the media of anchorage-independently cultured cells 
ranged from 1036 pg/10
6 
cells to 1321 pg/10
6 
cells.   
 
3.2.6. Anchorage-independent cell culture induction of VEGF-A expression is NDRG1 
dependent  
Whilst  evidence  in  the  literature  suggests  that  NDRG1  acts   as  an anti-angiogenic 
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Figure 3.11. Anchorage-independent growth increases VEGF-A protein levels in the 
media of OSCC cell lines. VEGF-A ELISA was performed to detect levels of VEGF-A 
secreted into the media of OSCC cell lines cultured under anchorage-dependent 
conditions for 24 hours (0 hr) or anchorage-independent conditions for 24 hr, 48 hr and 
72 hr.  The quantity of VEGF-A was normalised to the number of cells at the time of 
conditioned medium harvest and reported as picograms (pg) per 10
6
 cells.  Results 
shown are the mean ± SD of experiments performed in triplicate and repeated at least 
two times.  
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factor[137-139] others have proposed that NDRG1 expression correlates positively 
with VEGF-A expression and tumour vasculature[97].  In our anchorage-independent 
cell culture system there appears to be a positive correlation between NDRG1 and 
VEGF-A mRNA and protein expression.  We therefore explored the relationship 
between NDRG1 and VEGF-A expression in our anchorage-independent cell culture 
system, using siRNA. 
 
To determine whether NDRG1 expression was indeed necessary for VEGF-A 
expression, cell lines were transiently transfected with NDRG1 siRNA and then cultured 
under anchorage independent conditions for 72 hours.  Real-time RT-PCR, Western 
blot analysis and VEGF-A ELISA were all performed on the same pool of transfectants 
to determine the efficiency of NDRG1 knock-down and observe any effects on VEGF-A 
expression.  Real-time RT-PCR analysis showed that NDRG1 mRNA expression was 
effectively inhibited by NDRG1 siRNA OSCC cell lines cultured in an anchorage-
independent manner (Fig. 3.12.A.).  NDRG1 knock-down was significant in all cell lines 
(p <0.01), most efficient in WHCO1, KYSE180 and KYSE450 cells and least efficient in 
KYSE70 cells with only a 2-fold decrease in NDRG1 mRNA levels.   Western blot analysis 
revealed similar results, where NDRG1 siRNA effectively inhibited NDRG1 protein 
expression in all OSCC cell lines cultured in an anchorage-independent manner (Fig. 
3.12.B.).      
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Figure 3.12. NDRG1 siRNA inhibits NDRG1 mRNA and protein expression in OSCC cell 
lines cultured under anchorage-independent conditions. WHCO1, WHCO6, KYSE70, 
KYSE180 and KYSE450 cell lines were transfected with 20 nM of control or NDRG1 
siRNA and cultured in an anchorage-independent manner for 72 hours. A. Real-time RT-
PCR performed on RNA. Results are normalised to GUSB expression and expressed 
relative to control siRNA transfected cells (*p < 0.01). B. Western Blot analysis on 20 µg 
of whole cell lysate. β-tubulin was used as a loading control. Results showed that 
NDRG1 siRNA effectively knocked down NDRG1 mRNA and protein expression in cell 
lines cultured under anchorage-independent conditions for 72 hours.  
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Given that NDRG1 expression was effectively downregulated with transient, target 
specific NDRG1 siRNA, we next examined its effect on VEGF-A expression.  Real-time 
RT-PCR analysis showed that in all NDRG1 siRNA transfected cells, VEGF-A mRNA 
expression was significantly reduced (p < 0.05) (Fig. 3.13.A.).  In fact, the extent of 
VEGF-A mRNA reduction was consistent with the level of NDRG1 mRNA knockdown 
observed in the various cell lines.  Where NDRG1 inhibition was least effective (i.e. in 
KYSE70 cells), VEGF-A levels were the least effected (0.7-fold decrease).  The most 
effective downregulation of VEGF-A expression was observed in WHCO1 cells at 25-
fold (Fig 3.13.A.).  VEGF-A ELISA performed on the media from NDRG1 siRNA 
transfected cells also showed a significant downregulation in VEGF-A protein levels 
secreted into the media (p < 0.01) (Fig. 3.13.B.).     
 
3.2.7. NDRG1 affects VEGF-A expression through the modulation of its promoter 
activity 
Through the transient downregulation of NDRG1 expression with siRNA we have 
shown that NDRG1 effects VEGF-A expression in OSCC cell lines cultured in an 
anchorage-independent manner.  Potential mechanisms by which modulation of VEGF-
A expression can occur include altering its promoter activity, or through stabilisation of 
its mRNA transcript.  We addressed the former possibility by first performing a VEGF-A 
reporter assay, whereby the VEGF-A promoter region (-2018 to +50) fused to the 
luciferase reporter gene in the plasmid pVEGF-Luc (Fig. 3.14.i) was transfected into 
OSCC   cell   lines,   and   luciferase   activity   assayed   after  48  hours  of  anchorage -  
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Figure 3.13. NDRG1 siRNA inhibits VEGF-A mRNA expression and VEGF-A cytokine 
production of OSCC cell lines cultured under anchorage-independent conditions. A. 
WHCO1, WHCO6, KYSE70, KYSE180 and KYSE450 cell lines were transfected with 20 nM 
of control or NDRG1 siRNA and cultured in an anchorage-independent manner for 72 
hours.  Real-time RT-PCR analysis, relative to control siRNA transfected cells, showed 
that NDRG1 siRNA effectively knocked down VEGF-A mRNA in cell lines cultured under 
anchorage-independent conditions for 72 hours (*p < 0.05). B. VEGF-A ELISA showed 
that NDRG1 siRNA was effective at knocking down VEGF-A cytokine release into the 
media of cells cultured in an anchorage-independent manner (*p < 0.01).   
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Figure 3.14. Activity of human VEGF-A (-2018 to +50) promoter in OSCC cell lines 
cultured under anchorage-dependent or -independent conditions. (i). Schematic 
representation of the VEGF-A promoter (-2018 to +50) reporter construct, pVEGF-Luc. 
(ii). pVEGF-Luc and pGL3-Basic plasmids were transiently transfected into WHCO1(A), 
WHCO6(B), KYSE70(C), KYSE180(D) and KYSE450(E) cell lines.  Cell were then cultured 
under anchorage-dependent or -independent conditions for 48 hours. Significant 
induction of VEGF-A promoter activity was observed in cell lines cultured in an 
anchorage-independent manner (*p < 0.05).  The pGL3-Basic vector control showed no 
significant activity in cells cultured in an anchorage-independent manner. pRL-TK was 
used as an internal control for transfection efficiency and luciferase activity was 
normalised to Renilla luciferase.  
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independent growth.  The results showed that VEGF-A transcriptional activity was 
significantly increased in cells cultured for 48 hours under anchorage-independent 
growth conditions (p < 0.05) (Fig. 3.14.ii.), where the lowest fold change was observed 
in WHCO1 cells (3-fold) and the highest in KYSE180 cells (30-fold). Moreover, it was 
observed that WHCO1 showed the highest VEGF-A promoter activity under anchorage-
independent conditions which is in agreement with the ELISA performed on the media 
of adherent cells (Fig. 3.11.).   
 
To establish whether the increase in VEGF-A promoter activity was NDRG1-dependent, 
pVEGF-Luc was transfected into control or NDRG1 knock-down cells, and luciferase 
activity measured after 48 hours of anchorage-independent growth.  The results 
showed that VEGF-A promoter activity was significantly decreased in cells treated with 
NDRG1 siRNA compared to control cells (p < 0.05) (Fig.3.15.).  This downregulation in 
VEGF-A promoter activity was observed in WHCO1, WHCO6, KYSE70, KYSE180 and 
KYSE450 cell lines. 
 
3.2.8. VEGF-A produced by anchorage-independent growth of OSCC cell lines is 
functionally active 
Since we had shown that anchorage-independent growth induced VEGF-A promoter 
activity and expression in an NDRG1-dependent manner, we next examined whether 
the VEGF-A released into the media of cultured OSCC cell lines was functionally active.   
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Figure 3.15. NDRG1 siRNA inhibits VEGF-A promoter activity in cells cultured under 
anchorage-independent conditions. Cell lines were transfected with 20 nM of control 
or NDRG1 siRNA, the VEGF-A reporter, pVEGF-Luc and pRL-TK.  After 48 hours of 
anchorage-independent cell culture, luciferase levels were assayed and normalised 
using Renilla.  NDRG1 siRNA significantly suppresses VEGF-A promoter activity in cells 
cultured in an anchorage-independent manner (* p < 0.05). Results are expressed 
relative to control siRNA transfected cells and represent the mean ± SD of experiment 
performed twice in triplicate.  
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Since VEGF-A acts as a chemotactic agent to endothelial cells, we explored the 
potential of conditioned media from OSCC cell lines to induce transwell filter migration 
of human umbilical vein endothelial cells (HUVECs).  After 72 hours of anchorage-
independent cell culture, WHCO1 and KYSE180 cells were removed from their growth 
media by centrifugation and the conditioned medium used in a transwell migration 
assay.  Conditioned media from WHCO1 and KYSE180 cells was able to induce 
chemotaxis of HUVECs compared to the unconditioned media control (Fig. 3.16.).  The 
extent of HUVEC migration was reduced by the inclusion of a VEGF-A neutralising 
antibody showing that HUVEC migration is VEGF-A-dependent. 
 
Taken together these results show that anchorage-independent cell culture of OSCC 
cell lines induces VEGF-A expression in an NDRG1-dependent manner, and this VEGF-A 
is capable of inducing endothelial cell migration. 
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Figure 3.16. Endothelial cell migration is induced by VEGF-A secreted into the media 
of OSCC cell lines. Starved HUVECs were seeded into the upper chambers of a 8-μm 
filter transwell plates and allowed to migrate for 8 hours in response to cell culture 
media alone, conditioned media from WHCO1 or KYSE180 cells cultured for 72 hours 
under anchorage-independent conditions, or conditioned media containing 5 μg/ml 
neutralising VEGF-A antibody.  Cells remaining in the upper chamber were removed 
and the migrated cells were visualised by staining with crystal violet.  Results showed 
that HUVEC migration was VEGF-A-dependent (*p < 0.001).  Values are mean ± SD for 
each condition in duplicate wells, counted in quadruplicate fields.  
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3.3. DISCUSSION       
The raised expression of NDRG1 in the tumours of our cohort of South African OSCC 
patients suggests that NDRG1 plays a role in tumour biology and maintenance.  We 
report here that anchorage-independent culture conditions induce a strong and 
sustained upregulation in NDRG1 expression.  However, our analysis showed that this 
overexpression had no effect on many of the cellular processes that we measured.  
Specifically, NDRG1 inhibition with siRNA had no effect on anchorage-independent cell 
proliferation or apoptosis.  Similar studies report that exogenous overexpression of 
NDRG1 in NIH3T3 mouse fibroblasts, as well as prostate cancer cell lines, induced no 
changes in the cells’ ability to form colonies in soft agarose, but, in the latter, was able 
to suppress spontaneous lung metastasis in vivo[94;176].    Notably, neither of these 
studies reports the expression levels of NDRG1 in cells grown in an anchorage-
independent manner.  One could speculate that if endogenous NDRG1 is induced in 
these culture conditions, exogenous overexpression may be redundant due to 
saturation.  However, in contrast, Kurdistani et al. [54] showed that exogenous 
overexpression of NDRG1 in the breast cancer cell line MCF-7, and EJ bladder 
carcinoma cells, compromised the cell lines’ ability to form colonies in soft agarose.  
Indeed, this once again raises the possibility, mentioned in Chapter 1, that NDRG1 may 
have a tissue or cell type-specific function.  To this end, when we examined the 
localisation of NDRG1 in OSCC cells cultured in an anchorage-independent manner, we 
observed differential localisation of NDRG1, despite examining cell lines derived from 
the same tissue type.  Examination of NDRG1 localisation in anchorage-dependently 
cultured cells revealed that NDRG1 is largely located in the cytoplasm.  However, 
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NDRG1, in WHCO1 and WHCO6 cells cultured under anchorage-independent 
conditions, was strongly upregulated and localised to the cytoplasm and possibly 
nucleus.  This is in contrast to that observed in KYSE70 and KYSE180 cells, where 
anchorage-independent cell culture induced the expression of NDRG1 at periphery of 
cells, reminiscent of plasma membrane localisation.  To our knowledge, this is the first 
description of NDRG1 expression and localisation in cells cultured in an anchorage-
independent manner.  This finding corroborates, to an extent, that reported by Sibold 
et al.[101] where in vivo cell growth (in mouse xenografts) was able to induce NDRG1 
localisation to the plasma membrane.  Indeed, taken together these results suggest 
that the approach to exploring NDRG1 function in vitro cannot be simplistic and should 
take into consideration the fact that in vitro cell culture does not effectively mimic in 
vivo tissue systems.  
 
Interestingly, although we show that NDRG1 upregulation, in cells cultured in an 
anchorage-independent manner, does not contribute to cell proliferation or apoptosis, 
we do show a correlative relationship between NDRG1 and VEGF-A expression.  In fact, 
anchorage-independent cell culture conditions lead to an upregulation in VEGF-A 
promoter activity, mRNA expression and secretion into the media of cells, in an 
NDRG1-dependent manner.   Whilst the expression of VEGF-A has not been examined 
in our cohort of OSCC patients, it is reportedly overexpressed in   31 % - 93 %[177-180] 
of patients with squamous cell carcinoma of the oesophagus.  This pro-angiogenic 
molecule promotes stromal degradation, through the activation of proteolytic 
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enzymes[181], enhances vascular permeability[182], and stimulates proliferation and 
migration of endothelial cells, giving rise to vessel sprouting[183]. Indeed, evidence in 
the literature suggests that VEGF-A expression is induced in tumours in response to 
low oxygen tension, and this induction is mediated by the activation of HIF-1α 
(amongst others)[184]. High HIF-1α expression reportedly correlates with stage, depth 
of invasion, lymph node metastasis, distant metastasis and poor survival in 
oesophageal cancer sufferers[185].  VEGF-A therefore contributes to the aggressive 
characteristics of oesophageal cancer, through tumour angiogenesis and, in all 
likelihood, facilitates the spread of the tumour through the body.  A positive 
correlation between NDRG1, VEGF-A and tumour microvascular density (MVD) in 
cervical adenocarcinoma specimens was recently reported[97]. However, in contrast, 
Maruyama et al.[93] reported an inverse relationship between MVD and NDRG1 
expression in specimens of pancreatic ductal adenocarcinoma.  This finding was 
supported by in vitro experimental evidence where exogenous overexpression of 
NDRG1 in cultured PANC cells led to a downregulation in VEGF-A expression[93].   The 
mechanism through which NDRG1 imparted its effect on VEGF-A in was reportedly 
through NF-κB signalling attenuation[137] (see Chapter 1, section 1.7.6).  Conversely, 
we report here that NDRG1 induces VEGF-A expression in OSCC cell lines cultured 
under anchorage-independent conditions.  Since in vitro cell proliferation does not 
depend on vessel growth, it is understandable that no phenotypic effects of NDRG1 
knock-down were observed in our anchorage-independent cell culture system.  
Nevertheless, we did show that VEGF-A secreted into the media of OSCC cell lines 
cultured in an anchorage-independent manner was biologically active and capable of 
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inducing endothelial cell migration.  Interestingly, despite the variable staining pattern, 
reflecting NDRG1 localisation, in cell lines cultured under anchorage-independent 
conditions, NDRG1 knockdown imparted the same effect on VEGF-A expression.  The 
link between NDRG1 and VEGF-A upregulation in our system has, however, not been 
explored.  One might hypothesise that NDRG1 imparts its upregulatory effect on VEGF-
A through the inverse mechanism reported by Hosoi et al.[137], namely through the 
induction of NF-κB signalling.  Our group has recently reported that expression of p65 
(one of the subunits of the NF-κB complex) is elevated in 78 % of tumour tissue derived 
from patients with OSCC, compared to normal oesophageal epithelium[186].   This 
may provide the link between NDRG1 and VEGF-A expression and will be explored 
further in our laboratory.  In addition, while the increase in VEGF-A levels was 
explained in part by the increase in VEGF-A promoter activity, the possibility that 
VEGF-A mRNA levels were stabilised, under conditions of anchorage-independent cell 
culture, was not examined.  Indeed, VEGF-A mRNA levels have been reported to be 
stabilised in response to hypoxia[187;188] – a stress pathway that may be induced by 
anchorage-independent cell culture.  Interestingly, Bcl-2 overexpression in human 
melanoma cells was shown to induce angiogenesis through both HIF-1-mediated 
stimulation of VEGF-A transcriptional activity and the stabilisation of VEGF-A 
mRNA[187].  Thus, the potential role of NDRG1 in stabilising VEGF-A mRNA should be 
examined.   
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The results presented in this chapter support an oncogenic role for NDRG1 in 
oesophageal cancer.  If indeed the relationship between NDRG1 and VEGF-A observed 
in vitro can be supported by in vivo studies, NDRG1 too will be classified under one of 
the hallmarks of cancer.    
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CHAPTER 4 
INVESTIGATION OF THE TRANSCRIPTIONAL REGULATORY MECHANISMS 
THAT REGULATE NDRG1 EXPRESSION 
 
4.1. INTRODUCTION 
In the previous chapters we described the altered expression of NDRG1 in OSCC 
tumour tissue relative to that of normal oesophageal tissue and suggested that it 
associates with differentiation and cancer.  Furthermore, we also demonstrated that 
NDRG1 expression may play an important role in promoting angiogenesis through the 
induction of VEGF-A expression.  We were particularly interested in the transcriptional 
regulatory mechanisms that account for altered NDRG1 expression in OSCC cells.  
Indeed, although we examined a small cohort of patients, the identification of 
increased NDRG1 mRNA in cancer cells compared to normal cells (Chapter 2) suggests 
that its altered expression arises through deregulated transcription.  
 
Transcription is a highly synchronised process whereby transcription (or trans-acting) 
factors initiate and facilitate the production of RNA from DNA.  This occurs through the 
highly specific and co-ordinated binding of transcriptional activator, or repressor, 
proteins to cis recognition elements within the promoter of genes, in response to 
cellular signalling and/or an environmental stimulus.  In cancer however, misdirected 
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cellular signalling and transcription factor activation gives rise to aberrant gene 
expression which, in many cases, contributes to the progression of the disease. 
 
We suggest that the induction of NDRG1 expression observed in OSCC patients is the 
culmination of deregulated gene expression and altered transcriptional regulation of 
the NDRG1 promoter.  While some studies have examined the regulation of the 
NDRG1 promoter (see Chapter 1, section 1.7.7) there have been no studies reporting 
its transcriptional control in oesophageal cancer.  Since our non-adherent cell culture 
system is technically cumbersome, we opted to use TPA, a phorbol ester, as a stimulus 
to study the transcription factors that activate NDRG1 expression.  Phorbol esters, well 
described inducers of differentiation, are able to induce NDRG1 expression in 
keratinocytes[114], monocytic U937 cells[113;115] and trophoblasts[116].  TPA 
functions as a diacyglycerol analogue, diffusing into cells, activating protein kinase C 
(PKC) and downstream mitogen activated protein kinase (MAPK) pathways, 
culminating in the transcription of many genes.    
 
The objective of this study was therefore, using TPA as a stimulus, to analyse the 
NDRG1 promoter, and to identify activating transcription factors that affect the 
expression of NDRG1 in oesophageal epithelial cells.  These results may provide clues 
about those genes that regulate the altered expression of NDRG1 in oesophageal 
cancer, and that may contribute to the tumourigenic state in this pernicious disease.   
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4.2. RESULTS 
4.2.1. TPA induces NDRG1 expression in a subset of OSCC cell lines 
Firstly, in order to establish that NDRG1 expression is induced in OSCC cell lines by TPA 
treatment, preliminary Western blot analysis was performed.  OSCC cell lines were 
seeded subconfluently, and the next day, cells were either left untreated or treated for 
16 hours with 20 nM TPA.  Western blot analysis on whole cell lysates revealed NDRG1 
protein is induced by TPA in WHCO1, WHCO6, KYSE70, KYSE180 and KYSE450 cell lines 
(Fig. 4.1).  WHCO5 and KYSE520 cell lines showed no NDRG1 response to TPA in two 
independently performed experiments. The exposure time of the x-ray film in this 
experiment was selected to minimise overexposure of the NDRG1 bands in WHCO1 
and KYSE70.  The time was too short to detect basal NDRG1 expression in KYSE180 and 
KYSE450 cells, which were observed on longer exposures.  It was therefore determined 
that TPA was an appropriate stimulus to further examine the transcriptional regulation 
of NDRG1 in a subset of OSCC cell lines. 
 
4.2.2. Cloning the NDRG1 promoter 
Two thousand one hundred base pairs upstream of the NDRG1 transcription start site, 
together with 12 bp of the 5’ untranslated region (downstream of the transcription 
start site), was amplified by PCR using specific primers designed to the published 
sequence for NDRG1 and its contiguous regions (GenBank accession number 
NT_008046; appendix 1). The amplified NDRG1 (-2100 to +12) DNA fragment was 
cloned into the shuttle vector, TOPO-XL, and individual clones sequenced.  The 
sequence  correct  2112  bp  fragment  was  then  cloned  into  the  KpnI  and  XhoI sites  
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Figure 4.1. TPA induces NDRG1 expression in a subset of OSCC cell lines. Western blot 
analysis of NDRG1 expression in cell lines either untreated (-) or treated (+) with 20 nM 
TPA for 16 hours.  Twenty micrograms of whole cell lysate was subjected to analysis 
and showed that NDRG1 is induced by TPA in WHCO1, WHCO6, KYSE70, KYSE180 and 
KYSE450 cell lines. β-tubulin was used as a control for equal protein loading. Results 
shown are representative of independent experiments performed two times.  
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within pGL3-Basic vector, upstream of the luciferase reporter gene.  Since a 
recognition sequence for the restriction enzyme BamHI lies in both the insert and the 
pGL3-Basic vector, correct clones were identified by BamHI restriction digestion.  This 
yielded two bands of the expected size, namely 2827 bp and 4166 bp (Fig. 4.2.A). The 
pGL3-Basic vector contains no eukaryotic promoter and enhancer sequences; 
therefore the luciferase generated using a cloned promoter fragment in this vector, 
exclusively represents the activity of the cloned promoter in question.   
 
To determine the whether the cloned NDRG1 (-2100 to +12) promoter fragment was 
indeed functional, luciferase assays were performed on transiently transfected 
WHCO1, KYSE70 and KYSE520 cells.  The pRL-TK vector was used as an internal control 
reporter.  This vector contains the herpes simplex virus thymidine kinase promoter, 
which drives expression of Renilla luciferase, and allows for normalisation of 
transfection efficiency.  Cells were transfected with the pGL3- NDRG1 (-2100 to +12) 
construct and then either left untreated or treated for 16 hours with 20 nM TPA.  In 
addition, WHCO1 cells were transfected with the parental vector pGL3-Basic to serve 
as a background control.  Luciferase activity derived from the -2100 to +12 NDRG1 
promoter fragment in untreated WHCO1 cells was approximately 209-fold higher than 
that derived from the empty vector alone (the luciferase activity of which measured 
0.199) indicating that the -2100 to +12 region of NDRG1 was capable of driving 
significant levels of transcription (Fig. 4.2. B).  Moreover, treatment with 20 nM TPA 
was able to induce the NDRG1 -2100 to +12 promoter activity in WHCO1 and KYSE70 
cells by 3- and 6.5-fold,  respectively.  In KYSE520  cells TPA was not,  however,  able to  
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Figure 4.2. Promoter activity of human NDRG1 (-2100 to +12) cloned into the pGL3-
Basic reporter vector. A. Schematic diagram of the cloned NDRG1 (-2100 to +12) 
promoter fragment in pGL3-Basic. The promoter fragment was inserted upstream of 
the luciferase reporter gene using KpnI and XhoI restriction sites present in the multiple 
cloning site of pGL3-Basic. B. BamHI digestion of NDRG1 (-2100 to +12) in pGL3-Basic. 
The undigested plasmid was electrophoresed alongside the digested product on a 1 % 
agarose gel using 1 Kb Plus DNA Ladder as a marker (M; Invitrogen). Lane 1). Uncut 
pGL3-Basic-NDRG1 (-2100 to +12); Lane 2). BamHI-digested pGL3-Basic-NDRG1 (-2100 
to +12). C. Luciferase assay showing significant promoter activity in the NDRG1 (-2100 
to +12) cloned fragment compared to the empty vector in WHCO1 cells. Treatment for 
16 hours with 20 nM TPA was able to induce NDRG1 promoter activity in WHCO1 and 
KYSE70 cells, but not KYSE520 cells.  pRL-TK was used as an internal control for 
transfection efficiency and luciferase activity is normalised to Renilla luciferase. The 
results show the mean ± standard deviation of experiments performed in triplicate, 
three times.  
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induce activity of the NDRG1 -2100 to +12 fragment.  This finding correlates with the 
data (shown in Figure 4.1) where NDRG1 protein is induced by TPA in WHCO1 and 
KYSE70 cells, but not KYSE520 cells.         
 
4.2.3. TPA activates MAPK pathways and induces NDRG1 expression 
Initial experiments with TPA had been carried out using an arbitrary concentration of 
20 nM.  We were, however, interested to see whether the NDRG1 response was TPA 
dose-dependent.  Since it had been reported previously that 4 hours of treatment with 
TPA was capable of activating MAPK pathways in cultured cells[189], the effect of TPA 
on NDRG1 expression in KYSE450 cells was therefore determined by treating cells with 
increasing concentrations of TPA for 4 hours (Fig. 4.3.).  Western blot analysis revealed 
that treatment from 10 nM up to 320 nM TPA induced NDRG1 protein expression to 
similar extents.  In addition, as little as 10 nM TPA exposure led to the activation of the 
ERK, p38 and JNK MAPK pathways, whereas the AKT pathway, which was 
phosphorylated in the absence of TPA, was suppressed by the presence of the phorbol 
ester.  Our next step was to determine the dose response of the NDRG1 promoter to 
TPA treatment so that an optimal working TPA concentration could be identified for 
further analysis.  Cells were therefore transfected with the (-2100 to +12) NDRG1 
luciferase reporter plasmid and treated with 10 nM to 320 nM TPA for 4 hours (Fig. 
4.4.). A significant upregulation in NDRG1 promoter activity was achieved after 
exposure to as little as 10 nM TPA for 4 hours (p < 0.005) and, as with the protein 
levels, luciferase activity did not display a linear relationship with TPA dose.   From  this  
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Figure 4.3. Twenty nanomolar TPA is sufficient to upregulate NDRG1 expression and 
induces phosphorylation of MAPK pathways.  KYSE450 whole cell lysates were 
prepared 4 hours after treatment with various concentrations of TPA.  Forty 
micrograms of protein were separated by SDS-PAGE and immunoblotted with 
antibodies against NDRG1 and phosphorylated and unphosphorylated MAPK proteins. 
Levels of unphosphorylated MAPK proteins and β-tubulin were used as loading 
controls.  D, DMSO (0.005 %) solvent control 0, untreated cells.  
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Figure 4.4. Twenty nanomolar TPA is sufficient to upregulate NDRG1 (-2100 to +12) 
promoter activity in KYSE450 cells. and induces phosphorylation of MAPK pathways.  
NDRG1 (-2100 to +12) promoter activity was analyzed by dual luciferase reporter 
system.  KYSE450 cells were transiently co-transfected with NDRG1 reporter construct 
and pRL-TK.  The next day cells were either left untreated (Utx) or treated with 
different concentrations of TPA for 4 hours.  NDRG1 relative luciferase activity is 
expressed as a ratio of luciferase activity of treated cells relative to untreated cells.  
Renilla luciferase was used as an internal control.  The DMSO (0.005 %) solvent control 
showed no significant difference in promoter activity compared to untreated cells.  The 
results show the mean ± standard deviation of experiments performed in triplicate, 
three times (* p < 0.005).  
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data it was decided that 20 nM TPA was a suitable concentration to continue further 
experiments. 
 
To further understand the effect of TPA treatment on NDRG1 expression we treated 
KYSE450 cells with 20 nM TPA for various times and measured NDRG1 and MAPK 
pathway responses by Western blot (Fig. 4.5.).  As short as 1 hour exposure to 20 nM 
TPA was able to induce measurable levels of NDRG1 protein, where maximal levels 
were observed at 8 - 10 hours of exposure, after which NDRG1 levels began to decline.  
Strong activation of the ERK and JNK pathways was observed between 1 and 4 hours 
after TPA treatment and p38 phosphorylation was also observed after TPA exposure, 
albeit at a later stage.  Additionally, TPA resulted in a decrease in phospho-AKT levels 
from 1 - 8 hours of exposure.  These results suggest that TPA induces NDRG1 via a 
MAPK pathway in a time-dependent manner.  Moreover, NDRG1 upregulation is 
paralleled with the activation of MEK/ERK, JNK and p38 MAPK pathways, and the 
inhibition of AKT signalling.  
 
4.2.4. Analysing NDRG1 promoter activity through the generation of deletion 
constructs and identification of evolutionary conserved regulatory regions 
The NDRG1 -2100 to +12 upstream regulatory region is capable of driving transcription 
and responds to TPA stimulation as expected.  However, one cannot exclude the 
possibilty that additional untranslated regions may also play a part in regulating 
NDRG1 expression.  In order to gain a better understanding of the elements important 
for  regulating  NDRG1  transcription,  additional reporter constructs were synthesised,  
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Figure 4.5.  TPA rapidly induces NDRG1 expression and activates MAPK signalling 
pathways.  Western blot analysis of whole cell lysates from KYSE450 cells treated with 
20 nM TPA for the indicated times. Forty micrograms of protein were 
electrophoretically separated and probed with antibodies against NDRG1, β-tubulin 
and phosphorylated and unphosphorylated MAPK proteins. Levels of 
unphosphorylated MAPK proteins and β-tubulin were used as loading controls.  
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using PCR, and cloned into the pGL3-Basic reporter plasmid.  These constructs included 
the NDRG1 putative promoter regions (-4819 to +305), (-4819 to +12), (-2100 to +305), 
(-1500 to +12), (-1200 to +12), (-900 +12), (-298 to +12), as shown in Fig. 4.6, in 
addition to the already cloned (-2100 to +12) NDRG1 promoter construct described 
earlier.  All PCR amplified promoter products were confirmed by sequencing. 
 
Since we had shown that the NDRG1 (-2100 to +12) promoter fragment was capable of 
driving luciferase expression in response to TPA, we again used this system, in KYSE450 
cells, to explore the functionality of all promoter constructs.  NDRG1 promoter 
deletion constructs were thus transfected into KYSE450 cells; the next day cells were 
either left untreated or treated with 20 nM TPA for 8 hours (where maximal induction 
of NDRG1 protein was observed) and luciferase activity measured.  Results showed 
that all constructs displayed significantly more activity in the TPA-treated cells versus 
untreated cells (Fig. 4.6.).  As little as 298 bp upstream of the transcriptional start site 
to +12 bp was capable of driving a 2-fold increase in promoter activity when treated 
with TPA, while the (-900 to +12) fragment induced a near 4-fold induction of 
luciferase activity (p < 0.005).  Maximal induction of promoter activity was achieved in 
TPA-treated cells transfected with the NDRG1 (-1200 to +12) reporter, suggesting that 
transcription factor binding sites, important for inducing NDRG1 expression in 
response to TPA, lie within the -1200 bp to +12 bp region of the NDRG1 promoter.  
Both the (-4819 to +305) and (-2100 to +305) reporter constructs showed lower 
activity when compared to the (-4819 to +12) and (-2100 to +305) reporters, 
respectively.  This  is  likely  explained  by  the  presence  of  the  Myc repressor binding  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 105 
0 1 2 3 4 5
Relative luciferase activity
-TPA
+TPA
luc
-4819 +305+1
luc
-298 +12+1
luc
-900 +12+1
luc
-1200 +12+1
luc
-1500 +12
+1
luc
-2100 +12
+1
luc
-2100 +305+1
luc
-4819 +12
+1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Relative luciferase activity of the NDRG1 promoter deletion contructs in 
KYSE450 cells.  Luciferase reporter constructs containing different regions of the 
human NDRG1 promoter were transiently transfected into KYSE450 cells.  The next day 
cells were either left untreated, or treated for 8 hours with 20 nM TPA.   All constructs 
showed a response to TPA stimulation, varying from between 2- and 4-fold induction.  
The smallest promoter fragment (-298 to +12) showed a 2-fold response to TPA 
treatment.  An additional 602 bp upstream (-900 to +12) induced a further and 
significant TPA response (*p < 0.005). Nucleotides are numbered relative to the 
transcription start site (+1). The results shown are the mean ± standard deviation of 
experiments performed in triplicate, three times and luciferase activity is expressed 
relative to untreated cells. 
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sequence within the NDRG1 core promoter region (from -33 bp to +103 bp) that was 
reported recently[112].  Interestingly, no significant upregulation in reporter activity 
was observed when base pairs as far as -4819 were included in reporter constructs, 
compared to the (-2100 to +12), (-1500 to +12), (-1200 to +12) and (-900 +12) reporter 
plasmids and further suggests that key NDRG1 regulatory elements lie within 2100 bp 
of the transcriptional start site.    
 
Since regulatory elements, important for gene transcription are often conserved 
phylogenetically[190] regions of conserved 5’ cis acting elements, potentially 
regulating NDRG1 transcription, were identified by performing a hierarchical sequence 
alignment.    Sequences approximately 5 Kb upstream of the NDRG1 transcriptional 
start site to +1 bp for human, chimpanzee, rat, mouse and bovine NDRG1 were 
retrieved from the NCBI database; ClustalW multiple sequence alignment was 
performed, using BioEdit Sequence Alignment Editor[191;192], and showed that 
sequence homology increased with proximity to the transcriptional start site, notably 
from -500 bp to +1 bp of the putative promoter region (Fig. 4.7.).  
 
4.2.5. TPA induces NDRG1 expression via PKC  
Since we had shown that TPA induces NDRG1 expression and activates MAPK 
pathways we determined the role of PKC in the TPA response observed.  Although it is 
well known that TPA is responsible for PKC activation, it may also lead to activation of 
other kinases, such as EGFR[193;194].  To inhibit the activity of PKC, we used the PKC 
antagonist GF109203x  (Bisindolylmaleimide I),  an inhibitor that shows high  selectivity  
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TATA box +1
 
 
Figure 4.7. Hierachical multiple sequence alignment showing regions that are 
conserved in the putative NDRG1 promoter.  ClustalW software was used to align the 
putative NDRG1 promoter sequences of human, chimpanzee, rat, mouse and bovine.  
Regions of 100 % homology across species are highlighted and show that identity 
increases with proximity to the transcriptional start site.  Sequences start at 
approximately -762 bp (marked here as 4239) and end at +1 bp. The putative TATA box 
and transcriptional start site (+1) are indicated.  
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for PKCα, βI, βII, γ, δ, and ε isozymes.  KYSE450 cells were pre-treated with 40 μM 
GF109203x for 1 hour and then stimulated with 20 nM TPA for 8 hours.  Western blot 
analysis showed that the presence of the PKC antagonist inhibited TPA-induced NDRG1 
protein expression (Fig. 4.8.A.).  Immunoblotting with phospho-p38 antibody 
confirmed the activity of GF109203x.   
 
To confirm that the TPA stimulation of NDRG1, mediated by PKC, occurred at the 
transcriptional level, a luciferase reporter assay was performed.  Since we had shown 
that TPA-induced NDRG1 promoter activity did not extend beyond the -2100 bp to + 12 
bp regulatory region, KYSE450 cells were transiently transfected with the NDRG1 (-
2100 to +12) reporter construct along with pRL-TK.  The next day cells were either left 
untreated, treated with PKC inhibitor alone, treated with TPA alone or pre-treated for 
1 hour with PKC inhibitor, followed by 8 hours of TPA stimulation.  NDRG1 (-2100 to 
+12) reporter activity was diminished 4-fold, to basal levels, when cells were treated 
with TPA in the presence of the PKC inhibitor (p < 0.01), compared to cells treated with 
TPA alone.  Taken together these results suggest that the NDRG1 response to TPA is 
mediated by PKC and converges on the -2100 bp to +12 bp region of the NDRG1 
promoter.   
   
4.2.6. TPA signals to NDRG1 via MEK/ERK and JNK 
Exposure of cells to a stimulating agent such as TPA leads to the modulation of 
intracellular signalling pathways and expression of transcription factors, culminating in 
the transcription of target genes.  TPA treatment resulted in NDRG1 upregulation,  and  
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Figure 4.8. TPA induced upregulation of NDRG1 is mediated by PKC. A. Western blot 
analysis of KYSE450 cell lysates pre-treated for 1 hour with 40 μM PKC inhibitor 
(GF109203x) followed by 20 nM TPA treatment for 8 hours.  Forty micrograms of 
protein lysates were probed with antibodies to NDRG1, β-tubulin and phosphorylated 
and unphosphorylated p38 proteins. B. NDRG1 luciferase reporter activity was 
determined in KYSE450 cells transiently co-transfected with the (-2100 to + 12) NDRG1 
reporter construct and pRL-TK.  The day after transfection cells were either left 
untreated, treated with GF109203x alone, treated with TPA alone or pre-treated for 1 
hour with 40 µM PKC inhibitor (GF109203x) followed by 20 nM TPA treatment for 8 
hours (* p < 0.01). The results shown are the mean ± standard deviation of experiments 
performed in triplicate, three times.  
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associated activation of the MEK/ERK, JNK and p38 MAPK pathways and the 
dephosphorylation of AKT.  We sought to determine which MAPK pathways were 
involved in the TPA-stimulated expression of NDRG1 by utilizing target specific 
antagonists.   
 
To determine which MAPK pathways play a role in the NDRG1 response to TPA 
treatment, KYSE450 cells, were pre-treated with either the MEK inhibitor (PD98059), 
AKT inhibitor (Akti-1/2), JNK inhibitor (SP600125) or p38 inhibitor (SB203580) for 1 
hour followed by stimulation with 20 nM TPA for 8 hours.  The levels of NDRG1 protein 
in cells stimulated with TPA in the presence of the MAPK inhibitors was determined by 
Western blot analysis and showed that the AKT and p38 inhibitors had little inhibitory 
effect on TPA-induced NDRG1 expression, whereas the MEK and JNK inhibitors were 
able to reduce the extent of TPA-stimulated induction of NDRG1 (Fig. 4.9.).  Here, the 
MEK inhibitor suppressed NDRG1’s TPA response by 80 % whilst the JNK inhibitor 
reduced NDRG1 expression by approximately 45 %, as determined by densitometric 
quantification, using Quantity One software (version 4.6.6).  Immunoblotting against 
phosphorylated MAPK proteins and phospho-cJun confirmed inhibition of signalling 
pathways by the specific inhibitors.  In the case of the p38 MAPK pathway and 
SB203580, this antagonist prevents the activity of p38 but not its transactivation, 
hence an apparent increase in phospho-p38 is observed[195].   
 
To show that the MEK/ERK and JNK MAPK signalling converges on the NDRG1 -2100 bp 
to  +12 bp promoter region,  luciferase reporter assays were performed. KYSE450 cells,  
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Figure 4.9. TPA induced upregulation of NDRG1 protein is suppressed by MEK and 
JNK inhibitors. Western blot analysis performed on 40 μg KYSE450 cell lysates pre-
treated for 1 hour with MAPK inhibitors followed by 20 nM TPA treatment for 8 hours.  
Protein lysates were probed with antibodies to NDRG1, β-tubulin and phosphorylated 
and unphosphorylated MAPK proteins and revealed that MEK (PD98059) and JNK 
(SP600125) inhibitors were able to abrogate, albeit to differing degrees, the induction 
of NDRG1 by TPA treatment.   
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transiently transfected with the NDRG1 (-2100 to +12) luciferase reporter plasmid and 
pRL-TK, were pre-treated with various MAPK inhibitors for 1 hour followed by TPA 
stimulation for 8 hours.  As observed in the Western blot analysis, the presence of 
either the AKT or p38 inhibitor had little effect on the TPA-induced up-regulation of 
NDRG1 promoter activity (Fig 4.10.).  However, the presence of the MEK and JNK 
inhibitors abrogated the TPA-stimulated reporter response by 82 (p < 0.005) and 35 (p 
< 0.05) percent, respectively.  Thus, it appears that MEK/ERK is the predominant MAPK 
mediator of the NDRG1 TPA response and JNK plays a partial role.  As an aside, it was 
interesting to note that the AKT inhibitor alone induced basal levels of NDRG1 (-2100 
to +12) reporter activity by 1.5-fold (p < 0.005) while the MEK inhibitor alone repressed 
basal NDRG1 (-2100 to +12) transcription by almost 4-fold (p < 0.001).  This leads one 
to speculate that the MEK/ERK and AKT pathways may be key regulators of basal 
NDRG1 transcription and expression. 
 
 
4.2.7. EGR-1 and cJun mediate the TPA-stimulated NDRG1 response 
MAPKs transmit stimuli from the extracellular environment to the nucleus giving rise 
to transcription factor activation and recruitment to target genes.     In KYSE450 cells 
the TPA stimulus is relayed to NDRG1 predominantly via the MEK/ERK MAPK pathway.   
In order to identify candidate transcription factors that promote NDRG1 transcription 
in response to TPA, an in silico bioinformatics analysis was perfomed.  Here, the 2100 
bp 5’ to + 12 region was subjected to a transcription factor binding site search using 
MatInspector[196]  and Conreal  (conserved  regulatory  elements  anchored alignment  
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Figure 4.10. TPA-induced NDRG1 promoter activity is stimulated through MEK/ERK 
and JNK MAPK pathways. NDRG1 luciferase reporter activity was determined in 
KYSE450 cells transiently co-transfected with the (-2100 to +12) NDRG1 reporter 
construct and pRL-TK.  The day after transfection cells were pre-treated for 1 hour with 
the indicated concentrations of  inhibitors,  followed  by treatment  with 20 nM TPA for 
8 hours.  The MEK and AKT inhibitors had a significant effect on basal activity of the 
NDRG1 (-2100 to +12) promoter, while the MEK and JNK inhibitors were able to inhibit, 
to different extents, TPA-induced NDRG1 promoter activity.  The results show the mean 
± standard deviation of experiments performed in triplicate, three times (* p<0.001, ** 
p<0.005, *** p<0.05).   
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algorithm)[197].  Multiple candidate transcription factor binding sites were retrieved 
including those for c-Ets-1, TGF-β, E2-F, AP-1 as well as EGR-1 (data not shown). 
 
Since the TPA-stimulated expression of NDRG1 is mediated by MEK/ERK and JNK, 
particular focus was placed on transcription factors known to lie downstream of these 
MAPK pathways.  In particular, we examined the role of EGR-1 and AP-1, specifically 
cJun, in modulating NDRG1 expression.   
 
It has been shown that EGR-1 lies downstream of ERK and responds to TPA in other 
systems[198].  Likewise, TPA activates JNK MAPK, which is responsible for the 
transactivation of the AP-1 transcriptional complex[199;200], comprising of Jun 
homodimers and Jun/Fos heterodimers[201].  To elucidate whether EGR-1 and/or cJun 
were necessary for NDRG1 gene expression following TPA exposure, a siRNA approach 
was used.  KYSE450 cells were transiently transfected with 20 nM control, EGR-1 or 
cJun siRNA.  Twenty-four hours later transfectants were either left untreated or 
treated with 20 nM TPA for 8 hours.  Western blot analysis on whole cell lysates 
revealed that TPA-induced NDRG1 expression was downregulated by 30 % in the 
presence of EGR-1 and cJun siRNA compared with cells transfected with control siRNA 
(Fig. 4.11.A.).  Immunoblotting with antibodies against EGR-1 and cJun confirmed the 
efficient knockdown (although not complete) effect of the target specific siRNA.  
Interestingly, it appeared that the presence of cJun siRNA also resulted in a 
downregulation of EGR-1 expression in the presence of 20 nM TPA.  This suggests that  
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Figure 4.11. EGR-1 and cJun mediate TPA-stimulated up-regulation of NDRG1. A. 
KYSE450 cells transfected with 20 nM control (Ctl) siRNA, EGR-1 siRNA or cJun siRNA, 
and left untreated or treated for 8 hours with 20 nM TPA, were examined by Western 
blot.  Whole cell lysates were subjected to SDS-PAGE and immunoblotted with 
antibodies against EGR-1, NDRG1, cJun and β-tubulin. B. NDRG1 promoter activity was 
determined in KYSE450 cells transiently co-transfected with the NDRG1 (-2100 to +12) 
promoter construct alone or the NDRG1 promoter construct with either 20 nM of 
control siRNA, EGR-1 siRNA or cJun siRNA.  TK driven Renilla luciferase served as an 
internal control.  Twenty four hours after transfection, cells were treated with 20 nM 
TPA for 8 hours and assayed for luciferase activity (* p < 0.001). The results show the 
mean ± standard deviation of experiments performed in triplicate, three times.  
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cJun may affect NDRG1 expression directly through regulation of the promoter as well 
as indirectly, through modulation of EGR-1 expression.    
 
The effect of EGR-1 and cJun siRNA on NDRG1 (-2100 to +12) reporter activity was next 
determined by luciferase reporter assay.  KYSE450 cells transiently transfected with 
either the NDRG1 (-2100 to +12) reporter construct alone or the reporter construct 
and control siRNA, showed no significant difference in luciferase activity when treated 
with 20 nM TPA (Fig. 4.11.B.).  However, luciferase reporter assays performed in the 
presence of either EGR-1 or cJun siRNA resulted in a 53 and 36 percent decrease in 
TPA-induced luciferase activity (p < 0.001).  Taken together these results suggest that 
both EGR-1 and cJun regulate NDRG1 expression in response to TPA, and this effect is 
mediated at the transcriptional level. 
 
To confirm that this observation was in fact true in other OSCC cell lines, and not an 
artefact of cell culture, Western blot analysis was performed on whole cell lysates from 
WHCO1, KYSE70 and KYSE180 cell lines that had been transiently transfected with 
control, EGR-1 or cJun siRNA and treated with 20 nM TPA.  Results showed that, as in 
KYSE450 cells, both EGR-1 and cJun mediate the TPA-induced upregulation of NDRG1 
expression (Fig. 4.12.). 
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Figure 4.12. TPA-stimulated NDRG1 expression is mediated by EGR-1 and cJun in 
WHCO1 (A), KYSE70 (B) and KYSE180 (C) cells. Cells were transfected with 20 nM of 
either control (Ctl), EGR-1 or cJun siRNA.  The next day transfectants were treated with 
20 nM TPA for 8 hours.  Western blot analysis of whole cell lysates showed that TPA-
induced upregulation of NDRG1 is abrogated by the presence of EGR-1 or cJun siRNA. 
β-tubulin was used as a control for protein loading.  
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4.2.8. An EGR-1 site and two AP-1 sites are important regulatory elements within the 
NDRG1 -2100 bp to +12 bp region 
Since the siRNA approach had shown that both EGR-1 and cJun relayed the TPA-
induced signal to the NDRG1 promoter, we next showed that this was a direct effect 
on the promoter by mutating the predicted EGR-1 and AP-1 (cJun) transcription factor 
binding sites within the NDRG1 (-2100 to +12) reporter plasmid.  Site-directed 
mutagenesis was employed to alter respective sites by mutating at least one base of 
the site of interest, without disrupting any other transcription factor binding sites and 
so as not to introduce any new transcription factor binding sites.  Mutagenesis of the 
EGR-1 site was carried out as reported previously[153], and mutations were confirmed 
by restriction digestion analysis (data not shown).  The sequence of wildtype and 
mutated sites, as well as their relative positions, are depicted in Figure. 4.13.A.  
 
Mutated NDRG1 (-2100 to +12) promoter constructs were transiently transfected into 
KYSE450 cells.  Figure 4.13.B shows that mutation of the EGR-1 binding site in the 
proximal NDRG1 promoter resulted in a 90 percent downregulation in NDRG1 (-2100 
to +12) luciferase activity in response to TPA (p < 0.001).  In addition, mutation of 
either the (-788 to -778) AP-1 site or the (-1123 to -1113) AP-1 site resulted in 
approximately 50 and 40 percent decrease in promoter activity, respectively (p < 0.01; 
p < 0.05).  While the cumulative effect of the AP-1 sites was not examined, the data 
presented here suggests that the predominant regulator of the NDRG1 -2100 bp to +12 
bp promoter region is EGR-1. 
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Figure 4.13.  Site-directed mutagenesis of EGR-1 and AP-1 transcription factor binding 
sites in the (2100 to +12) NDRG1 promoter abrogate the TPA-induced transcriptional 
activity in KYSE450 cells. A. Site-directed mutagenesis was performed on the NDRG1 
(2100 +12) promoter construct, using mutagenic primers. The consensus binding sites 
are in red, with the bases chosen for mutation analysis in green. Positions of the 
binding sites and restriction enzymes used to identify mutants are shown.  Mutagenesis 
was performed to eliminate the potential EGR-1 and two AP-1 sites within the -2100 bp 
to +12 bp region of the NDRG1 promoter. B. Luciferase activity of wildtype and mutated 
NDRG1 (-2100 to +12) promoters in response to  8 hours treatment with 20 nM TPA (*p 
< 0.001, **p < 0.01, *** p < 0.05).  The parental vector pGL3-Basic showed no 
significant activity.  Schematic depiction of the positions of mutations on the NDRG1 (-
2100 to +12) promoter are shown. The results show the mean ± standard deviation of 
experiments performed in triplicate, three times.   
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4.2.9. EGR-1 binds to the proximal promoter of NDRG1 following TPA stimulation 
As EGR-1 is necessary for TPA-induced up-regulation of NDRG1, we sought to verify 
that EGR-1 bound the NDRG1 promoter in vivo following TPA stimulation.  First, we 
examined the time course of EGR1 protein response to 20 nM TPA treatment in 
KYSE450 and WHCO1 cells.    Treatment with TPA led to a strong and transient 
upregulation of EGR-1 protein in both KYSE450 and WHCO1 cells, within 1 hour of 
exposure (Fig. 4.14.).  Maximal levels were achieved after 2 hours of exposure in 
KYSE450 cells, and 1.5 hours in WHCO1 cells, after which EGR-1 levels declined to basal 
levels by 10 to 16 hours.   
 
Having determined the time of maximal induction of EGR-1 we performed Chromatin 
Immunoprecipitation (ChIP) assays using an antibody to EGR-1 with extracts from 
KYSE450 and WHCO1 cultured cells, untreated or treated for 2 hours with 20 nM TPA.  
Crosslinked chromatin was isolated from cells and sonicated to generate DNA 
fragments ranging in size from 500-700 bp.  DNA was then immunoprecipitated using 
an α-EGR-1 antibody, and DNA, bound to EGR-1, was precipitated using protein G 
agarose beads.  Following dissolution of cross-links, the DNA was subjected PCR 
analysis using primers spanning the EGR-1 site in the NDRG1 promoter (Fig. 4.15.A).  A 
positive band of the correct size of 142 bp was detected in TPA treated KYSE450 and 
WHCO1 cell lines after immunoprecipitation with the anti-EGR-1 antibody, confirming 
that EGR-1 binds in the NDRG1 promoter following TPA treatment (Fig. 4.15.B).    No 
PCR product was obtained from untreated cells.  Input chromatin served as a positive 
control,  while DNA  immunoprecipitated  without antibody was included as a negative  
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Figure 4.14. Timecourse induction of the EGR-1 protein response to TPA in KYSE450 
(A) and WHCO1 (B) cells. Western blot analysis of EGR-1 expression from whole cell 
lysates of cells treated over time with 20 nM TPA.  EGR-1 is rapidly and strongly induced 
between 1 and 4 hours after TPA treatment. β-tubulin was used as a loading control. 
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Figure 4.15. ChIP assay identifies the NDRG1 promoter as an EGR-1 target in KYSE450 
and WHCO1 cells. A. Schematic representation of the location of the primer set used in 
the ChIP assay in relation to the EGR-1 binding site. B. ChIP of EGR-1 was performed 
with KYSE450 and WHCO1 cells.  Chromatin from untreated cells or cells treated for 2 
hours with 20 nM TPA was immunoprecipitated with EGR-1 antibody or no antibody as 
a control.  PCR was performed with primers flanking the putative EGR-1 binding site 
within the NDRG1 proximal promoter region. C. Real-time RT-PCR using ChIP DNA and 
primers flanking the EGR-1 binding site within the NDRG1 promoter.  The data shown 
represents the fold change in EGR-1 binding to the NDRG1 promoter relative to ChIP 
input DNA (*p < 0.05). The results show the mean ± standard deviation of experiments 
performed in triplicate, three times.  
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control. The near absent presence of bands in the negative control confirmed specific 
immunoprecipitation of EGR-1 bound DNA.  
 
Quantitative real-time PCR was performed to demonstrate the increase in EGR-1 
binding to the endogenous NDRG1 promoter between untreated cells and cells treated 
with TPA (Fig. 4.15.C). The CT method was used for the calculation of expression fold 
change between samples relative to respective input DNA.  Results showed that in 
both KYSE450 and WHCO1 cells, EGR-1 binding to the NDRG1 promoter in vivo 
increased by approximately 3-fold in response to TPA treatment (p < 0.05).   
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4.3. DISCUSSION 
 
In order to understand the factors that drive the enhanced expression of NDRG1 in 
OSCC we cloned and partly characterised the putative NDRG1 promoter.  This study is 
novel in that it is the first, to our knowledge, that describes transcriptional regulation 
of NDRG1 in oesophageal cancer cells. 
 
Using 12-O-tetradecanoylphorbol 13-acetate as a stimulus, we identified the -2100 bp 
to +12 bp region of the NDRG1 promoter as responsible for induced transcription of 
NDRG1.  Within this region we identified two AP-1 sites at -788 bp to -778 bp and -
1123 bp to -1113 bp as significant regulatory elements stimulating the TPA response.  
In addition, an EGR-1 regulatory element was identified as essential for driving NDRG1 
transcription in response to TPA, and binding of this transcription factor to the NDRG1 
-49 bp to -41 bp promoter region was confirmed with ChIP assays in vivo.   Since target 
specific siRNA, as well as site-directed mutagenesis implicated both EGR-1 and AP-1 in 
regulating NDRG1 in response to TPA, we propose that these factors may be in part 
responsible for the elevated expression of NDRG1 seen in tumour tissue of our cohort 
of OSCC patients.  Although our initial results indicated that treatment of cells with TPA 
resulted in phosphorylation of ERK1/2, JNK and p38 (Fig. 4.3 and 4.5) we excluded p38 
as an important mediator of the TPA-induced NDRG1 response.  Phosphorylation was 
only detected 2 hours post-TPA treatment, and maximal levels of p38 phosphorylation 
was only observed 4 hours post-TPA treatment.  In contrast, maximal levels of ERK1/2 
and JNK phosphorylation was observed 1 hour post-TPA treatment, consistent with 
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elevated levels of NDRG1 detected 1 hour post-TPA treatment (Fig. 4.5).  Furthermore, 
although the AKT inhibitor (Akti1/2) had no effect on the induction of NDRG1 in 
response to TPA treatment, blockade of AKT was associated with a significant increase 
in basal NDRG1 expression (Fig. 4.9 and 4.10).   
 
AP-1 has been implicated in many tumourigenic processes including metastasis, 
enhanced proliferation, apoptosis and angiogenesis[159;202;203] and the 
transactivation of AP-1 has been shown to be an essential component of tumour 
progression in epidermal keratinocytes[204].  Of the AP-1 constituent proteins, c-Jun, 
c-Fos and Fos B are highly efficient in transforming cells[205-207], and enhanced c-Jun 
and c-Fos expression has been associated with oesophageal cancer[208].  Although we 
do not show specific binding of cJun to the NDRG1 promoter, our finding, using siRNA 
and site-directed mutagenesis, that AP-1 regulates NDRG1 at the transcriptional level 
supports a previous report that a dominant-negative AP-1 weakened the response of 
NDRG1 to hypoxia[86].  Specific binding of cJun at the AP-1 sites (-788 to -778) and (-
1123 to -1113 bp) will be addressed in the future.   
 
Although evidence by others indicates that EGR-1 plays an important role in regulating 
NDRG1 expression in response to hypoxic conditions[153], we have shown that this 
transcriptional factor also modulates NDRG1 expression in response to other signalling 
conditions.  Indeed, this is the first in vivo demonstration of EGR-1 binding to the 
NDRG1 proximal promoter region, and reports that the EGR-1 binding motif within the 
NDRG1 promoter is conserved between human, mouse, rat, chimpanzee and bovine 
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species[153] suggests that this transcription factor is important for NDRG1 regulation.  
As with AP-1, EGR-1 has been implicated in tumour growth, proliferation and 
angiogenesis[186;209].  In fact, our group has recently shown that EGR-1 forms a 
critical link in proliferative autocrine GRO/CXCR2 signalling in oesophageal 
cancer[186;210].  Moreover, using the same cohort of patients as in Chapter 2, EGR-1 
was shown to be overexpressed in 80 % of the oesophageal tumour tissue 
studied[186].  Thus, there appears to be a correlation between the frequency of 
NDRG1 and EGR-1 overexpression in oesophageal tumour tissue compared to normal 
tissue.     
 
Interestingly, while the AP-1 sites within the NDRG1 promoter were shown to play a 
part in TPA-induced NDRG1 expression, cJun siRNA appeared to have a repressive 
effect on EGR-1 expression in KYSE450 cells treated with TPA.  We propose that cJun 
may regulate NDRG1 indirectly, at least in part, through the modulation of EGR-1 
expression.  Since cJun has been implicated in the regulation of EGR-1 in other 
systems[211] and the EGR-1 promoter does contain AP-1 binding sites[211;212], this 
possibility will be explored further, and in additional cell lines.      
 
Taken together, we have characterised factors that regulate the upstream promoter 
region of NDRG1, leading to its induced expression in response to TPA.  Both EGR-1 
and AP-1 have been implicated in carcinogenesis and are associated with oesophageal 
cancer.  We show that TPA-induced NDRG1 expression is mediated by MEK/ERK – EGR-
1 and JNK-cJun/AP-1 and that this signalling converges at the NDRG1 promoter.  We 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 127 
are however cognisant that TPA induces multiple MAPK pathways.  Therefore, in order 
to more accurately understand the regulation of the NDRG1 promoter, further work 
will be carried out to investigate the effects of exogenous EGR-1 and AP-1 on NDRG1 
expression.  
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CHAPTER 5 
CONCLUSIONS 
Over the last decade, evidence presented in the literature has implicated NDRG1 in 
tumourigenesis.  This has not been without controversy, where the reported 
expression of NDRG1 in some cancers, as well as its relationship to metastasis is not 
always consistent.    Since a preliminary study in our laboratory, using differential-
display RT-PCR and microarray technology, identified NDRG1 as differentially 
expressed in OSCC tissue compared to normal tissue, we sought to characterise its role 
and regulation in OSCC further.   
 
Analysis of NDRG1 mRNA expression in 8 oesophageal cancer tissue biopsies compared 
to 6 normal tissue biopsies, by quantitative real-time RT-PCR, revealed that NDRG1 
was significantly overexpressed in tumour tissue compared to normal tissue.  This 
observation was consistent with our immunohistochemical analysis of NDRG1 protein 
expression on a cohort of eighty-three OSCC patients, where NDRG1 expression was 
found to be 2.6-fold higher in tumour tissue compared to normal tissue.  These results 
are in contrast with others describing NDRG1 expression in OSCC[104;105] which only 
adds to the controversy surrounding NDRG1’s role in cancer.  Indeed, this highlights 
the need for further population based studies on NDRG1 expression in OSCC, where 
the population’s genetic milieu, environment and aetiological agents may differ.   
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Moreover, the methodology of these studies should be synchronised to reduce the 
potential of variability. 
 
Our immunohistochemical study also revealed that NDRG1 localises to different 
compartments within oesophageal epithelial cells, and this localisation tracks with the 
maturation of the cells.  In normal oesophageal epithelium, cells in the basal and 
parabasal layers display plasma membrane-localised NDRG1 while maturing cells are 
positive for NDRG1 largely in the cytoplasm and nucleus.  Interestingly, both dysplastic 
tissue as well as poorly differentiated OSCC displayed plasma membrane-associated 
NDRG1, whilst moderately and well differentiated tumours stained positively for 
NDRG1 in the cytoplasm, nucleus and plasma membrane.  The predominant 
association of NDRG1 with the plasma membrane of dysplastic cells could suggest that 
OSCC arises through the malignant expansion of the basal layer of the epithelium 
where stem cells are proposed to reside[109;175]. Indeed, the fact that NDRG1 is 
associated with early changes in oesophageal cancer suggests that this protein could 
probably be used as an early marker for this disease.  Moreover, since NDRG1 shows a 
positive correlation with differentiation in other systems, one might speculate that the 
cytoplasmic and nuclear localisation of NDRG1 is associated with a commitment of cell 
fate to differentiate.  Interestingly, a recent report by Sibold et al[101] showed that 
while hepatocellular carcinoma cells cultured in vitro displayed cytoplasmic localisation 
of NDRG1, in vivo growth of the same cells as xenografts gave rise to plasma 
membrane-associated NDRG1. This implicated the tumour microenvironment in 
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influencing NDRG1 localisation.  Indeed, it may be useful to examine the localisation 
and function of NDRG1 in cultured cells grown on denuded, acellular oesophageal 
connective tissue, which has been shown to give rise to reconstituted oesophageal 
epithelium[109].  To this end, we examined NDRG1 expression in cultured OSCC cell 
lines cultured under anchorage-independent conditions, since the function of NDRG1 
expression in cultured OSCC cells has, to date, not been demonstrated.  Anchorage-
independent cell culture resulted in a strong upregulation of NDRG1 protein 
expression that was sustained for at least 72 hours in WHCO1, WHCO6, KYSE70, 
KYSE180 and KYSE450 cell lines.  Interestingly, immunocytochemistry performed on 
sections of cultured cells that had been embedded in paraffin blocks, revealed that in 
WHCO1 and WHCO6 cells, anchorage-independent growth resulted in strong 
cytoplasmic and nuclear localisation of NDRG1.  In KYSE70 and KYSE180 cells, cultured 
in the same manner, NDRG1 appeared to localise to the plasma membrane.  This is, to 
our knowledge, the first description of NDRG1 expression in cells cultured under 
anchorage-independent conditions.  Interestingly, NDRG1 displayed markedly different 
localisation in cultured cells derived from the same tissue type, suggesting that even 
cells from the same tissue may express NDRG1 differently.     
 
To determine whether anchorage-independent upregulation of NDRG1 expression 
imparted a biological effect on cultured OSCC cell lines, small interfering RNA was used 
to specifically knock down NDRG1 expression.  Effective knock-down of NDRG1 
expression was achieved with siRNA but had no effect on anchorage-independent 
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proliferation or apoptosis of cultured OSCC cell lines.  Since no effect was observed 
here, we next examined the expression of genes involved in angiogenesis and invasion 
in cell lines cultured under-anchorage-independent conditions.  Real-time RT-PCR 
results indicated that mRNA expression of invasion genes, MMP-2 and MMP-9 
decreased with time of anchorage-independent cell culture.  Likewise, genes involved 
in angiogenesis, Ang-1, PDGF-B and VEGF-C also exhibited a downward trend in mRNA 
expression in cells cultured under anchorage-independent conditions.  However, in 
contrast, mRNA expression of the angiogenic cytokine, VEGF-A, increased with time of 
anchorage-independent cell culture, reminiscent of the increase observed for NDRG1 
mRNA under the same culture conditions.  A link between NDRG1 and VEGF-A 
expression was demonstrated, again using NDRG1 siRNA.  Specific knock-down of 
NDRG1 expression with siRNA resulted in reduced expression of VEGF-A mRNA, as well 
as reduced levels of VEGF-A protein secreted into the media of cell lines cultured 
under anchorage-independent conditions.  Luciferase reporter assays demonstrated 
that VEGF-A promoter activity, induced by anchorage-independent cell culture, was 
NDRG1-dependent.   
 
NDRG1 expression did not appear to have an impact on tumour cell biology (i.e. 
proliferation and apoptosis) in vitro, but since in vitro cell culture does not depend on 
angiogenesis it is reasonable that no phenotypic changes would be observed.  In fact, it 
would be useful to examine whether NDRG1 modulates neovascularisation and VEGF-
A expression in an in vivo mouse xenograft model, using the same cell lines stably 
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transfected with control or NDRG1 siRNA.  Moreover, it is of interest to us by what 
mechanism NDRG1 modulates VEGF-A expression.  Since Hosoi et al. [137] reported 
that NDRG1 abrogates VEGF-A expression in cultured pancreatic cells, through the 
attenuation of NF-κB signalling, it may be useful to determine whether the inverse is 
true in our culture system.  In fact, our group recently reported the upregulation of 
p65 (one of the subunits of the NF-κB heterodimeric complex) in the same cohort of 
OSCC patients used in this study[186].  Indeed, this may implicate a role for NDRG1 in 
the angiogenic switch essential for OSCC growth and provide a new target for cancer 
therapy since targeting VEGF-A using neutralising antibodies and tyrosine kinase 
inhibitors has been successful in the treatment of colorectal carcinoma, and has shown 
promising results for other cancers[213]. 
 
Our evidence that NDRG1 plays an oncogenic role in OSCC provided us with the 
impetus to examine what factors may be responsible for its upregulation in this 
disease.  Using TPA as a system to drive NDRG1 expression, we showed that induced 
NDRG1 lies downstream of the ERK1/2 and JNK MAPK pathways.  By cloning and 
analysing the NDRG1 promoter we showed that TPA-induced NDRG1 expression is 
largely dependent on EGR-1 and cJun/AP-1 transcription factors.  Since EGR-1 and AP-1 
have both been associated with OSCC[186;208] it will be useful to further examine 
their role in the modulation of NDRG1 expression.  Specifically, since it has been 
reported that EGR-1 is a key regulator in GRO/CXC proliferative signalling in 
oesophageal cancer[186], the expression of NDRG1 in this system may be of interest.  
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Indeed, this may provide further evidence that EGR-1 contributes to tumourigenesis of 
oesophageal epithelial cells through the upregulation of NDRG1, and therefore VEGF-
A.   Another point to consider is that in other cell systems, namely prostate cancer 
cells, hypoxia resulted in an EGR-1-dependent transcriptional activation of HIF-
1α[214].  Since VEGF-A is a transcriptional target of HIF-1 and is also induced by low 
oxygen tension[184], a link between EGR-1, HIF-1α and VEGF-A seems apparent.  This 
will be a useful pathway to examine in oesophageal cancer, in the context of NDRG1 
induction.  Indeed, experiments exploring NDRG1, EGR-1, HIF-1α and VEGF-A 
expression in cell lines cultured in a hypoxic chamber will answer this question.   
 
The study has given rise to new questions with regards to NDRG1 regulation and 
expression in OSCC.  In the first instance, we know that in a subset of our cell lines 
NDRG1 expression is induced by TPA through PCK/MEK/ERK- EGR-1 and cJun/AP-1.  
However, both WHCO5 and KYSE520 cell lines exhibit no NDRG1 response to TPA, at 
both the protein expression and transcriptional level.  Whether this is due to a lack of 
EGR-1 and AP-1 activation by TPA, or whether TPA induces expression of factors that 
dampen the EGR-1 and AP-1 effect, should be explored.  Indeed, this observation could 
be a reflection of the different internal milieus within the cells.  In addition, while the 
NDRG1 TPA response has been, in part, characterised, the factors responsible for 
NDRG1 expression under conditions of anchorage-independent cell culture should be 
examined.  Specifically, we will address the possible role of EGR-1 and AP-1, amongst 
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others, in regulating NDRG1 expression under anchorage-independent cell culture 
conditions.   
 
The possible role of NF-κB in mediating the VEGF-A response to NDRG1 expression has 
been discussed.  However, a time course microarray study should be performed to 
determine what other effectors may respond to NDRG1 upregulation, under 
conditions of anchorage-independent cell culture, and to determine what proteins 
may result in changes in phenotype, specifically related to angiogenesis.   
    
In conclusion, this study describes the transcriptional regulation of NDRG1 expression 
by EGR-1 and cJun/AP-1 and implicates an oncogenic role for NDRG1 in the 
development of OSCC by modulating VEGF-A cytokine expression.  The mechanism by 
which NDRG1 induces VEGF-A transcription and expression must be investigated 
further.   
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CHAPTER 6 
MATERIALS AND METHODS 
 
6.1. Tissue samples for immunohistochemistry and real-time quantitative PCR 
Archived paraffin embedded oesophageal tissues (squamous cell tumour tissue and 
matched normal tissue from the same patient) were derived from 83 patients who 
underwent oesophageal resection at the Department of Cardiothoracic Surgery, 
Groote Schuur Hospital (Observatory, South Africa), with histologically confirmed 
oesophageal squamous cell carcinoma.  These patients, comprised of 20 females and 
63 males, were treated between 1986 and 2006 with ages ranging from 23 to 80 years 
(mean 53.3 ± 10.1 years).  Sections from the tumour-spanning region of the 
oesophagus occasionally contained regions of epithelium with dysplasia.  Normal 
sections were obtained from the resection margins of the tissue.  Oesophageal tissue 
biopsies from which RNA was prepared were snap frozen in liquid nitrogen and stored 
at -70
o
C. Ethics approval for this study was granted by the Research Ethics Committee 
of the University of Cape Town (REC. REF: 320/2004).  
 
6.2. Immunohistochemistry 
Oesophageal tumour sections (2 µM thickness) and corresponding adjacent normal 
oesophageal epithelium from 83 patients who had undergone oesophagectomies were 
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used for the immunohistochemical analysis.  After sections were dewaxed and 
rehydrated, antigen retrieval was carried out by pressure-cooking the sections in 10 
mM citrate buffer (pH 6.0) for 2 minutes. The sections were blocked for endogenous 
peroxidase using 1 % hydrogen peroxide and subsequently blocked for non-specific 
binding by incubation in 5 % normal goat serum (DakoCytomation, Denmark) for 20 
minutes. Staining was performed as previously described using a rabbit polyclonal 
antiserum (diluted 1:500) raised to NDRG1 that has been used previously to detect 
NDRG1 in cancer cell lines[113]. This was a generous gift from Prof. T. Commes 
(University of Montpellier, France).   The tissue sections were stained in an automated 
DAKO Universal stainer using the IHC software (DakoCytomation). The primary 
antibody was detected using Envision
TM 
rabbit/mouse peroxidase (DakoCytomation) 
and the development of colour carried out using diaminobenzidine (DAB) 
(DakoCytomation). The slides were briefly counterstained in hematoxylin, mounted in 
Entellen (Merck, Germany) and examined under various magnifications using an 
Axioskop 2 Mot microscope (Zeiss, Germany).  Images were captured with a Zeiss 
AxioCamHR camera and Axiovisio (version 4.7) software (Zeiss). The specificity of the 
NDRG1 stain was confirmed by using two additional primary antibodies against 
NDRG1, namely rabbit anti-Cap43 (1:50; 52-3557, Zymed, San Francisco, CA, USA) and 
mouse anti-NDRG1 (1:100; sc-100786, Santa Cruz Biotechnology, Santa Cruz, CA, USA).  
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6.3. RNA isolation from tissue biopsies 
Total RNA was prepared from tissue biopsies using TRIzol reagent (phenol/guanidine 
isothiocyanate) (Invitrogen, Rockville, MD, USA), according to the manufacturer’s 
recommendations.  In short, tissue was weighed and 1 ml of TRIzol added to 100 mg 
tissue. Tissue samples were homogenised and left to stand at room temperature for 5 
minutes.  Centrifugation was then carried out at 10 000 x g for 10 minutes at 4°C and 
the supernatant transferred to a new tube while the insoluble material was discarded. 
One fifth of a millilitre of chloroform per ml TRIzol was added and the samples shaken 
vigorously, by hand, for 15 seconds and then placed on ice for 10 minutes.  Separation 
of the mixture into three phases: an upper colourless, aqueous phase containing RNA, 
an interphase containing DNA, and a lower phase containing protein, was performed 
by centrifugation at 10 000 x g for 15 minutes at 4°C.  The aqueous phase was removed 
to a new tube and RNA precipitated using 0.5 ml isopropanol/ ml TRIzol. Samples were 
incubated at -20°C overnight and then centrifuged at 10 000 x g for 20 minutes at 4°C.  
RNA pellets were washed with 75 % ethanol, air-dried and resuspended in 300 µl 0.01 
% diethylpyrocarbonate(DEPC)-treated dH2O. To further purify the RNA 200 µl 
isopropanol and 20 µl 3 M Sodium Acetate was added and the solution incubated for 1 
hour at -20°C.  Centrifugation was then carried out at 12 000 x g for 30 minutes at 4°C 
to pellet the RNA, followed by washing with 70 % ethanol.  Lastly, RNA was air-dried 
and resuspended in 30 µl DEPC-treated dH2O. RNA was quantified using a UV 
spectrophotometer and RNA integrity established by denaturing MOPS/formaldehyde 
agarose gel electrophoresis. 
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6.4. Cell culture 
6.4.1. Cell lines and medium requirements 
The human oesophageal squamous cell carcinoma cell lines WHCO1, WHCO5 and 
WHCO6, derived from South African patients, were a gift from Prof. R. Veale 
(University of Witwatersrand)[215]. KYSE30, KYSE70, KYSE180, KYSE450 and KYSE520 
cell lines, established by Shimada et al.[216] were purchased from German Resource 
Centre for Biological Material, DSMZ GmbH (Braunschweig, Germany).  All 
oesophageal cancer cell lines were maintained in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with streptomycin (100 µg/mL), penicillin (100 U/mL) and 10 % 
Fetal Calf Serum (FCS) (Gibco, Paisley, Scotland).  HUVEC cells, a gift from Dr. N. Davies 
(University of Cape Town) were grown in DMEM supplemented with streptomycin (100 
µg/mL), penicillin (100 U/mL), 10 % Fetal Calf Serum (FCS), epidermal growth factor (10 
ng/ml), hydrocortisone (1 µg/ml) and 2 mM L-Glutamine (Sigma-Aldrich Inc., St Louis, 
USA).  All cell lines were cultured in a humidified atmosphere of 5 % carbon dioxide at 
37
o
C and routinely tested for mycoplasm contamination using Hoechst 33258 
fluorochrome stain (Sigma-Aldrich, Inc.). 
 
6.4.2. Subculturing cells 
Cells in a 100 mm culture dish were washed with 2 ml of trypsin-EDTA trypsinisation 
solution and the solution aspirated off.  Three millilitres of fresh trypsin-EDTA solution 
was added to the cells and trypsinisation monitored with a microscope (Zeiss).  When 
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70-80% of cells were trypsinised, the reaction was stopped with the addition of 3 ml of 
fresh DMEM medium containing serum.  The cell suspension was transferred to a 10 
ml Falcon tube and centrifuged at 250 x g for 5 min at 4
o
C.  The medium/trypsin 
solution was aspirated off and the cells resuspended in 1 ml of culture medium.  
Approximately 200 µl of this cell suspension was then inoculated into 10 ml of fresh 
medium in a 100 mm culture dish.  For anchorage-independent cell growth assays, cell 
lines were cultured at a concentration of 0.5 x 10
6
 cells/ml in culture dishes coated 
with Poly(2-hydroxyethyl methacrylate) (poly-HEMA; Sigma-Aldrich Inc.) that had been 
dissolved in 96 % ethanol (10 mg/ml)[217].   
 
6.4.3. Freezing and thawing cells 
A confluent dish of cells was trypsinised, neutralised with complete medium, followed 
by centrifugation to remove cells from trypsinisation solution.  Cells were suspended in 
5 ml of pre-chilled freezing medium (70 % culture medium, 20 % FCS and 10 % 
dimethylsulfoxide (DMSO)) and transferred into cryotubes.  Tubes were left at -80
o
C 
overnight and then transferred to liquid nitrogen. 
 
To thaw cells, the frozen cell suspension was quickly thawed in a 37
o
C waterbath and 
then cells transferred to a 10 ml tube containing 8 ml of complete growth medium.  
Cells, pelleted by centrifugation at 250 x g for 5 min at 4
o
C, were resuspended in 2 ml 
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of complete growth medium and inoculated into 10 ml of fresh medium in a 100 mm 
culture dish.   
 
6.5. Drugs and inhibitors 
12-o-tetradecanoylphorbol-13-acetate (TPA) was purchased from Sigma (Sigma-Aldrich 
Inc.). PKC inhibitor (GF109203x), JNK inhibitor (SP600125), MEK inhibitor (PD98059), 
Akt inhibitor VIII (Akti1/2) and p38 inhibitor (SB203580) were purchased from 
Calbiochem (EMD Biosciences, Inc.  San Diego, USA). EGFR inhibitor (AG1478) was 
purchased from Biomol International (Exeter, UK).   All drugs were resuspended in 
tissue culture grade DMSO (Sigma-Aldrich Inc.) unless otherwise stated.   
 
6.6. Preparation of cultured cell blocks for immunocytochemistry 
Cells were cultured under anchorage-dependent or -independent conditions for 48 
hours.  Adherent cells were lifted from plates using 0.2 % (w/v) EDTA in PBS.  Cells 
from both conditions were then collected by gentle centrifugation for 5 min at 100 x g 
in 50 ml tubes.  All but 5 ml of PBS was aspirated off, and to this 5 ml of ice cold 
buffered 4 % paraformaldehyde.  After gentle mixing, the cells were transferred to a 12 
ml tube and centrifuged as before.  The supernatant was discarded and 10 ml of fresh 
ice cold 4 % paraformaldehyde was gently added on top of the cell pellet.  This was left 
to stand for two hours at 4
o
C.  Again, the supernatant was removed and the cell pellet 
was gently flushed with PBS, without mixing.  After recentrfugation, 10 ml of room 
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temperature 80 % ethanol was added to the cell pellet.  Fixed cells were embedded in 
paraffin blocks and sectioned at American HistoLabs (Gaithersburg, MD, USA). 
 
6.7. RNA isolation from cultured cells 
RNA was harvested from cells, subjected to the appropriate treatment, using Qiazol 
(Qiagen, Hilden, Germany), according to the manufacturer’s recommendations.  In 
short, 0.2 ml chloroform was added per ml of Qiazol used, samples were mixed 
vigorously for 15 seconds and left on ice for 10 minutes.  Centrifugation was carried 
out at 10 000 x g and the upper aqueous phase removed to a new eppendorf tube.  
RNA was precipitated using 0.5 ml isopropanol per ml Qiazol at -20°C overnight.  The 
next day, samples were centrifuged at 10 000 x g for 20 minutes and RNA pellets 
washed with 75 % ethanol.  The RNA pellets were subsequently air-dried and 
resuspended in 30 µl 0.01 % DEPC-treated dH2O. RNA was quantified using a UV 
spectrophotometer and RNA integrity established by denaturing MOPS/formaldehyde 
agarose gel electrophoresis. 
 
6.8. RNA quantification and MOPS/formaldehyde agarose gel electrophoresis 
RNA was quantified using an ultra violet (UV) spectrophotometer.  The RNA suspension 
was diluted 1:250 and the UV absorbance measured at 260 nm and 280 nm on a 
Beckman DU 650 Spectrophotometer (Beckman, Brea, CA, USA).  The concentration of  
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RNA was calculated as follows:   
RNA (µg/ml) = OD260 nm x e x dilution factor 
Where e (extinction coefficient) for RNA = 40 
The purity of RNA was tested by measuring OD260 nm/OD280 nm where only ratios of less 
than 2.0 were considered for use. 
 
RNA quality was determined by MOPS/formaldehyde agarose gel electrophoresis.  
Briefly, 2 µg of each RNA sample was prepared in a final volume of 13 µl of 1 x RNA 
loading buffer.  To prepare a 50 ml gel, 1.5 % (w/v) agarose was dissolved by heating in 
1 x MOPS solution and allowed to cool.  Two and a half microlitres of ethidium 
bromide (10 mg/ml) and 2.7 ml of 37 % formaldehyde were then added, and the gel 
cast.  Once the gel had set, RNA samples were electrophoresed using 1 x MOPS buffer 
until 28s, 18s and 5s rRNA bands could be visualised under UV light.  Samples were 
only considered for use if bands were visible and of a good quality as seen in Figure 
6.1. 
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Figure 6.1.  MOPS/formaldehyde agarose gel electrophoresis of RNA samples 
prepared using Qiazol.  RNA prepared from cultured cell lines (WHCO1, WHCO5, 
WHCO6, KYSE70, KYSE180 and KYSE450) was subjected to electrophoresis on a 
MOPS/formaldehyde agarose gel to assess RNA quality.  Positions of 28s, 18s and 5s 
rRNA are indicated.    
 
6.9. Quantitative real-time RT-PCR 
Quantitative real-time RT-PCR analysis on RNA extracted from tissue biopsies and cell 
lines was carried out using the StepOne Real-time PCR System (Applied Biosystems, 
Foster City, CA, USA).  Reverse transcription cDNA synthesis was performed using 2 µg 
of total RNA from each sample, 2.5 μM oligo (dT)20 primer,  2 mM MgCl2, 1 mM dNTPs, 
1 µl ImPromII Reverse Transcriptase II (Promega, Madison, WI, USA), 1 µl RNAsin 
(Promega) and 1 X ImPromII reaction buffer (Promega) in a final volume of 20 µl.  
cDNA was subsequently amplified using the KAPA SYBR Fast qPCR Master Mix (KAPA 
Biosystems, Woburn, MA, USA) and 200 nM of the primer pairs presented in Table 6.1. 
All primer pairs were designed to  span  introns  to  exclude  amplification of  
contaminating genomic DNA.  PCR cycling conditions were 95°C for 3 minutes, 
followed  by  40  cycles  of  95°C  for  1  second  and  Ta  for  20  seconds.   Results  were 
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Table 6.1. Real-time RT-PCR primer sequences, annealing temperatures and product 
sizes 
Gene/Primer Sequence PCR product 
size (bp) 
Ta (°C) 
NDRG1 Forward 5’ GTGCGGAAGGCTGGATGG 3’ 
NDRG1 Reverse 5’ ACAATGTGCTGGCGGTAGG 3’ 
144 60 
VEGF-A Forward 5’ TTCATGGATGTCTATCAGCG 3’ 
VEGF-A Reverse 5’ GCTCATCTCTCCTATGTGCT 3’ 
236 60 
VEGF-C Forward 5’ GCCAACCTCAACTCAAGGAC 3’ 
VEGF-C Reverse 5’ CCCACATCTGTAGACGGACA 3’ 
200 60 
Ang-1 Forward 5’ GGACAGCAGGAAAACAGAGC 3’ 
Ang-1 Reverse 5’ TAATCGCTTCTGACATTGCG 3’ 
292 60 
PDGF-B Forward 5’ TTATGAGATGCTGAGTGACCAC 3’ 
PDGF-B Reverse 5’ CCTTCTTCCACGAGCCAAG 3’ 
156 55 
MMP-2 Forward 5’ CCCTCGCAAGCCCAAGT 3’ 
MMP-2 Reverse 5’ GCACGAGCAAAGGCATCAT 3’ 
102 60 
MMP-9 Forward 5’ CCTGGGCAGATTCCAAACCT 3’ 
MMP-9 Reverse 5’ GCAAGTCTTCCGAGTAGTTTTGGAT 3’ 
88 53 
Cyclophilin D Forward 5’ TGAGACAGCAGATAGAGCCAAGC 3’ 
Cyclophilin D Reverse 5’ TCCCTGCCAATTTGACATCTTC 3’ 
94 60 
GusB Forward 5’ CTCATTTGGAATTTTGCCGATT 3’ 
GusB Reverse 5’ CCGAGTGAAGATCCCCTTTTTA 3’ 
81 60 
Ta refers to the annealing temperature used in the cycling stage of the real-time RT-
PCR 
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standardised using the house-keeping genes, β-glucuronidase (gusB) and/or cyclophilin 
D. Data was analysed using the comparative threshold cycle (CT) method to compute 
the expression fold change between samples[218]. 
 
6.10. Immunofluorescent analysis of cultured cells 
For immunofluorescent analysis of protein expression and localisation, cultured cells 
were seeded, at a density of 2 x 10
5
, on sterile coverslips in 35 mm dishes and left to 
grow for 36 hours.  Cells were fixed in 4 % paraformaldehyde at room temperature for 
20 minutes. To permeabilise the cells, coverslips were soaked in 0.1 % Triton X-100 in 
PBS for 5 minutes followed by 50mM NH4Cl in PBS for 5 minutes to quench the 
reaction, and blocked in 0.2 % gelatin for 45 minutes.  Coverslips were then incubated 
with primary antibody; specifically, rabbit α-NDRG1 primary antibody (1:500) and/or 
mouse α-E-cadherin primary antibody (1:2; 08-1223, Zymed) overnight in a humidified 
chamber at 4
o
C.  The next day, primary antibody was removed by 3 washes in PBS, and 
secondary antibodies, Cy3-conjugated goat anti-rabbit antibody (1:300; Jackson 
ImmunoResearch, West Grove, PA, USA), Cy3-conjugated goat anti-mouse antibody, 
(1:300; Jackson ImmunoResearch) or Alexa488-conjugated goat anti-rabbit antibody 
(1:400; Invitrogen), were applied for a further 45 minutes. Cell nuclei were stained 
with DAPI (100 ng/ml) for 5 minutes, followed by washing in PBS. Coverslips were 
mounted on slides with Mowiol. Slides were examined under various magnifications 
using an Axiovert 200M microscope (Zeiss).  Images were captured with a Zeiss 
AxioCamHRm camera and Axiovisio (version 4.7) software (Zeiss). 
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6.11. Anchorage-independent cell proliferation (MTT) assay 
The effect of control and NDRG1 siRNA on anchorage-independent cell proliferation 
was measured using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) assay.  In short, cells were transfected with 20 nM of either control or NDRG1 
siRNA.  The next day, transfectants were seeded into poly-HEMA coated 96-well plates, 
in a final volume of 100 µl, at a concentration of 10 000 cells/well.  After the prescribed 
time of growth, 10 µl of MTT reagent (Roche, Basel, Switzerland) was added per well, 
and the plates were incubated at 37
o
C for 4 hours.  One hundred microlitres of 
solubilisation solution was then added to each well.  After overnight incubation at 
37
o
C, absorbencies were read at OD595 nm using a microplate reader (BioTek, Winooski, 
VT, USA).  
 
6.12. Caspase-Glo®3/7 Apoptosis assay 
The extent of apoptosis was determined by measuring Caspase-3/7 activity, using the 
Caspase-Glo®3/7 Assay (Promega), according to the manufacturer’s instructions. Cells 
were seeded into normal, or poly-HEMA coated 96-well plates, in a final volume of 100 
µl, at a concentration of 8000 cells/well.  After 72 hours of anchorage-dependent or -
independent growth, 100 µl of Caspase-Glo 3/7 reagent was added to each well.  The 
plates were left at room temperature for 1 hour, after which 100 µl of cell/Caspase-Glo 
3/7 suspension was transferred to a white 96-well plate (Nunc, Rochester, NY, USA).  
Luminescence was measured using the Glomax 96 Microplate Luminometer 
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(Promega).  To determine the effect of control or NDRG1 siRNA on apoptosis, cells 
were first transfected with 20 nM of control or NDRG1 siRNA.  The next day cells were 
seeded into poly-HEMA coated 96-well plates. The cells were then cultured for 72 
hours, and the Caspase-Glo®3/7 Assay performed as described above. 
 
6.13. In vitro transwell migration assay 
Transwell inserts with 8 µM pores were used in this assay (Greiner bio-one, Solingen 
Germany).  Conditioned medium, to act as HUVEC chemoattractant, was prepared by 
culturing OSCC cell lines, at a density of 0.5 x 10
6
 cells/ml, in an anchorage-
independent manner for 72 hours.  Cells were removed from the medium by 
centrifugation (100 x g, 5 min) and 1 ml of the cell-free supernatant transferred to each 
well of a 12-well transwell plate.  HUVECs, which had been starved overnight in 
complete medium containing 5 % FCS, were seeded into the top chambers of the 
transwell plate at a density of 2.0 x 10
5
 cells/well.  After an 8 hour incubation, non-
migrated cells, on the upper surface of the transwell filter, were gently removed with a 
cotton swab.  Cells which had migrated through the filter were fixed in 100 % 
methanol, for 10 minutes at room temperature, after which the filters were air dried.  
Cells were stained with crystal violet (2 % (v/v) ethanol, 0.2 % (w/v) crystal violet) for 
20 minutes and then washed gently with distilled water to remove excess stain.  Cell 
were then visualised under a microscope and counted in four fields of view, on 
duplicate filters.  To neutralise VEGF-A, 5 µg/ml of rabbit anti-human VEGF-A antibody 
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(PeproTech Asia, Rehovot, Israel) was added to the conditioned medium in the bottom 
wells, where applicable.   
 
6.14. VEGF-A ELISA   
VEGF-A ELISA, to measure the concentration of VEGF-A secreted into the medium, was 
performed as described by the manufacturer (PeproTech Asia).  Briefly, cell lines were 
cultured under anchorage-dependent or -independent conditions for the indicated 
times.  Media, with or without cells, was removed to a tube and centrifuged (200 x g, 5 
min) to remove cells.  The supernatant was transferred to a new tube and kept at -
80
o
C.  ELISA microplates (Nunc) were coated with capture antibody overnight at room 
temperature, and then washed.  After blocking for 1 hour, and washing, standards and 
100 µl of each sample (thawed to room temperature) were added to wells, in 
triplicate, and left at room temperature for 2 hours.  Following incubation with the 
detection antibody for 2 hours, avidin-HRP conjugate was added, and the colour 
development carried out using ABTS liquid substrate (Sigma-Aldrich Inc.).  Absorbance 
was measured on a microplate reader (BioTek) at 405 nm.    
 
6.15. Western blot analysis 
6.15.1. Preparation of whole cell lysates and protein quantification 
For anchorage-dependent cultured cells, cells were treated with drug, or grown in the 
prescribed fashion, for the indicated times.  Medium was removed, cells rinsed twice 
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with chilled phosphate-buffered saline (PBS), and rinses and media were subjected to 
centrifugation (150 x g, 5 min) to pellet any non-adherent cells.  Cells in the culture 
dish were lysed using a rubber policeman, on ice, in radioimmunoprecipitation assay 
(RIPA) buffer containing 1 x complete protease inhibitor cocktail (Roche) and 1 mM 
sodium orthovanadate and 20 mM sodium fluoride, to inhibit the action of 
phosphatases.  The pellet of non-adherent cells was taken up in the resulting lysis 
solution.  For cells cultured in an anchorage-independent manner, cells were grown for 
the indicated times and then pelleted by centrifugation (150 x g, 5 min).  The resulting 
cell pellet was washed twice with chilled PBS and the cells then resuspended in RIPA 
buffer using a pipette.  All lysates were subjected to sonication at 4
o
C and stored at -
80
o
C. 
 
Protein quantification was carried out in 96-well plates using the Bicinchoninic Acid 
(BCA) protein assay kit (Pierce, Thermo Scientific, Rockford, IL, USA), according to the 
manufacturer’s instructions.  Absorbencies of BSA protein standards and cell lysates 
were read at OD595 nm using a microplate reader (BioTek). 
 
6.15.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
protein transfer 
The SDS-PAGE was performed using the BioRad MINI PROTEIN II gel system (BioRad, 
Hercules, CA, USA).  Protein samples were prepared by mixing equivalent amounts of 
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protein with protein loading dye, and boiling for 5 minutes at 90
o
C.  SDS-
polyacrylamide gels were prepared with 10 % acrylamide separating and 4 % 
acrylamide stacking gels.  Samples were loaded into the wells of SDS-10 % 
polyacrylamide gels and subjected to electrophoresis at 150 volts, for the appropriate 
time.  Kaleidoscope protein molecular weight marker (BioRad) was used to determine 
the size of the proteins.  Following separation, proteins were transferred to 
HybondTM-ECL
TM 
nitrocellulose membrane (Amersham Biosciences, Buckinghamshire, 
UK) using a buffered tank transfer system, at 100 volts for 1 hour.   
 
6.15.3. Immunoblotting and chemiluminescent detection 
Following protein separation and transfer, membranes were blocked with a solution of 
5 % (w/v) fat free milk (referred to from now on as milk) diluted in Tris-buffered saline 
(pH 7.4) containing 0.1 % Tween-20 (TBST), for 1 hour at room temperature. 
Subsequent to blocking, primary antibody was added (Table 6.2) and the membranes 
left overnight at 4
o
C, with shaking.  The next day, after primary antibody was removed 
and the membrane washed three times for 10 minutes with TBST, the secondary 
antibody was added for 1 hour at room temperature.  After another three washes with 
TBST antibody detection was performed, using the Supersignal West Pico or 
Supersignal West Dura kits (Pierce), depending on the strength of the signal.  
Chemiluminescent light emission was detected on X-ray film (AGFA) and visualised by 
developing  the  film  by  hand,  for 2 minutes in developer (AGFA G128), washed for 2  
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Table 6.2. Antibodies and conditions used for Western blot analysis 
Primary Antibody Primary 
Antibody 
Conditions 
Secondary 
Antibody 
Secondary 
Antibody 
Conditions 
Substrate 
NDRG1                                               
[sc-30040, SCBT*] 
1:1000 in 5 % 
Milk in TBST 
Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Dura 
β-Tubulin                                           
[sc-9104, SCBT] 
1:1000 in TBST Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Pico 
EGR-1                                                     
[4153, CST**] 
1:1000 in 5 % 
BSA in TBST 
Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Dura 
phospho-ERK1/2 (Thr 202/Tyr 204)                     
[9106, CST] 
1:750 in 2.5 % 
BSA in TBST 
Goat anti-Mouse 
[BioRad] 
1:1000 in 2.5 % 
Milk in TBST 
West Dura 
ERK2                                          
[sc-154, SCBT] 
1:1000 in 1 % 
Milk in TBST 
Goat anti-Rabbit 
[BioRad] 
1:1000 in 2.5 % 
Milk in TBST 
West Pico 
phospho-cJun (Ser 63/73)                            
[sc-16312-R, SCBT] 
1:1000 in 5 % 
BSA in TBST 
Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Pico 
cJun                                                    
[sc-1694, SCBT] 
1:1000 in 5 % 
BSA in TBST 
Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Pico 
phospho-p38 (Thr 180/ Tyr 182)                               
[9211, CST] 
1:1000 in TBST Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Dura 
p38                                                                
[M 0800, Sigma] 
1:5000 in TBST Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Pico 
phospho SAPK/JNK                                 
(Thr 183/ Tyr 185)                                                 
[9251,CST] 
1:1000 in 5 % 
Milk in TBST 
Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Dura 
SAPK/JNK                                          
[9258, CST] 
1:1000 in 5 % 
Milk in TBST 
Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Pico 
phospho-AKT (Ser 473)                     
[9271,CST] 
1:1000 in 5 % 
Milk in TBST 
Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Dura 
AKT                                                      
[9272, CST] 
1:1000 in 5 % 
Milk in TBST 
Goat anti-Rabbit 
[BioRad] 
1:1000 in 5 % 
Milk in TBST 
West Dura 
*SCBT - Santa Cruz biotechnology  **CST - Cell Signaling Technology, Danvers, MA, USA BSA - Bovine serum albumin 
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minutes with water, and then fixed for 5 minutes in AGFA G333C fixative, as 
recommended by the manufacturer.   
  
6.15.4. Stripping and reprobing blots 
After detection blots were stripped by soaking in stripping buffer at room temperature 
for 20 minutes, without shaking.  Membranes were then washed four times with TBST 
after which blocking and reprobing with a new antibody could proceed.   
 
6.16. RNA interference 
Small interfering RNA was purchased from Santa Cruz Biotechnology.  EGR-1 (sc-
29303) and cJun (sc-29223) siRNAs are 20-25 nucleotides designed to specifically knock 
down expression of target genes.  Control siRNA (sc-37007) is non-targeting 20-25 
nucleotide siRNA designed as a negative control.  Transient transfection of siRNA was 
performed using Transfectin transfection reagent (BioRad).  Depending on the 
application, either 35 mm or 60 mm culture dishes containing 40-60 % confluent cells 
were transfected.  For a 35 mm culture dish or a single well of a 6-well plate, 0.625 µl 
of Transfectin reagent was added to 50 µl of serum-, penicillin- and streptomycin-free 
medium in an eppendorf tube.  After a 5 minute incubation at room temperature, 2 µl 
of 10 µM siRNA was added and the tube left again at room temperature for 20 
minutes.  The transfection cocktail was then added dropwise to the cells in 1 ml of 
media (with 10 % FCS and streptomycin (100 µg/mL), penicillin (100 U/mL)), giving a 
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final concentration of 20 nM siRNA.  The next day media was changed and the cells 
were treated or grown as described.  To transfect cells plated in 60 mm culture dishes, 
the reaction was scaled up accordingly. 
 
6.17. VEGF-A reporter assay 
The VEGF-A promoter (-2018 to +50) reporter construct, pVEGF-Luc, was a generous 
gift from Prof. Alan Knox, University of Knottingham, UK.  To examine the activity of 
the VEGF-A promoter (-2018 to +50) reporter construct in cultured cells, Effectene 
transfection reagent (Qiagen) was used to transfect cells, at 70 % confluence, in 60 mm 
culture dishes.  Briefly, 1 µg of pVEGF-Luc or pGL3-Basic, 10 ng of pRL-TK (that encodes 
Renilla luciferase) and 8 µl of Enhancer solution were added to 150 µl of EC buffer and 
left at room temperature for 5 minutes.  Twenty-five microlitres of Effectene reagent 
was then added to the transfection mix.  After 10 minutes at room temperature, 1 ml 
of complete growth medium was added and the transfection mix added dropwise to 
the cells in 4 ml of complete growth medium.  The next day, cells were trypsinised and 
subjected to anchorage-dependent or -independent growth for 48 hours.  Total cell 
lysates were prepared in 200 µl of 1 X Passive Lysis Buffer (Promega) and firefly 
luciferase activity was assayed using the Dual Luciferease Kit (Promega) and the 
Glomax 96 microplate luminometer (Promega). Activity was normalised to the Renilla 
luciferase activity from pRL-TK in the same lysate.  
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To determine the effect of control or NDRG1 siRNA on pVEGF-Luc activity in cells 
cultured under anchorage-independent conditions, cells, at 40 % confluence in 60 mm 
dishes were first transfected with siRNA as described in section 6.16.  The next day, 
media was changed and the cells were transfected with pVEGF-Luc and pRL-TK and 
subjected to anchorage-independent growth and analysis as described above.   
 
6.18. Preparation of NDRG1 5’ regulatory region reporter plasmids 
6.18.1. PCR amplification of NDRG1 (-2100 to +12), (-1500 to +12), (-1200 to +12), (-
900 to +12) and (-298 to +12) regulatory regions 
Primers were designed to amplify the NDRG1 -2100 bp to +12 bp promoter fragment, 
and deletion mutants thereof, from the published genomic sequence for NDRG1 and 
its contiguous regions (GenBank accession number NT_008046; appendix 1).  The 
primer sequences, relative positions and annealing temperature used for PCR are listed 
in Table 6.3.   
 
The DNA template, used for PCR amplification of the 5’ NDRG1 regions, was genomic 
DNA that had previously been extracted from the blood of a normal individual.  The 
PCR reactions were performed using the Expand High Fidelity
PLUS
 PCR System (Roche, 
Mannheim, Germany) as follows:  400 ng of template DNA, 0.5 µM of the appropriate 
forward primer, 0.5 µM of +12 reverse primer, 5 % (v/v) DMSO, 0.2 mM dNTPs, 2.5 U 
Expand
PLUS
 high  fidelity  DNA  Polymerase, 3 mM  MgCl2  and  1 X  Polymerase Reaction 
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Table 6.3.  Primers used to amplify NDRG1 regulatory sequences 
Primer 
name 
Sequence Position 
PCR product 
size (bp) 
Ta 
(°C) 
-2100 F 5’ GTCTCATTATGTTGCTCAGA 3’ -2100 to -2080 2112 57 
-1500 F 5’ CTCTCCCTTTGCCAGTGAGA 3’ -1500 to -1480 1512 57 
-1200 F 5’ TTGCCCTGGGTCTGGTCCTG 3’ -1200 to -1180 1212 57 
-900 F 5’ CATATGCAGTAGGGGTTGAG 3’ -900 to -880 912 57 
-298 F 5’ CCCGCTGCACAGGCCGAG  3’ -298 to -280 310 57 
+12 R 5’ GCGAGGTTTGTTTACGTCCG 3’ -8 to +12 -  
PCR product size refers to the size of PCR product using the listed forward primers with 
the +12R reverse primer 
 
Buffer.  PCR cycling conditions were: 94°C for 4 minutes, followed by 30 cycles of 94°C 
for 40 seconds, 57°C for 40 seconds and 72°C for two and a half minutes, and a final 
extension step of 72°C for 7 minutes.  PCR products were subjected to 1 % agarose gel 
electrophoresis.  Bands of the correct size were cut out of the gel and purified using 
the Wizard
R
 SV Gel and PCR Clean-Up System (Promega) and eluted in 40 µl of distilled 
water.  
 
6.18.2. 3’-Adenine tailing reactions 
Since a high fidelity, proof reading polymerase was used to generate the PCR products, 
a 3’ adenine  tailing  reaction  was  performed,  to facilitate thymidine/adenine cloning 
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into the TOPO-XL PCR cloning vector (Invitrogen).  Briefly, 3’ adenine residues were 
added to 10 µl of purified PCR product in a reaction containing 5 U Taq polymerase 
(Stratagene, La Jolla, CA, USA), 1 X Taq buffer, 2.5 mM MgCl2 and 0.2 mM dATP.  
Reactions proceeded at 70°C for 30 min.  
 
6.18.3. Subcloning of A-tailed promoter PCR products into pCR-TOPO-XL 
After the A-tailing reaction, PCR products were ligated directly with the pCR-TOPO-XL 
vector.  In short, 4 µl of A-tailed reaction was ligated with 1 µl of pCR-TOPO-XL vector.  
After 5 minutes at room temperature, 1 µl of 6 x TOPO Cloning Stop Solution 
(Invitrogen) was added, and the tubes placed on ice.  Two microlitres of the TOPO 
cloning reaction was used to transform one vial of One Shot cells (Invitrogen) by 
incubating on ice for 30 minutes, followed by heat shock at 42
o
C for 30 seconds, and 
then placed on ice for a further 2 minutes.  To the transformation reaction 250 µl of 
S.O.C. medium (Invitrogen) was added followed by incubation of the bacterial cells at 
37
o
C for 1 hour with shaking (200 rpm).  One hundred microlitres of each 
transformation was spread on a pre-warmed LB agar plate containing 50 µg/ml 
kanamycin, for clone selection.   
 
6.18.4. Small scale plasmid preparation of pCR-TOPO-XL-NDRG1 promoter constructs 
The next day, colonies were selected and inoculated into 5 ml of LB broth containing 
50 µg/ml kanamycin.  After approximately 16 hours of incubation at 37
o
C, with shaking 
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(220 rpm), glycerol stocks were prepared by mixing 500 µl of overnight culture with 
500 µl sterile 80 % Glycerol and storing at -80°C.  The remaining cultures were 
subjected to small scale plasmid preparation using the QIAGEN Miniprep Kit (Qiagen), 
as recommended by the manufacturer.   
 
The identity of correct pCR-TOPO-XL-NDRG1 promoter constructs was confirmed by 
ApaI restriction digestion (Promega).  Since ApaI cuts once in pCR-TOPO-XL and once in 
the 3’ end of all PCR products, two restriction products were expected for all plasmids 
generated.  ApaI restriction fragment sizes of pCR-TOPO-XL-NDRG1 promoter 
constructs, with NDRG1 promoter fragments in the correct orientation, are listed in 
Table 6.4. 
 
Table 6.4. ApaI restriction products of pCR-TOPO-XL-NDRG1 promoter constructs 
Plasmid ApaI restriction products 
TOPO(-2100 to +12) 5304 bp and 308 bp 
TOPO(-1500 to +12) 4704 bp and 308 bp 
TOPO(-1200 to +12) 4404 bp and 308 bp 
TOPO(-900 to +12) 4092 bp and 308 bp 
TOPO(-298 to +12) 3490 bp and 308 bp 
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6.18.5. Sequence analysis 
Plasmids with inserts of the correct size and orientation were subjected to sequence 
analysis using the UCT Human Genetics Sequencing Unit.    The sequencing reaction 
was performed with the ABI PRISM BigDye Terminator v3.0 Cycle Sequencing Ready 
Reaction Kit (Applied Biosystems).  Sequencing reactions were performed with 4 µl of 
Big Dye Mix on 300 ng of template DNA with 2 µM of primer in a total volume of 20 µl.  
Primers used in independent sequencing reactions on each sample are listed in Table 
6.5.  The cycling conditions were as follows:  96
o
C for 1 min, followed by 25 cycles of Ta 
for 15 sec and 60
o
C for 4 min.  Samples were subjected to automated sequencing and 
data collected using ABI Prism Model 3100, Version 3.7 collection software. 
 
Table 6.5. Primers used in pCR-TOPO-XL-NDRG1 promoter construct sequencing 
Primer Sequence 
Position in 
promoter 
Ta (°C) 
T7 primer 5’ TAATACGACTCACTATAGGG 3’ In pCR-TOPO-XL 45 
M13 Reverse 5' CAGGAAACAGCTATGAC 3' In pCR-TOPO-XL 45 
-1500 F 5’ CTCTCCCTTTGCCAGTGAGA 3’ -1500 to -1480 57 
-900 F 5’ CATATGCAGTAGGGGTTGAG 3’ -900 to -880 57 
-298 F 5’ CCCGCTGCACAGGCCGAG  3’ -298 to -280 57 
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6.18.6. Preparation of pGL3-NDRG1-promoter reporter plasmids 
Sequence confirmed NDRG1 promoter fragments were released from recombinant 
pCR-TOPO-XL-NDRG1 constructs by restriction enzyme digestion with KpnI and XhoI 
(Invitrogen).  Released promoter fragment inserts with 5’ KpnI and 3’ XhoI restriction 
overhangs were gel purified and ligated with pGL3-Basic, which had also been digested 
with KpnI and XhoI, upstream of the luciferase gene.     
Using the equation: 
               ng vector/Kb vector X Kb insert X molar ratio (insert(4):vector(1)) = ng insert 
and using 100 ng of vector, insert and vector DNA were combined and ligations were 
performed using 3 U T4 DNA ligase (Promega) and 1 X T4 DNA ligase buffer in a final 
volume of 10 µl.  Ligations were performed overnight at 16°C.  The next day, 5 µl of 
ligation reaction was transformed into highly competent JM109 cells and positive 
clones selected on LB agar plates containing 50 µg/ml ampicillin. Colonies were picked 
the next day, glycerol stocks prepared, and screened for the correct inserts by KpnI and 
ApaI restriction enzyme digestion analysis (data not shown), and BamHI in the case of 
pGL3-NDRG1-(2100 to +12) (Chapter 4, Fig. 4.2) based on restriction enzyme 
availability at the time.   
 
6.18.7. Large scale plasmid preparation of pGL3-NDRG1-promoter reporter plasmids 
Positive clones identified above were cultured for large-scale plasmid preparation 
using the Qiagen Plasmid Maxi-Prep Kit.  Plasmid DNA was prepared as recommended 
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by the manufacturer (QIAGEN). Starter cultures were prepared by inoculating 5 µl of 
glycerol stock into 5 ml of LB Broth containing 50 µg/ml ampicillin.  Cultures were 
grown for approximately 8 hours at 37
o
C with shaking at 200 rpm.  The starter culture 
was then diluted 1/500 to 400 ml with LB broth containing 50 µg/ml ampicillin.  
Cultures were grown at 37
o
C for approximately 12 hours with shaking (200 rpm).  
Bacterial cells were harvested by centrifugation (6000 x g, 15 min, 4
o
C) in a Beckman 
JA-10 rotor (Beckman, J-21B centrifuge) and the supernatant discarded.  The cell pellet 
was resuspended in 10 ml of Buffer P1 (containing RNaseA) followed by lysis with the 
addition of 10 ml Buffer P2.  After 5 minutes at room temperature, 10 ml of chilled 
Buffer P3 was added and the solution left on ice for 20 minutes.  The solution was then 
centrifuged (20 000 x g, 30 min, 4
o
C) in a Beckman JA-20 rotor after which the 
supernatant was removed to a new tube and centrifuged as before for 15 minutes.  
Applying 10 ml Buffer QBT and allowing it to enter the column by gravity flow 
equilibrated the QIAGEN-tip 500 column.  The supernatant was then applied and 
allowed to enter the resin by gravity flow.  The column was washed twice with 30 ml 
Buffer QC to remove contaminants.  Plasmid DNA was then eluted with 15 ml of high 
salt Buffer QF and precipitated with the addition of 10.5 ml of room-temperature 
isopropanol.  Precipitated plasmid DNA was collected by centrifugation at 15 000 x g 
for 30 minutes at 4
o
C and the supernatant discarded.  The DNA pellet was washed with 
5 ml of room temperature 70 % ethanol and centrifuged at 15 000 x g for 10 minutes 
at 4
o
C.  The supernatant was discarded and the DNA pellet left to air-dry. Finally, the 
plasmid DNA was resuspended in an appropriate amount of TE, pH 8.0.  Isolation of the 
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correct plasmids was again confirmed by KpnI and ApaI restriction enzyme digestion 
and BamHI digestion in the case of pGL3-NDRG1-(-2100 to +12). 
 
6.18.8. Preparation of pGL3-NDRG1-(-2100 to +305) reporter plasmid 
Primers were designed to PCR amplify the NDRG1 regulatory region from -296 to +305 
for subcloning into the pGL3-NDRG1(-2100 to +12) reporter plasmid.  Primers were 
designed against the published genomic sequence for NDRG1 and its contiguous 
regions (appendix 1).  The reverse primer was designed to generate a PCR product 
containing a 3’ XhoI restriction site.  Primers are described in Table 6.6.   
 
PCR reactions and cycling conditions were as described in section 6.18.1, using a Ta of 
62
o
C The resulting PCR product was cloned into pCR-TOPO-XL as described in section 
6.18.3. and sequence confirmed using the T7 primer.  Correct clones were cultured and 
large scale plasmid preparations performed.  The -243 to +305 NDRG1 regulatory 
region was released from the pCR-TOPO-XL-NDRG1(-296 to +305) plasmid by ApaI and 
XhoI restriction enzyme digestion, and isolated by agarose gel electrophoresis and gel 
purification.   This fragment was cloned into ApaI and XhoI digested pGL3-NDRG1(-
2100 to +12) plasmid to generate the pGL3-NDRG1(-2100 to +305) reporter construct.  
Identity of this construct was confirmed by NcoI digestion, which gave the correct size 
fragment of 1683 bp and 5521 bp (data not shown). 
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Table 6.6. Primers used to PCR amplify the NDRG1 -296 to +305 regulatory region 
Primer Sequence 
Position in 
promoter 
Ta (°C) 
NDRG1-300FWD 5’ CGCTGCACAGGCCGAG 3’ -296 to -281 62 
NDRG1+300REV 5' GACTCGAGCGGTGTCTGCACCCAA 3' +288 to +305 62 
The XhoI restriction site incorporated into the reverse primer is underlined 
 
6.18.9. Preparation of pGL3-NDRG1-(-4818 to +12) and (-4818 to +305) reporter 
plasmids 
Primers were designed to PCR amplify the NDRG1 regulatory region from -4819 to -
1280 for subcloning into the pGL3-NDRG1(-2100 to +12) and pGL3-NDRG1(-2100 to 
+305)  reporter plasmids.  Primers were designed against the published genomic 
sequence for NDRG1 and its contiguous regions (appendix 1).  The forward primer was 
designed to generate a PCR product containing a 5’ KpnI restriction site.  Primers are 
described in Table 6.7 below.   
 
Table 6.7. Primers used to PCR amplify the NDRG1 -4819 to -1280 regulatory region  
Primer Sequence 
Position in 
promoter 
Ta (°C) 
NDRG1 proForward   5’ CAGGTACCGGCATGCTTGCAGATAAC 3’ -4819 to -4793 48 
NDRG1 proRevNco   5' TCTGTGCCAACCCATGC 3' -1297 to -1280 48 
The KpnI restriction site incorporated into the forward primer is underlined 
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PCR reactions and cycling conditions were as described in section 6.18.1, using a Ta of 
48
o
C The resulting PCR product was cleaned using the Wizard
R
 SV Gel and PCR Clean-
Up System and digested with KpnI and NcoI restriction enzymes, releasing the -4819 to 
-1319 NDRG1 promoter fragment.  This fragment was cloned into the KpnI and NcoI 
restriction sites of the pGL3-Basic vector as described in section 6.18.6.  Correct 
plasmid constructs were identified by NcoI restriction enzyme digestion (data not 
shown) analysis and prepared by large scale plasmid preparation.  The plasmids listed 
in Table 6.8 were digested with the appropriate enzymes to release NDRG1 promoter 
fragments.  These were ligated with the KpnI and XhoI digested pGL3-Basic vector to 
generate the pGL3-NDRG1(-4819 to +12) reporter plasmid.  To generate the pGL3-
NDRG1(-4819 to +305) construct, the pGL3-NDRG1(-2100 to +305) was digested with 
NcoI and XhoI to release the NDRG1 -1319 to +305 regulatory region.  This was ligated 
with the -4819 to -1319 NDRG1 region and the KpnI/XhoI  digested  pGL3-Basic  vector  
as  for pGL3-NDRG1(-4819 to +12).  The identity of 
 
Table 6.8. Plasmids and restriction enzymes used to generate pGL3-NDRG1(-4819 to 
+12)   
Plasmid Restriction enzymes Fragment 
pGL3-NDRG1(-4819 to -1319)   KpnI and NcoI -4819 to -1319 
pGL3-NDRG1(-2100 to +12)   NcoI and XhoI -1319 to +12 
pGL3-Basic KpnI and XhoI Linearised pGL3-Basic 
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the pGL3-NDRG1(-4819 to +12) and pGL3-NDRG1(-4819 to +305) reporter plasmids 
was confirmed by NcoI restriction enzyme digestion, which generated expected DNA 
fragments of 8269 bp and 1350 bp or 1650 bp, respectively.  Correct clones were then 
sequence confirmed using the primers listed in Table 6.9. and prepared by large-scale 
plasmid preparation.   
 
Table 6.9. Primers used to sequence the -4819 to -1297 NDRG1 region in pGL3-
NDRG1(-4819 to +12) and pGL3-NDRG1(-4819 to +305) 
Primer Sequence 
Position in 
promoter 
Ta (°C) 
RVprimer3 5’ CTAGCAAAATAGGCTGTCCC 3’ In pGL3-Basic 55 
NDRG1 proRevNco   5' TCTGTGCCAACCCATGC 3' -1297 to -1280 48 
 
6.19. Luciferase assays 
Cells were seeded at a density of approximately 1 x 10
5
 cells per well of a 6-well plate 
and trasfected with luciferase reporter plasmids using Effectene Transfection Reagent 
(Qiagen).  Briefly, 0.3 µg of pGL3-NDRG1-promoter plasmid, 10 ng of pRL-TK (that 
encodes Renilla luciferase) and 3.2 µl of Enhancer solution were added to 100 µl of EC 
buffer and left at room temperature for 5 minutes.  Ten microlitres of Effectene 
reagent was then added to the transfection mix.  After 10 minutes at room 
temperature, 600 µl of complete growth medium was added and the transfection mix 
added dropwise to the cells in 1.6 ml of complete growth medium.  The next day, cells 
were subjected to treatment conditions, as described.  Total cell lysates were prepared 
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by vigorous scraping in 100 µl of 1 X Passive Lysis Buffer (Promega) and firefly 
luciferase activity was assayed using the Dual Luciferease Kit (Promega) and Glomax 96 
microplate luminometer (Promega).  Activity was normalised to the Renilla luciferase 
activity from pRL-TK in the same lysate.  
 
To determine the effect of control, EGR-1 or cJun siRNA on NDRG1 promoter reporter 
activity cells, at 40 % confluence in 6-well culture plates were first transfected with 
siRNA as described in section 6.16.  The next day, media was changed and the cells 
were transfected with the pGL3-NDRG1(-2100 to +12) reporter plasmid and pRL-TK, 
using Effectene Transfection Reagent and subjected to TPA treatment and analysis as 
described.   
 
6.20. Site-directed mutagenesis 
Mutations of putative transcription factor binding sites in the NDRG1 (-2100 bp to +12 
bp) promoter region were performed by site-directed mutagenesis.  Primers were 
designed to incorporate the appropriate mutation, to specifically disrupt the 
transcription factor binding site and not any other site, and without incorporating an 
additional site into the promoter region. Primer design and melting temperature 
calculation was performed using Primer X software 
(http://www.bioinformatics.org/primerx/) and these are described in Table 6.10 
below.  Mutation of the EGR-1 site was performed as described before[153].   
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Mutagenesis was performed by PCR as recommended by the Stratagene QuikChange 
site-directed mutagenesis kit, using the Expand High Fidelity
PLUS
 PCR System (Roche).  
Reaction conditions were as follows:  100 ng template pGL3-NDRG1-(-2100 to +12), 
125 ng forward primer, 125 ng reverse primer, 0.2 mM dNTPs, 2.5 U Expand
PLUS
 high 
fidelity DNA Polymerase and 1 X Polymerase Reaction Buffer. PCR cycling conditions 
were: 95°C for 30 seconds, followed by 18 cycles of 95°C for 30 seconds, 55°C for 1 
minute and 72°C for 6 minutes, and  a  final  extension  step  of  72°C  for  1 hour.  After 
cooling the PCR reaction, 10 U of DpnI enzyme (Promega) was added directly to the 
PCR product and parental template DNA digested at 37
o
C for 2 hours.  Highly 
competent JM109 bacterial cells (Promega) were transformed with 5 µl of the DpnI 
digest and plated on LB agar plates containing 50 µg/ml ampicillin.    The identity of the 
EGR-1  mutant  plasmid  was  confirmed  by  BfmI  digest  (Fermentas, Ontario, Canada) 
 
Table 6.10. Primers used for site-directed mutagenesis 
Name Sequence Tm (
o
C) 
EGR1-mut-F 5' GAGGGGCGAGGCtataGGGCGGGGCCGC 3' 76 
EGR1-mut-R 5' GCGGCCCCGCCCtataGCCTCGCCCCTC 3' 76 
AP1(1)-mut-F 5' CTAAGGTTGGAAAGGGTGcGcCATGAAAGTTCAGGAAATC 3' 76 
AP1(1)-mut-R 5' GATTTCCTGAACTTTCATGgCgCACCCTTTCCAACCTTAG 3' 76 
AP1(2)-mut-F 5' GGTGCCAGCTGTGcGTCAGACTTCC 3' 76 
AP1(2)-mut-R 5'   GGAAGTCTGACgCACAGCTGGCACC 3' 76 
Mutated bases are highlighted in bold, lowercase. 
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while the AP1(1) and AP1(2) mutants were both confirmed using SchI restriction 
enzyme (Fermentas).     
 
6.21. Chromatin Immunoprecipitation Assay 
Cells were seeded at 1 x 10
7 
cells per 150 mm tissue culture dish and left overnight.  
The next day cells were grown in the presence or absence of 20 nM TPA for 2 hours.  
Cross-linking of protein-DNA complexes was performed with 1 % formaldehyde, added 
directly to the culture medium, for 10 minutes at room temperature followed by 
neutralization with Glycine, pH 2.5, to a final concentration of 0.125 M, for 5 minutes.  
Cells were washed twice with ice-cold PBS, like cells combined and pelleted at 200 x g 
for 5 min at 4
o
C.  The pellet was resuspended in 300 μl of lysis buffer and left on ice for 
10 min.  Each lysis solution was sonicated four times on maximum power with a probe 
sonicator (Heat System-Ultrasonics, Inc., Plainview, NY), and cell debris was pelleted at 
4
o
C for 10 min at 15 000 x g.  Twenty microlitres of the soluble chromatin preparation 
was set aside as the input fraction while the reminder was diluted 1:10 in dilution 
buffer.  Protein G Plus-Agarose beads (Calbiochem, EMD Biosciences) were blocked in 
a 1:10 solution of lysis buffer:dilution buffer containing 5 % BSA and 100 μg/ml 
sheared salmon sperm DNA (Invitrogen), for 8 hours at 4
o
C.  Beads were pelleted at 
200 x g for 5 min at 4
o
C, washed with twice with ice-cold PBS and finally resuspended 
in a 1:10 solution of lysis buffer:dilution buffer.  The soluble chromatin was precleared 
with blocked protein G beads for 2 hours at 4
o
C.  The beads were then removed by 
centrifugation at 4
o
C for 1 min at 15 000 x g.  Twenty microlitres of EGR-1 antibody 
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(no. 4152, Cell Signaling Technology), or no antibody, was added to the pre-cleared 
chromatin and the solution was incubated at 4
o
C overnight.  The next day 45 μl of 
blocked Protein G Plus-Agarose beads were added and the solution left for a further 2 
hours at 4
o
C.  The beads were collected by centrifugation and washed successively for 
10 min each with TSE I, TSE II, buffer III, and TE, pH7.4.  DNA was eluted from the 
beads twice at room temperature with 100 μl elution buffer, followed by incubation 
overnight at 65
o
C to reverse cross-links.  DNA was purified with the Wizard
R
 SV Gel and 
PCR Clean-Up System (Promega) as per the manufacturer’s instructions.  Purified DNA 
was amplified by real-time PCR using NDRG1 promoter primers, designed to span the 
EGR-1 binding site (Table 6.11), on a StepOne Real Time PCR System (Applied 
Biosystems) using the KAPA SYBR qPCR Universal Kit (KAPA Biosystems).  Real-time RT-
PCR cycling conditions were 95°C for 3 minutes, followed by 40 cycles of 95°C for 1 
second and 55°C for 20 seconds. 
 
 
Table 6.11 Primers used in ChIP assay 
Primer  Sequence Position 
PCR 
product 
size (bp) 
Ta 
(°C) 
EGR1ChIPF 5' CTGCGTGCTGGGACTGC 3' -88 to -72 
EGR1ChIPR 5' CGGATGGTGAACTGACGAG 3’ +36 to +54 
142 55 
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6.22. Statistical Analyses 
Experiments were performed in triplicate (or quadruplicate) and results are the mean 
± standard deviation (SD) or standard error (SE) of two or more independent 
experiments.  For data comparisons the Student’s t-test (unpaired or paired) was 
performed, where appropriate. A P value of <0.05 was considered statistically 
significant.   
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6.23. Solutions 
6.23.1. Tissue culture solutions 
 
Trypsin-EDTA 
0.5 g trypsin 
8 g NaCl 
1.45 g Na2HPO4.2H2O 
0.2 g KCl 
0.2 g KH2PO4 
10 mM EDTA, pH 8.0 
Made up to 1 litre with PBS 
 
PBS 
137 mM NaCl 
2.7 mM KCl 
4.3 mM Na2HPO4.7H2O (pH 7.4) 
1.4 mM KH2PO4 
 
             4 % paraformaldehyde 
40 g paraformaldehyde dissolved in 900 ml PBS. 
Heat to 50
o
C and add 1-2 NaOH pellets 
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6.23.2. RNA solutions 
 
10 X MOPS Buffer 
0.2 M [N-morpholino]propanesulfonic acid (MOPS) 
0.05 M NaAcetate 
0.01 M EDTA 
 
RNA Loading Buffer 
0.72 ml Formamide 
0.16 ml 10 X MOPS Buffer 
0.26 ml 37 % Formaldehyde  
0.18 ml dH2O 
0.1 ml 80 % Glycerol 
0.08 ml 0.25 % Bromophenol Blue  
 
             1.5 % MOPS/formaldehyde agarose gel 
0.75 g Agarose 
50 ml 1 X MOPS 
2.7 ml 37 % Formaldehyde 
2.5 µl Ethidium Bromide (10 mg/ml) 
 
6.23.3. VEGF-A ELISA solutions 
             
            Wash Buffer 
             0.05 % Tween-20 in PBS 
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            Block Buffer 
            1 % BSA in PBS 
             
 
6.23.4. Protein and Western blot solutions 
 
RIPA Buffer 
150 mM Sodium Chloride 
1 % Triton X-100 
1 % Sodium Deoxycholate 
0.1 % SDS 
10 mM Tris-Cl, pH 7.4 
 
4 X Protein Loading Dye 
250 mM Tris-Cl, pH 6.8 
6 % SDS 
0.005 % Bromophenol Blue 
40 % Glycerol 
10 % β-mercaptoethanol 
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             4 % Acrylamide Stacking Gel 
7.3 ml dH2O 
1.25 ml 1 M Tris-Cl, pH 6.8 
100 µl 10 % SDS 
1.3 ml 30 % Acrylamide 
120 µl 10 % Ammonium Persulphate 
12 µl TEMED 
 
             10 % Acrylamide Separating Gel 
5.5 ml dH2O 
7.5 ml 1 M Tris-Cl, pH 8.8 
200 µl 10 % SDS 
6.7 ml 30 % Acrylamide 
400 µl 10 % Ammonium Persulphate 
40 µl Temed 
 
             Acrylamide/Bisacrylamide (37.5:1, 30%) 
30 g Acrylamide 
0.8 g Bisacrylamide 
0.1 g SDS 
Up to 100 ml with dH2O 
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10 X Running Buffer 
20 g Glycine 
31.6 g Tris 
50 ml 10 % SDS 
Up to 500 ml with dH2O 
 
10 X Transfer Buffer 
72 g Glycine 
19 g Tris 
Up to 500 ml with dH2O 
 
             1 X Transfer Buffer 
100 ml 10 X Transfer Buffer 
200 ml Isopropanol/Methanol 
700 ml dH2O 
 
Stripping Buffer 
100 mM β-Mercaptoethanol 
2 % SDS 
62.5 mM Tris-HCl, pH 6.7 
 
Rapid Coomassie Staining Solution 
0.024 % Coomassie Brilliant Blue 
10 % Acetic Acid 
90 % dH2O 
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Destain 
10 % Glacial Acetic Acid 
10 % Methanol 
 
TBST 
50 mM Tris-Cl, pH 7.5 
150 mM NaCl 
0.1 % Tween-20 
 
6.23.5. DNA solutions 
 
TE Buffer 
10 mM Tris-Cl, pH 8.0 
1 mM EDTA, pH 8.0 
 
10 X TBE 
108 g Tris 
55 g Boric Acid 
7.4 g EDTA 
Up to 1 l with dH2O 
 
10 x TAE Buffer 
0.4 M Tris 
0.01 M EDTA 
pH to 7.8 with acetic acid 
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6.23.6. Bacterial solutions 
 
Luria Broth (LB) medium 
10 g Tryptone 
5 g Yeast Extract 
10 g NaCl 
1 mM NaOH 
Up to 1 litre with dH2O 
 
LB agar 
Same as LB medium, but with 15 g Agar 
 
Ampicillin (10 mg/ml) and Kanamycin (10 mg/ml) 
1 mg Ampicillin or Kanamycin 
10 ml dH2O 
Filter-sterilised 
Store at -20°C 
 
6.23.7. ChIP Solutions 
 
Lysis buffer 
1 % SDS 
5 mM EDTA 
50 mM Tris-Cl, pH 8.1 
1 X Complete Protease Inhibitor (Roche) 
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             Dilution buffer 
1 % Triton X-100 
2 mM EDTA 
150 mM NaCl 
20 mM Tris-Cl, pH 8.1 
1 X Complete Protease Inhibitor 
 
TSEI 
0.1 % SDS                                                                                                                                 
1 % Triton X-100                                                                                                                     
2 mM EDTA                                                                                                                                  
20 mM Tris-Cl, pH 8.1                                                                                                             
150 mM NaCl 
 
TSEII 
0.1 % SDS                                                                                                                                      
1 % Triton X-100                                                                                                                          
2 mM EDTA                                                                                                                                  
20 mM Tris-Cl, pH 8.1                                                                                                              
500 mM NaCl                                                                                                                       
 
 
Buffer III                                                                                                                                     
0.25 M LiCl                                                                                                                                  
1 % NP-40                                                                                                                                     
1 % Sodium Deoxycholate                                                                                                          
1 mM EDTA                                                                                                                                   
10 mM Tris-Cl, pH 8.1 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 178 
Elution Buffer 
1 % SDS 
0.1 M NaHCO3 
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APPENDIX 1 
Exert from NT_ 008046 Chromosome 8 genomic contig. 
mRNA is in bold, capital letters 
The -2100 bp to +1 bp region is highlighted in turquoise  
TATA box is highlighted in purple 
 
 
LOCUS       NT_008046              63001 bp    DNA     linear   CON 20-AUG-2004 
DEFINITION  Homo sapiens chromosome 8 genomic contig. 
ACCESSION   NT_008046 REGION: complement(47467000..47530000) 
VERSION     NT_008046.15  GI:51467074 
KEYWORDS    . 
SOURCE      Homo sapiens (human) 
  ORGANISM  Homo sapiens 
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; 
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; 
            Hominidae; Homo. 
REFERENCE   1  (bases 1 to 63001) 
  AUTHORS   International Human Genome Sequencing Consortium. 
  TITLE     The DNA sequence of Homo sapiens 
  JOURNAL   Unpublished (2003) 
COMMENT     GENOME ANNOTATION REFSEQ:  Features on this sequence have been 
            produced for build 35 version 1 of the NCBI's genome annotation 
            [see documentation]. 
            On Aug 20, 2004 this sequence version replaced gi:37555983. 
            The DNA sequence is part of the third release of the finished human 
            reference genome. It was assembled from individual clone sequences 
            by the Human Genome Sequencing Consortium in consultation with NCBI 
            staff. 
FEATURES             Location/Qualifiers 
     gene            2324..62408 
                     /gene="NDRG1" 
                     /note="Derived by automated computational analysis using 
                     gene prediction method: BestRefseq. Supporting evidence 
                     includes similarity to: 1 mRNA" 
                     /db_xref="GeneID:10397" 
                     /db_xref="MIM:605262" 
     mRNA            join(2324..2445,15250..15330,19312..19347,34927..35032, 
                     37412..37532,40349..40411,41153..41213,42716..42802, 
                     44984..45040,49036..49139,50808..50864,51653..51704, 
                     52916..52963,55189..55224,57505..57556,60460..62408) 
                     /gene="NDRG1" 
                     /product="N-myc downstream regulated gene 1" 
                     /note="unclassified transcription discrepancy; Derived by 
                     automated computational analysis using gene prediction 
                     method: BestRefseq. Supporting evidence includes 
                     similarity to: 1 mRNA" 
                     /transcript_id="NM_006096.2" 
                     /db_xref="GI:37655182" 
                     /db_xref="GeneID:10397" 
                     /db_xref="MIM:605262" 
     CDS             join(15268..15330,19312..19347,34927..35032,37412..37532, 
                     40349..40411,41153..41213,42716..42802,44984..45040, 
                     49036..49139,50808..50864,51653..51704,52916..52963, 
                     55189..55224,57505..57556,60460..60701) 
                     /gene="NDRG1" 
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   ORIGIN       
        1 atgcacctgt agaaaatgtt tttgcctttt cagtcctttc ccagtggcgg agtacaggac 
       61 ccagctcata agagcagctc aattctgtca tttgtggaat gacagaataa ataagtttca 
      121 gggcctaggg aggcaaggct cctgccttag cctcccaagt agctggaact acagctgcat 
      181 gccactaagc ccacctgatt ttttattttc ttgtagagat gatgtctcat tatgttgctc 
      241 agacttttct ggaactcctg ggctcaagca atcctcccac ctctgcctct gaagtagctg 
      301 ggactacagg tacttgccac caggcctggc tagctttcat cttttttgta gagatgggac 
      361 atcactatgt tgtgaaggct ggtctcaaac tcctggactc aagagaggct tctgcattgg 
      421 cctcccaaag tgctgggatt acaggtgtaa gccactctac ctggacacaa cattttattt 
      481 gaaataagaa aaattttccc tcactgggaa tgctgcagtt gaactagttc aaatccataa 
      541 agaatggaag actgcccagt ggtcattcat tcacttatta attctagatg ttaaattttc 
      601 tagggtgggg gaatgtgctc ctacattcaa ggcattcttg aatgtagcca aactttgtag 
      661 tttagccaaa cttcatagct aatagccaaa ctttgtagtt tagccaaact cttctagcag 
      721 caaaacccat gacactggaa ctctgttctt cacactggtc atttgtaata gaataacaga 
      781 gctttagcac tagataggtt ctgaaagatc attgaatcta atcctctccc tttgccagtg 
      841 agaattctga agcccagatt tgttgatttg tgatcgatag tgtcaaagac aggcctgaaa 
      901 cacagatgtc ctgggtccta gaggtgctgt ttgcccctct ccatatttct tttgttccag 
      961 aaaacccttc tccaaaactg gccctaataa tcagagggga aagccatggc ccctgccttg 
     1021 gggacagcat gggttggcac agaaaagagg tttacaattc agcaggaagt gttgtgcgtg 
     1081 cgcgcgtgtg tgtctgtgga ggcgcaggga gggtcacctg agcttgccct gggtctggtc 
     1141 ctgggctcag tggcaaattc aacgctgggc aggtggcctg aggacaatga cggtgccagc 
     1201 tgtgagtcag acttccttta ttcataaaat catgttcctc catgcagtgc ttctcaacct 
     1261 ggctgcacgt caggagccac ctgggtagct ttgtaaaaac cccaatgccc agttggtttg 
     1321 caccccctga gattctgatt aaactgttct ggagtccatc tctctctttt tattatctat 
     1381 ctatttattt attttttaat ttggcggctc ctctgggact tctcatatgc agtaggggtt 
     1441 gagaattgct ggtttctttg gccagatggg aacatgcagg ccaatagtta cgcacaaaca 
     1501 gagcagcaga gcaggacggt gctaaggttg gaaagggtga gtcatgaaag ttcaggaaat 
     1561 cagaatagga aggggtgaga atcctctcat ctgggcttgt ggggcaggag agaagagccc 
     1621 agtgggcaag gtccagtgag tgtgcttaga actgggaaga tgaggggaag ggtaagcgct 
     1681 gggcggcggt gggcaagatg gacgagatta aacgggagcg aggatttcag cgagagcttt 
     1741 ggcgacacgg aaggctgaga atcggaggga gcctgtcggg cgaaagcgaa ggcggctgct 
     1801 gggcaggcag ccgaatccgg ctggagagcc gagctggtga gacctacagg aagtgaaggg 
     1861 agtcgctcag ggcgtggcgc aacgagactc ttagaagaaa ctctgaggca gagatggggg 
     1921 gcctccgccc atacggagac acaaggaagt ccacatgcac acgcacgagc gcgcacatga 
     1981 acacgcacaa gcacacaaac gcctcctccg ggcagggcac acgcgcccgc tgcacaggcc 
     2041 gaggccctgg actcggaggg gactgcagag ccgacccaca acccgggccc cgatgcccct 
     2101 cccggccgcg cccctacgac tgcttgcgca acaggcggcg gctccagtgg gcgcccgccg 
     2161 cgcgctgccg gagcccagcc cagcccggcg cgcccgggag gagggagcag ggagcgggga 
     2221 aggggtgtgt cccggctgcg tgctgggact gcgagggtct gggaggggcg aggcgcgggg 
     2281 gcggggccgc ggcgcctata aagtcgccct ccgcccggac gtaAACAAAC CTCGCCTGGC 
     2341 TCCCAgctgg tgctgaagct cgtcagttca ccatccgccc tcggcttccg cggggcgctg 
     2401 ggccgccagc ctcggcaccg tcctttcctt tctccctcgc gttaggtaag cccgcgccct 
     2461 cttctcccag gcgcgacgcg gagcagaaag gggccgcccg tgcggtgccg ctggagcgcc 
     2521 aggaccgccc tttgtagccc cgcgtactcc aggagtaagc gccccggagc tgcaagtgcg 
     2581 cggtcacccc ggggcgcggg cgcgaggggg ctttgggtgc agacaccgct gaagtggggg 
     2641 gttcaattac ggaaagggag gaaaaaaaga cagggtccca ttcatctccc ccctagctgg 
     2701 ggattggggt tctggaggtc gggaaggggg cgatgagacg gtccgaaaaa ataccaggat 
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